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Abstract 
Adam Eric Throup 
Title:  Synthetic Methodology and Application of Enamine [2+2] 
Cyclisations for Cyclobutane Synthesis 
Subtitle: Development of Integrin Antagonists as Anticancer Therapeutics 
Towards a Total Synthesis of Providencin 
Keyword: Cyclobutane, Cyclobutene, Cyclisation, Integrin, Providencin, 
Cancer, β3, Metastasis 
Cyclobutanes represent an underutilised structural feature in medicinal 
chemistry, partially due to difficulties in forming them in an easy and 
controlled manner. Herein is described their application to a drug discovery 
project and development of the enamine [2+2] cyclisation; a straightforward 
synthesis of functionalised cyclobutanes.  
A library of 30 cyclobutane based integrin antagonists have been designed 
and synthesised to explore the SAR around the hit dual β3 integrin antagonist 
ICT9055. Several of which were shown to be highly potent antagonists 
inhibiting cancer cell adhesion, migration and invasion while remaining non-
toxic. ICT9072 had comparable β3 activity to hit compound ICT9055 but also 
had activity against αvβ5 and therefore showed greater inhibition of migration 
of DLD-1 cells. This showed the ability to modify this scaffold for multi integrin 
antagonism and potential benefit of this. 
Synthetic studies towards the marine natural product providencin has led to 
the development of a previously unknown intramolecular enamine [2+2] 
cyclisation which has been shown to proceed in a diastereoselective manner. 
This reaction has been applied to the synthesis of a highly functionalised 
enatiopure cyclobutene suitable for inclusion into the total synthesis. A model 
furyl cyclobutane has also been synthesised to exemplify the route from the 
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enantiopure cyclobutene through to the furyl cyclobutane fragment of 
providencin. 
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1. Cyclobutanes 
Cyclobutanes are 4 membered carbocycles; due to the decreased bond 
angles they are inherently strained (strain energy 26.3 kcal/mol) and 
therefore more reactive compared to larger rings (cyclopentane 6.2 kcal/mol, 
cyclohexane 0.1 kcal/mol).1 Despite this cyclobutanes are found extensively 
in nature, where they are formed in general from photochemical [2+2] 
reactions of two alkenes. These natural cyclobutanes (for examples, see 
Figure 1) stem from a range of dimerisations, intramolecular cyclisations and 
ring contractions yielding very simple to highly complex molecules. 
Cyclobutane natural products have received a lot of attention from synthetic 
and medicinal chemists due to their interesting biological activities or 
complex molecular architecture.2 
 
Figure 1 Cyclobutane containing natural products 
Cyclobutanes are traditionally formed via photochemical [2+2] cyclisations 
between two alkenes. A thermal [2+2] cyclisation is disallowed due to orbital 
symmetry and therefore excitation of one of the alkenes to its triplet state is 
required before it can react. This excitation can be problematic in unactivated 
alkenes and becomes easier when activated alkenes are used (e.g. enones) 
but this can still require specialist uv lamps and equipment.  
 2 
 
 
Figure 2 Orbital overlap require for photochemical [2+2] cyclisation 
Once activated, the alkenes are highly reactive meaning often the reactions 
are not easily controlled getting a range of products and diastereomers and 
regioisomers from the reactions (Figure 3). The relative configuration of the 
original alkenes are maintained as in all pericyclic reactions, but the 
configuration between the two alkenes can differ; due to the high reactivity 
the usual steric effects that would lead to the all trans cyclobutane and 
potentially a particular regioisomer are minimised meaning mixtures of 
regioisomers and cis and trans products are gained. Homodimerisations are 
also possible with diastereomers and regioisomers of these dimers as well 
further complicating the mixture of possible products. Dimerisation reactions 
can be minimised by the use of activated alkenes with photosensitising 
groups attached ensuring that this alkene is all activated leaving it only the 
unactivated alkene to react with. Also by tuning the electronics of the 
substituents selectivity for a particular regioisomer can be gained.  
 
Figure 3 Possible products from a photochemical [2+2] cyclisation 
Synthesis of cyclobutanes can still prove challenging due to the inherent 
uncontrollability of photochemical [2+2] reactions. To overcome these issues 
several strategies have been explored including intramolecular reactions, 
tuning the electronics (using enol ethers, enones, ketenes) and adding steric 
bulk (including chiral auxiliaries), all to control the reactivity of the alkenes.2c, 
2d 
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1.1 Enamine [2+2] Cyclisations 
Brannock identified an enamine [2+2] cyclisation to form cyclobutanes3 in a 
controlled and straightforward manner. This is not a pericyclic reaction, as 
the photochemical [2+2] cyclisations, but instead proceeds via a stepwise 
mechanism. First there is a conjugate addition of the enamine 15 into the 
electron deficient alkene 16 (ester, cyano, nitro groups) to yield zwitterionic 
iminium/enolate 17, which then reacts internally to close the ring to form the 
cyclobutane 18 (as long as no water is present to hydrolyse the iminium and 
yield the 1,4-dicarbonyl compound 20). The cyclobutylamines can then be 
quaternised to give iminium salts 19 which can then be eliminated to yield the 
stable cyclobutenes 21 ready for further functionalization.  
 
Scheme 1 Mechanism of the enamine [2+2] cyclisation 
Brannock explored the scope of this reaction showing substrate tolerability: 
R1 on the enamine must be an alkyl chain and the electron deficient alkene 
could be acrylate, fumarate, nitro olefin, vinyl sulfone or acrylonitrile. 
The benefit of this reaction over the photochemical process is that it does not 
require any specialist equipment and is straightforward to set up. The 
reactions can be performed in one pot, with either preforming the enamine in 
situ followed by addition of the Michael acceptor or by simultaneous addition 
of all reagents.4 The only precaution required is to exclude moisture from the 
reaction to avoid formation of aldehydes (e.g. 20) from the iminium 
intermediate. The amine quaternisation and the elimination to cyclobutenes 
can be carried out on the crude mixtures with no need for purification (which 
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is useful as cyclobutylamines are somewhat unstable to column 
chromatography). The other great benefit over photochemical processes are 
the products from the reaction are predictable. The regiochemistry of the 
cyclobutane product is controlled by the enamine conjugate addition meaning 
the reactant can only react one way round; it is also impossible to get dimers. 
The cyclisations are also diastereoselective for the all trans cyclobutane 18 
(occasionally small amounts ~10% of cis cyclobutenes are isolated) due to 
the lowered reactivity and reversibility of the reaction steps meaning the 
steric effects of the side chains control the reactive conformations and also 
lead to the thermodynamic all trans cyclobutane product. 
1.1.1 Recent developments 
Several mechanistic insights have been achieved in recent years through 
investigation of organocatalyzed enantioselective Michael additions to nitro-
olefins using proline derivatives. This has also important ramifications for 
enantioselective enamine [2+2] cyclisations. Patora-Komisarska5 identified 
cyclobutanes 27 as a ‘parasitic’ intermediate in the catalytic cycle (Figure 4); 
rather than the zwitterion intermediate 26 being hydrolysed and continuation 
of the cycle, it exists in equilibrium with the cyclobutane 27 thus 
slowing/stopping the cycle. This also further demonstrated the need for 
anhydrous conditions if cyclobutanes 27 are the desired product. They also 
demonstrated the instability and reversibility of the cyclobutane formations as 
heating of these nitrocyclobutanes 27 resulted in regeneration of the nitro-
olefin 25 and enamine 24. Seebach6 then went on to further investigate the 
catalytic cycles and cyclobutane formation, again demonstrating that 
enantiopure nitrocyclobutanes can be formed but they are unstable and 
addition of any water or proton source leads to the formation of enantiopure 
nitro-aldehydes. They also demonstrated that heating preformed 
cyclobutanes 30 with a different nitro-olefin 31 leads to incorporation of this 
new nitro-olefin into a cyclobutane 32 (Scheme 2) further showing the 
instability of the cyclobutanes and that they exist in equilibrium with their 
starting materials with each step of their formation being reversible. 
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Figure 4 Organocatalytic cycle 
 
Scheme 2 Reversibility of cyclobutane formation 
Along with a general lack of methods for enantioselective cyclobutane 
formation, these pieces of research inspired several groups to investigate 
organocatalytic enantioselective methods for cyclobutane formation as it 
demonstrated it was possible to form these although they appeared to be 
somewhat unstable. 
Two groups, Jørgensen7 and Vicario8 both published work using dienamines 
for organocatalyzed enantioselective [2+2] cyclisations (Scheme 3). They 
used proline-based amines to form enantiopure dienamines and a dual H-
bond donor for activation of the nitro-olefin. Jørgensen combined the proline 
and H-bond donor into one single catalytic molecule 35 whereas Vicario 
opted for 2 separate catalysts 39 and 40 and also an α-hydroxymethylene 
nitro-olefin 38 which simultaneously formed a hemi-acetal as an extra driving 
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force for the reaction. By using the dienamines, anhydrous conditions were 
not needed as the intermediate enamine would be hydrolysed, driving the 
reaction forward and turning over the catalyst (also allowing sub-
stoichometric amounts of amine to be used) rather than destroying the 
cyclobutane as seen in the above mechanistic studies and Bannock’s work. 
Both methodologies were able to produce a range of nitro cyclobutanes 
36/41 in excellent yield (both up to 90%) and good enantiomeric excess 
(Jørgensen: 99% e.e., Vicario: 85-95% e.e.). Although both these 
methodologies represent a step forward in enantioselective cyclobutane 
formations they are both fairly limited in substrate scope only able to form 
these very specifically substituted cyclobutane derivatives. 
 
Scheme 3 Jorgensen's and Vicario's dienamine [2+2] cyclisations 
1.1.2 Previous Work Within the Group 
Work within the group has focused on enantioselective enamine [2+2] 
cyclisations, but on a more direct equivalent to Bannock’s work and also 
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using esters as the electron withdrawing group on the alkene, focusing on 
one-pot reactions without the need for added catalysts. A range of chiral 
amines were screened to form chiral enamines (42a-g) and in turn 
enantiopure cyclobutanes, unfortunately several of these did not form 
enamines easily and when forced using TiCl4 as catalyst at reflux the formed 
enamines proved unreactive in a ‘Brannock’ style enamine [2+2] cyclisation. 
After this set back, ester auxiliaries were screened using both acrylate (45a-
d) and fumarate (46a-d), the reactions times were considerably slower than 
‘simple’ substrates but cyclobutanes were isolated from the reactions. 
Unfortunately the screened auxiliaries gave no or a low level of 
enantioselectivity (~1:1-1:3). Thus still leaving the need for a straightforward 
and widely applicable enantioselective enamine [2+2] cyclisation 
methodology. 
 
Figure 5 Chiral auxiliaries screened in enamine [2+2] cyclisations 
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2. Integrins 
2.1 Introduction 
The integrins are noncovalent heterodimeric type 1 transmembrane proteins 
found throughout the metazoa,9 where they are responsible for  cell adhesion 
to the extracellular matrix (ECM)10 and integrating cellular response to these 
adhesion events through transmembrane signalling. Therefore, integrins play 
key roles in proliferation, migration, apoptosis, survival, wound healing, 
thrombosis and immune response.11,12 
Integrin heterodimers are formed from an α and a β subunit. In simple 
organisms such as C. elegans there are 2 distinct integrins formed from 2 α 
and 1 β subunit10 but as higher organisms have evolved and so too has the 
complexity of cellular interactions and the need to closely control these 
processes, therefore a greater number of integrins have also evolved.13 
Mammals have 24 different integrins formed from 18 α and 8 β subunits. The 
mammalian integrins are usually divided into 4 subfamilies based upon ligand 
binding specificities and localisation, these are; the RGD (arginine glycine 
aspartic acid) receptors, laminin receptors, collagen receptors and the 
leucocyte integrins (Figure 6).  
All 24 integrins have been demonstrated to be required for healthy 
functioning of an organism through mouse gene knock out (KO) studies,10 
with all but 2 α subunits being  knocked out individually and their phenotypes 
classified (Table 1).14  Several KO’s showed very severe phenotypes such as 
those involved in laminin binding.14 Unsurprisingly β1 KO caused embryonic 
lethality; due to its ubiquitous nature this modification  KO’s half the integrin 
heterodimers present.14 KO within the collagen-binding and some RGD 
binding integrins led to less severe phenotypes suggesting greater overlaps 
in function or compensation from other integrins. 
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Figure 6 Integrin receptor subfamilies (taken from Sheldrake et al.15) 
The RGD binding integrins represent the largest subfamily, and are 
responsible for cell adhesion to the ECM during several vital biological 
processes and, through their signalling pathways control cell proliferation, 
survival and migration. This means these integrins play important roles in 
tissue development, remodelling and growth. The αv and α5 containing 
integrins are particularly important for angiogenesis,16 and knockout of either 
proves lethal due to their roles in developmental angiogenesis, 
lymphangiogenesis and vascular remodeling.17 The RGD motif is present in 
many different extracellular proteins, therefore this subfamily of integrins is 
highly promiscuous with each receptor recognising several different ligands 
(summarised in Table 2), although with varying affinities.18 This leads to 
some overlap/compensation of function particularly in the angiogenic, αv and 
α5 integrins but there is but also some specificity, αv is particularly important 
for developmental angiogenesis,17 α5β1 antagonists specifically inhibit 
lymphangiogenesis19 and αvβ8 is required for vascular development within 
the brain.16 The αv integrins can have similar angiogenic effects but do these 
through different signalling pathways.16 αv can also, to some extent, 
compensate for α5 knockout in mice.17 
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Knockout  Phenotype 
α1 V,F ↑ collagen synthesis  
α2 V,F developmental defects, delayed platelet aggregation 
α3 L kidney, lungs, cerebral cortex defects, skin blistering 
α4 L cardiac development, chorioallantois fusion defects 
α5 L embryonic vascular development defects 
α6 L cerebral cortex, retina defects, skin blistering 
α7 V,F muscular dystrophy 
α8 L/V,F small or absent kidneys, inner ear defects 
α9 L bilateral chylothorax 
α10 V,F growth plate chondrocyte dysfunction 
α11 V,F dwarfism 
αv L placenta, CNS, blood vessel defects, cleft palate 
αD - no KO 
αL V,F impaired leucocyte recruitment 
αM V,F impaired phagocytosis 
αX - no KO 
αE V,F inflammatory skin lesions 
αIIb V,F platelet aggregation defects 
β1 L inner cell mass deterioration 
β2 V,F impaired leucocyte recruitment, skin infections 
β3 V,F platelet aggregation defects, osteosclerosis 
β4 L skin blistering 
β5 V,F no apparent phenotype 
β6 V,F skin, lung inflammation, impaired lung fibrosis 
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β7 V,F abnormal Peyer’s patch, ↓ intraepithelial lymphocytes 
β8 L placenta, CNS, GI blood vessel defects, cleft palate 
V viable, F fertile, L lethal 
Table 1 Integrin knockout studies in mice (adapted from Zent et al.14) 
 
Table 2 RGD Binding integrins and their ligands (adapted from Sutherland et al.20) 
Integrin Ligands Role 
αvβ1 Fg, Fn, Vn, OPN, TGF-β Tissue fibrosis 
αvβ3 
Fg, vWF, Fn, Vn, BSP, 
OPN, TGF-β 
Angiogenesis, Bone resorption 
αvβ5 Fn, Vn, BSP, TGF-β Angiogenesis, vascular permeability 
αvβ6 Fn, Vn, OPN, TGF-β Lung physiology, TGF-β activation 
αvβ8 Vn, TGF-β 
TGF-β activation, angiogenesis, brain 
development 
α5β1 Fn, OPN Angiogenesis 
α8β1 Fn, Vn, OPN, TGF-β kidney/lung development 
αIIbβ3 Fg, Fn, Vn, vWF platelet aggregation 
Fg Fibrinogen, Fn Fibronectin, Vn Vitronectin, OPN Osteopontin, TGF-β Transforming 
Growth Factor-β, vWF von Willibrand Factor, BSP Bone sialoprotein 
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2.1.1 Integrin Structure 
 
Figure 7 Integrin structure 
The integrin αβ heterodimers comprise of a large extracellular domain, a 
transmembrane domain and a cytoplasmic tail. 
The extracellular ligand binding site is located in the large head group in the 
cleft between the 7-bladed β propeller on the α subunit and the i-like domain 
of the β subunit which contains a MIDAS (Metal-ion dependant adhesion site) 
in the majority of integrins. In the case of a subgroup of integrins known as 
the I-domain integrins, the ligand binding site is located in an additional I-
domain, ~200 amino acids inserted within the β propeller on the α subunit. 
The head group is supported upon 2 ‘legs’ followed by a transmembrane 
domain consisting of an α helix of ~25-30 amino acids. The cytoplasmic tails 
are generally short, <100 amino acids long, except in the case of β4 in which 
it is over 1000 amino acids long. The cytoplasmic tails contain important 
binding sites for intracellular proteins for signalling and adhesion, along with 
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an arginine-aspartate salt bridge between the α and β subunits required for 
stabilising the unactivated integrin. 
2.1.2 Integrin Activation 
Integrins exist in equilibrium between their extended form, with high affinity 
for extracellular ligands and their bent, low affinity form (Figure 8). This 
equilibrium is determined by the identity of the integrin and its environment, 
with some receptors predominantly activated, some unactivated and some in 
flux between the two forms. 
 
Figure 8 Crystal structures showing the low affinity bent form and high affinity extended form of 
αvβ3 (taken from Xiong et al.21) 
The two extreme forms have been confirmed by x-ray crystallography 
showing the unactivated form has bent ‘legs’ with the extracellular head 
group folded down towards the cell membrane and in the activated form the 
‘legs’ are straightened with the head group extending out above the cell 
surface. The exact mechanism and sequence of events leading from the bent 
to extended forms has not been fully confirmed with different theories being 
presented.14 The main differences being how and when ligand binding 
occurs; Lou et al. proposed the ‘switchblade’ model22 where ligand binding 
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occurs after conformational change to the extended form and Xiong et al. 
suggests the ‘deadbolt’ model23 where ligand binding occurs in the bent form 
which then causes the conformational change. 
On activation there is a disruption of the interaction of the two 
transmembrane helices14 and a separation of the cytoplasmic tails10 which 
interact with one another in the low affinity form through an Arg-Asp salt 
bridge.14 The separation of the cytoplasmic tails has been confirmed through 
FRET analysis24 and the importance of the salt bridge in stabilising the low 
affinity form has been proven through site directed mutagenesis where 
replacement of either amino acid with an Ala residue led to a permanently 
activated receptor.10 This separation in turn changes the affinity of the 
integrin for intracellular ligands. 
These changes in integrin conformation result in a change in affinity for its 
intracellular and extracellular ligands thus allowing the integrins to signal 
bidirectionally across the cell membrane. 
 
Figure 9 Integrin activation and signalling (taken from Srichai et al.14) 
Inside-out Signalling 
Inside-out signalling allows a cell to modulate its integrin mediated adhesion 
via internal stimulus. This activation is achieved by talin and kindlin binding 
the cytoplasmic tail of the integrin β subunit;14 this disrupts the salt bridge 
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with the α subunit causing the conformational changes and activation as 
described above.10 The importance of inside-out signalling is most evident in 
the case of αIIbβ3 present on platelets, which is required for thrombus 
formation. The integrins must be present in their inactive conformation to stop 
spontaneous thrombus formation but be able to be activated through inside-
out signalling in response to cellular cues to allow blood clotting when 
required. Talin and kindlin have been shown to be required for integrin 
activation25 as a loss of either of these proteins in the platelets lead to 
bleeding disorders similar to Glanzmann’s disease,26 which is a disease 
characterised by the inability to form blood clots properly, usually associated 
with the deletion or mutation of αIIbβ3. Their loss in leukocytes also leads to 
LAD, a severe immunodeficiency due to the inability of the leukocytes to 
adhere via the integrins. 
Outside-in Signalling 
Outside-in signalling allows messages to be passed into the cell caused by 
integrin binding to an extracellular ligand. When in the high affinity 
conformation, extracellular ligand binding stabilises this extended form and 
separation of the cytoplasmic tails. This allows talin and kindlin to bind the β 
subunit, and also leads to integrin clustering.14, 27 Focal adhesions are 
formed as other intracellular proteins such as FAK, vinculin and α actin 
associate with the integrin tail. This leads to a reorganisation of the 
cytoskeleton as the actin fibres assemble,27 these actin networks then allow 
the cell to adhere firmly to the ECM. The focal adhesions also contain several 
signalling proteins such as Ras, MAP kinase and FAK.28 Activation leads to 
signalling cascades resulting in a range of different outcomes including cell 
survival, proliferation and migration.10 An activated but unligated integrin can 
also relay signals into the cell to inform the cell it is not adhered which then 
activates intracellular pathways leading to anoikis or integrin mediated death. 
These two processes are important to ensure cells only grow in the correct 
environments and maintain tissue integrity. 
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2.1.3 αIIbβ3 
αIIbβ3 (also called GPIIbIIIa) is responsible for thrombus formation through its 
ability to bind fibrinogen. It is expressed solely in its inactive ‘bent’ form on 
platelets in healthy tissues with ~80,000 copies on the cell surface24 and 
more copies of the integrin stored inside the cell that can be recruited to the 
surface upon platelet activation.29 αIIbβ3 activation occurs through inside-out 
signalling in response to damage to the vasculature. This is triggered by 
soluble factors such as thrombin, thromboxane, epinephrine and adenosine 
diphosphate (ADP), which are released and interact with G-protein coupled 
receptors (GPCR) on the platelet surface,30,26 or by collagen binding to 
platelet α2β110. Once activated αIIbβ3 rapidly binds fibrinogen molecules which 
contain multiple RGD and KQAGDV sequences, allowing platelet-fibrinogen 
crosslinking.15,31 Binding also triggers outside-in signalling causing the 
release of further ADP and thromboxane which function in an autocrine loop, 
triggering further inside-out signalling and activation of more αIIbβ3 integrins 
allowing further crosslinking with fibrinogen,31 leading to stabilisation and 
growth of the thrombus.32 
Mutations in or deletion of αIIbβ3 lead to Glanzmann’s thrombasthenia which 
is characterised by increased bleeding times due to the platelets inability to 
crosslink with fibrinogen through αIIbβ3. The effects of Glanzmann’s 
thrombasthenia can range from severe, potentially life threatening 
haemorrhages to barely increased bleeding times. 
2.1.4 αvβ3 
αvβ3 plays important roles in angiogenesis and osteoclast mediated bone 
resorption. It is expressed in abundance on osteoclasts33 and on activated, 
but not quiescent endothelial cells.16 It is also present in low levels on some 
leucocytes and macrophages along with smooth muscle, intestinal and 
mature vascular cells.27 
Angiogenesis 
Angiogenesis is the formation of new blood vessels from the existing 
vasculature and αvβ3 is an important regulator of this, with pro and anti-
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angiogenic effects dependant on the cell type and its environment.34,35 In its 
pro-angiogenic roles, activated αvβ3 can bind Vn or Fn within the ECM 
triggering outside-in signalling leading to proliferation and migration along 
with activation of matrix metalloproteinases (MMP) which are required to 
remodel the ECM to allow for angiogenic sprout growth. The focal adhesions 
formed upon ligand binding also provide the cell with the physical traction to 
migrate through the ECM to assist sprout growth. αvβ3 can also indirectly 
have a pro-angiogenic effect through its complexation with vascular 
endothelial growth factor receptor 2 (VEGFR2) as upon complexation there is 
increased signalling from vascular endothelial growth factor (VEGF) binding 
the receptor.16 Along with stimulating angiogenesis αvβ3 also controls it 
through anoikis and integrin mediated death (IMD),35 as the new vascular 
sprouts grow, cells proliferate and migrate and it is important this process is 
controlled. If the new endothelial cells begin to grow in the wrong 
environment and αvβ3 is unligated then the cell will undergo apoptosis.36 αvβ3 
is also anti-angiogenic, binding anti-angiogenic agents such as 
thrombospondin, tumstatin, angiostatin and endostatin,28,34 although the 
exact basis of this effect has not been fully characterised.28 
Bone Resorption 
 
Figure 10 Osteoclast 
Osteoclasts are large multinuclear macrophage-related cells responsible for 
bone resorption.33 They bind osteopontin within the bone via αvβ337 allowing 
attachment and migration to areas for resorption.33 αvβ3 is required for the 
formation of the sealing zone around the resorptive pit and the accompanying 
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actin ring;33 this allows controlled excretion of lysosomal enzymes along with 
acid required for the breakdown of the bone matrix.38 αvβ3 polymorphisms 
that affect function correlate to an increased rate of fracture39 and αvβ3 
knockout mice show decreased bone resorption as a result of decreased 
osteoclasts migration along the bone and a lack of actin ring formation 
required for the sealing zone.38 This led to αvβ3 becoming a target for drug 
discovery in osteoporosis. 
2.1.5 β3 Integrins in Cancer 
During tumour progression there is often a change in integrin expression and 
activation on the tumour and associated cells. The β3 integrins are often 
upregulated and expressed in their active conformations and play an  
Integrin 
subunit/ 
heterodimer 
Cancer Type Effect Ref. 
β3 Melanoma ↑ progression Albelda40 
β3 Prostate ↑ angiogenesis Weis16 
αvβ3 Breast cancer 
↑ invasion, bone 
metastasis, migration 
Zhao41 
αvβ3 Glioblastoma ↑ invasion, migration D’Abaco42 
αvβ3 Cervical cancer ↓ progression free survival Chattopadhyay43 
αvβ3 Melanoma 
↑ growth, invasion, 
metastasis 
Petitclerc44 
Kumar27 
αvβ3 Prostate 
↑ metastasis (bone, lymph 
node) 
Cooper45 Weis16 
αvβ3 Pancreatic ↑ lymph node metastasis  Hosotani46 
αIIbβ3 Melanoma 
↑ tumour thickness, 
angiogenesis 
Trikha47 
αIIbβ3 Prostate ↑ invasion, metastasis Trikha48 
Table 3 β3 expression in cancer 
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important role in tumour progression, survival, invasion, metastasis and 
angiogenesis. Expression levels of the β3 integrins have been quantified in 
clinical tumours and tumour associated vasculature; increased expression 
has been shown to correlate to decreased survival, increased tumour grade 
and increased disease progression.16 
αvβ3 plays multiple roles in tumour angiogenesis (as detailed in Figure 11) 
and has the ability to mediate migration, invasion, survival and metastasis. 
Upregulation of αvβ3 has been shown to increase metastasis in melanoma, 
metastasis to bone in prostate45 and breast cancers41 and to lymph nodes in 
pancreatic cancer.46 αvβ3 expression has been shown to be increased at the 
invasive margins of glioblastomas and was seen to correspond to increased 
motility and invasion. The link between αvβ3 and invasion is also seen in 
breast cancers49 and melanoma.47 
 
Figure 11 αvβ3 roles in angiogenesis. αvβ3 recruits MMPs to break down the ECM, αvβ3 then 
regulates invasion, migration and then proliferation and survival of newly formed vessels. 
Taken from Danhier.50 
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αIIbβ3 expression is normally restricted to platelets but orthotopic expression 
has been seen clinically in melanoma and prostate cancer tumours47-48 and 
has been shown to increase metastasis, invasion and survival.12, 47-48 Much 
of the work on αIIbβ3 in cancer has focussed on melanoma where it has been 
shown to appear later in disease progression, compared with αvβ3 which is 
upregulated early on, and the constitutively activated integrin expression 
correlates with a switch to a vertically invasive tumour32 which is seen as a 
marker for disease progression and a worse prognosis.  Expression of αIIbβ3 
in mouse melanoma models, alongside αvβ3 has shown decreased apoptosis 
causing an increase of tumour growth by over 4 times.47 
Dual expression of the β3 integrins has been shown to decrease apoptosis 
but also increase angiogenesis therefore contributing to tumour growth in 2 
ways. The dual β3-expressing cells express both pro-angiogenic 
messengers; basic fibroblast growth factor (bFGF) and VEGF, whereas αvβ3 
expressing cells only express VEGF, thus leading to a greater angiogenic 
response.51 Along with increased angiogenesis, haematogenous metastasis 
is increased as both β3 integrins can bind fibrinogen, allowing cross-linking 
with platelets. This cross-linking can cause platelet activation and thrombus 
formation. 52,15 This firstly leads to greater survival time in the blood stream 
but also increased arrest in the blood vessels which is mediated through the 
β3 integrins. 
2.2 Medicinal Chemistry: RGD Binding Integrins 
Due to their roles in cancer and other pathologies the RGD binding integrins 
have received a lot of attention from drug discovery programmes.  
2.2.1 αIIbβ3 
αIIbβ3 and its role in thrombus formation was the first to gain significant 
attention and has led to 3 Food and Drug Administration (FDA) approved 
drugs; abciximab, a humanised monoclonal antibody developed by Lilly, 
Eptifibatide 47, a cyclic heptapeptide developed by COR therapeutics and 
Tirofiban 49, a small molecule developed by Merck. These 3 antagonists, all 
of which are administered intravenously, have been tested in clinical trials of 
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>12,000 patients undergoing percutaneous coronary interventions (PCIs) and 
shown a 16-56% reduction in ischemic events.53 Outside of the PCI setting 
these drugs have failed to show any benefit54 and due to the introduction of 
clopidogrel, a P2Y12 inhibitor they have found little use except high risk PCI 
patients.55 
Abciximab was the first antagonist to be approved and demonstrated αIIbβ3 
inhibition of platelet aggregation was safe and effective.56 It was developed 
from 7E3, a monoclonal antibody raised in mouse which was instrumental in 
validating the role of αIIbβ3 in early models.29 Interestingly abciximab is not 
highly specific not only having affinity for αIIbβ3 (IC50 6.2 nM) but alsoαvβ3 
(IC50 9.8 nM) and αMβ2 (IC50 160 nM)56,57 although the clinical consequences 
of this have not been fully investigated but it has been speculated this multi 
integrin activity increases effectiveness and safety.  This makes abciximab a 
useful test compound for investigating multiple integrin targeting and its effect 
on efficacy. 
Abciximab has also been studied in cancer. In a rat bone cancer model it was 
shown to have activity against a β3 negative tumour. Abciximab decreased 
tumour size by 35% and decreased blood vessel density58 by blocking host 
cell mediated angiogenesis rather than having a direct tumour effect. In 
mouse xenograft models Abciximab has also been shown to have direct 
antitumour effects as well.59 β3 expressing melanoma growth was decreased  
in vivo through a direct tumour effect as Abciximab has no activity against 
mouse integrins. These two studies demonstrated the utility of β3 antagonists 
in cancer treatment as they can directly and indirectly slow tumour growth of 
β3 positive or negative tumours. 
At the time of development the crystal structure of αIIbβ3 had yet to be solved 
and therefore early drug discovery efforts relied upon ligand pharmacophore 
modelling.  
Eptifibatide 47 was developed based upon the peptide barbourin, a 
disintegrin found in snake venom that had been shown to be highly potent 
and specific for αIIbβ3.29 The Lys-Arg-Asp (KGD) sequence was shown to give 
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barbourin its high potency and selectivity60,61 and this pharmacophore was 
used as the basis for thedesign of Eptifibatide’s 47. 
Eptifibatide 47, has also been shown to be effective in vivo at decreasing 
tumour volume in bone and reducing bone destruction in a mouse breast 
cancer model but has not progressed to clinical trials for this indication due to 
the limitations of constant i.v. infusion and risks of bleeding side effects.62 
 
Figure 12 Eptifibatide 
Tirofiban 49 was developed by Merck from hit compound 48, discovered by 
conducting a subset search of their compound library for compounds that 
contained a pharmacophore of acidic and basic groups separated by 10-12 
Å, the distance between the Arg and Asp side chains in the RGD 
sequence.63 The tyrosine scaffold was retained but with a changed basic 
pharmacophore and hydrophobic side chain on the Asp mimetic which both 
helped increase affinity. Importantly, this was the first compound to identify 
the importance of a hydrophobic sidechain present on the Asp mimetic. It 
was determined that N-α-sufonamides gave the highest activity at this 
position and it was shown to bind in a hydrophobic ‘exosite’ next to the 
MIDAS site in the β3 subunit.64 
 
Figure 13 Development of Tirofiban 
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After success with intravenously administered drugs in the PCI setting the 
search for orally administered drugs began to expand the utility of αIIbβ3 as a 
therapeutic target. Up to this date this search has categorically failed with no 
orally active αIIbβ3 antagonists being approved by the FDA and clinical trials 
of some agents leading to a greater mortality rate. Of the 5 large phase III 
trials of oral antagonists, 2 trials demonstrated no improvement over 
treatment with aspirin and 2 other trials were terminated due to an increase in 
mortality with an overall 35% relative increase.65 A general increase in 
thrombotic complications was also seen using these oral antagonists.66 This 
lead to the almost complete abandonment of the field by pharmaceutical 
companies. 
This result has spurred much research and review in the area to explain and 
overcome this issue.54-55, 67The trial results seems to stem from paradoxical 
platelet activation by the antagonists and a poor understanding of the 
antagonists pharmacokinetic (PK) profiles. At low concentrations the 
antagonists have the ability to act as partial agonists.66 With intravenous 
antagonists this is not seen as the plasma concentration is kept fairly 
constant but due to the poor bioavailability seen with many of the oral 
antagonists there are large peak to trough drug concentration ratios. At lower 
drug concentrations the antagonists still bind and have been shown to cause 
the conformational change to the active extended form of the integrin 
detected by ligand induced binding site (LIBS) specific antibodies.29 This can 
then act as a pre-activation along with receptor clustering, and as these are 
reversible inhibitors the antagonists can unbind leaving the activated integrin 
able to bind fibrinogen and begin forming thrombosis.55 At higher 
concentrations unbinding does not occur as the equilibrium is in favour of the 
bound antagonist. The conformational change upon antagonist binding can 
also trigger outside-in signalling in a similar manner to fibrinogen.68,66 This 
outside-in signalling can lead to an activated platelet which can then go on to 
release pro-thrombotic signalling molecules such as thromboxane which 
stimulate further platelet activation.68 
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To overcome these problems, a better understanding of the PK of the 
antagonists is necessary along with higher affinity compounds to keep the 
equilibrium shifted towards the bound form. Also, by just targeting the 
activated receptor, or designing compounds that do not cause conformational 
change to the activated form would help eliminate this issue with paradoxical 
activation. This is obviously a complex task and the structural information 
required for the rational design of antagonists that do this has only recently 
become available. 
Lamifiban 50 has been developed by Roche and has been shown to bind 
αIIbβ3 without causing a conformational change to the activated receptor and 
thus paradoxical platelet activation.69 Also an antibody developed by 
Schwarz et al.70 has been shown to only bind activated αIIbβ3 with no 
paradoxical activation. Although these strategies could lead to improved and 
safer αIIbβ3 antagonists the full clinical implications of lamifiban 50 and the 
activation specific antibody have not yet been fully investigated.  Nor has the 
structural features that allow lamifiban 50 to bind without causing a 
conformational change been identified. 
 
Figure 14 lamifiban 50 
2.2.2 αvβ3 
A vast range of agents targeting αvβ3 have been investigated in several 
disease types; rheumatoid arthritis, restenosis, osteoporosis and cancer. 
None of these agents have been approved by the FDA but several have 
reached clinical trials or shown promise in pre-clinical investigation. The area 
of αvβ3 antagonism has again been thoroughly reviewed30, 37, 39 over the past 
years and in particular its roles in cancer treatment has received a lot of 
attention.15, 52, 59, 71 
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Again, as for αIIbβ3, antibodies have been developed for αvβ3. The most 
extensively studied is LM609 a monoclonal antibody raised in mouse which 
has been further developed to give Vitaxin and Vitaxin II, both humanised 
with lower antigenicity and higher affinity for αvβ3.72 
LM609 has been shown in vivo to block angiogenesis, invasion and 
metastasis and cause apoptosis in cells in newly formed blood vessels as 
well as tumours.73,40,44 Despite promising preclinical data LM609 was not 
progressed to the clinic due to its low affinity for αvβ3 and due to concerns 
over antigenicity.59 Vitaxin entered the clinic with 2 phase I trials being 
undertaken on solid tumours (17 patients with stage IV cancers74 and 15 
patients with advanced gastrointestinal tumours75). In both trials Vitaxin was 
very well tolerated with no serious adverse events being recorded, due to this 
and a shortage of material no maximum tolerated dose (MTD) was 
established. In the first trial one partial response was recorded and 7 patients 
had stable disease with one remaining stable for 22 months. In the second 
trial no significant responses were recorded. Vitaxin has also been shown to 
block SMC migration and reduce neointimal hyperplasia in vivo after 
angioplasty in animal models and due to this has entered the clinic for this 
indication too.76 Problems with the manufacture and stability of Vitaxin have 
meant not much further clinical work has been conducted.27 Vitaxin II has 
entered phase I and II clinical trials. The phase I trial in solid tumours saw a 
third of patients experiencing stable disease >6 months with no serious 
adverse events.77 The phase II trial was in combination with dacarbazine or 
as mono-therapy for metastatic melanoma,78 both treatment arms saw similar 
responses of around 40% and again a low incidence of adverse events 
(<10% of patients) were seen. It is not clear whether this could be considered 
to be an improvement upon standard treatment though.  
SmithKline Beecham developed a range of αvβ3 antagonists based upon a 
phenyl fused 7-membered ring for varying indications. SB265123 51 was 
screened in vivo in a rat model of osteoporosis where it was the first agent to 
show inhibition of bone resorption in rat. SB265123 51 was given twice daily 
orally and had 100% bioavailability with a long half-life and low clearance, 
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thus showing that good PK and oral administration can be achieved.79 
SB273005 6 also showed promise in vivo in a rat model of inflammatory 
arthritis, a twice daily oral administration led to a decrease in joint swelling 
but also the destruction of cartilage and bone.80 
Figure 15 αvβ3 antagonists 
L000845704 (also known as MK-0427) 53 was also shown to be orally active 
in a rat model of osteoporosis and showed an increase in bone mineral 
density (BMD) by ~20%, equivalent to alendronate (a FDA approved 
treatment for osteoporosis).81 L000845704 53 then entered clinical trials in 
post menopausal women, it was well tolerated (only 6/227 patients were 
removed from the trial), orally active and showed dose dependant increases 
to BMD in the lumbar spine, hip and neck BMD.82 L000845704 53 also 
entered a phase I/II trial in prostate cancer bone metastasis. L000845704 53 
was again shown to be safe and well tolerated in patients and showed a 
reduction in bone turn over associated with bone metastasis.83 
Cilengitide 55 is the most studied of the αvβ3 antagonists reaching phase III 
trials before development unfortunately being stopped in 2014. Its 
discovery,84 progress and development through clinical trials, particularly in 
the area of glioma and glioblastoma has been thoroughly reviewed.85 
Cilengitide 55 is a cyclic pentapeptide αvβ3 antagonist developed by Kessler 
et al. and Merck in 1995.84 At the time no crystal structure of αvβ3 was 
available (it was not published until 2001 by Xiong)21 and therefore 
Cilengitide 9 was developed based upon the RGDFV sequence found in Vn 
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and Fn using a special screening technique incorporating one D-amino acid 
to induce a βII’ turn at different points in the cyclic peptide, allowing different 
conformations to be accessed without affecting the chemical nature of the 
peptide. This led to the discovery of EMD 66203 54 (c(RGDfV)) which 
showed increased activity of 2 orders of magnitude over the linear sequence 
for αvβ3 and excellent selectivity over αIIbβ3. An N-methyl scan was then 
performed on EMD 66203 54, with a methylated valine showing to increase 
activity giving Cilengitide 55 c(RGDf-N(Me)V). This ligand based approach 
and cyclic peptide optimisation techniques proved very successful, once 
Xiong et al. published the αvβ3 crystal structure, Cilengitide 55 was shown to 
adopt a conformation in solution almost identical to that when bound to the 
integrin.86 
Cilengitide 55 has affinity for αvβ3 (IC50 0.58 nM) but also αvβ5 (IC50 37 nM) 
and in vitro showed the ability to cause apoptosis in cells though inhibiting Vn 
binding.87In vivo Cilengitide 55 blocked tumour growth and metastasis, 
decreased vessel density and decrease osteolysis in mice.88,89,90 and also 
showed enhanced effects against brain tumours, presumably due to the 
higher levels of angiogenesis and increase in Vn levels. Unfortunately it was 
also shown in pre-clinical evaluation that Cilengitide 55 suffered from 
paradoxical integrin activation as seen with the αIIbβ3 antagonists, when 
constant low doses were administered increased tumour growth and 
angiogenesis were seen, suggesting possible therapeutic limitations.91 
Cilengitide 55 entered the clinic in phase I trials for a range of different 
tumour types and was shown to be well tolerated and safe with no dose 
limited toxicities and no MTD was established. A group of patients showed 
some response (3 partial, 26 stable disease) all of which had brain tumours, 
this led to phase II trials looking at glioma and glioblastoma along with 
metastatic melanoma and prostate cancer.30 These trials again showed 
Cilengitide 55 to be well tolerated but with low response rates leading to the 
investigation of combination treatments and a phaseI/II trial in glioblastoma 
alongside temozolomide (TMZ) and radiotherapy.92 Adding Cilengitide 55 to 
the treatment increased 6 month progression free survival from 54% to 69% 
 28 
 
and a subset of patients with O6-methylguanine-DNA methyltransferase 
(MGMT) promoter methylation showed an increase to 91%. This led to a 
phase III trial, again in combination with TMZ and radiotherapy, in patients 
with newly diagnosed glioblastoma with MGMT methylation. Cilengitide 55 
was again well tolerated but showed no increase in median overall survival 
as compared to TMZ and radiotherapy alone and has led to the termination 
of development of Cilengitide 55 as an anticancer agent.93 It is important to 
state the authors do not consider this as a failure for integrin antagonists in 
cancer therapy but just for Cilengitide 5593 and attribute it in part to poor PK 
and the need for better preclinical models to understand the behaviour 
compounds’ in biological systems and to therefore better design trials.94 
2.2.3 Dual/Multi Integrin 
Although most of the medicinal chemistry efforts towards the integrins have 
focused on gaining selectivity for a particular receptor (although other 
antagonists have been shown to have dual activity they were designed as 
single agents eg. abciximab, cilengitide), several compounds have been 
purposefully designed as dual/multi integrin antagonists with the rationale of 
them having more efficacy due to them simultaneously targeting more 
processes and potentially removing built in compensation mechanisms.  
 
Figure 16 Dual/Multi integrin antagonists 
MN447 10 was developed from an αIIbβ3 antagonist to target both β3 integrins 
and is the only such compound specifically designed as a dual antagonist. It 
was developed for the treatment of acute ischemic events and shown to be 
active in vivo for the treatment of thromboembolus-induced dysfunction of the 
heart muscle. MN447 56 is currently in preclinical development.  
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The exact structure of GLP0187 has not been published but from patent 
examination it appears to be molecule 57. It is targeted at 6 integrins 
including the αv receptors for the treatment of bone metastasis in prostate 
and breast cancers.95 In vivo, GLP0187 57 has reduced both angiogenesis 
and osteoporosis in bone metastasis and in phase I trials was shown to be 
safe and reduce biomarkers of bone turnover in healthy volunteers. It is 
currently progressed to trials in patients with late stage cancers.95 
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2.3 Discovery of Dual β3 Integrin Antagonist 
Lead Compound 
A small (~70 compound) library of RGD mimetics had previously been 
synthesised in the Sheldrake lab. The library was based upon a cyclobutane 
scaffold which was shown through molecular modelling to hold the Arg and 
Asp mimetics at the appropriate distance and in the correct geometry to 
mimic the RGD sequence binding to the β3 integrins. Cyclobutanes are also 
underused in medicinal chemistry and this gives an opportunity to explore 
their uses and properties and provide a contrast to the more traditionally 
used heterocyclic scaffolds seen in the literature. A range of heterocyclic Arg 
mimetics (chosen to reduce the polarity) and Asp mimetics seen in published 
antagonists were selected and the library synthesised. Compounds were 
prepared as methyl esters to facilitate purification and improve bioavailability; 
cellular esterases readily cleave esters to release the active carboxylic acid. 
 
Figure 17 In house library of RGD mimetics 
Sk-Mel-2, a αvβ3 expressing melanoma cell line was selected and the library 
was screened for cytotoxicity using an MTT assay. Compounds were then 
screened in a fibronectin binding assay at non-toxic doses (to ensure loss of 
adhesion not cell death was being measured). Active compounds were then 
screened in an ELISA assay for αIIbβ3 antagonism; The methyl esters were 
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chemically cleaved (HCl) to the corresponding carboxylic acids (as the 
methyl esters were not active or cleaved in the assay conditions). 
From these assays several compounds of interest were highlighted as potent 
antagonists of either αvβ3 or αIIbβ3, but ICT9055 69 (Figure 18) emerged as a 
hit compound for development of a dual β3 antagonist. ICT9055 69 was non-
toxic to Sk-Mel-2 cells at lower doses (although becoming toxic at higher 
doses) and showed good inhibition of both αvβ3 and αIIbβ3 adhesion and αvβ3 
mediated migration. 
 
ICT9055 (R = Me) 69 
ICT9064 (R = H) 70 
Cytotoxicity (Sk-Mel-2) IC50 18.7 µM 
αvβ3 adhesion             
(Fn, Sk-Mel-2) IC500.34 ± 0.33 μM 
αvβ3 migration            
(M14) IC50<0.1 μM 
 (ICT9064 70) 
αIIbβ3 adhesion 
(Fg, ELISA) 
IC50 1.17 ± 0.9 μM 
Figure 18 ICT9055 69 
This small library also began to develop an SAR around these compounds. 
The tetrahydronaphthyridine 63 Arg mimetic proved to be highly active 
against αvβ3 with good αIIbβ3 activity, and the naphthyridine 62 and amino 
pyrimidine 58 proved more active against αIIbβ3 but with little to no activity 
against αvβ3. This shows that selectivity can be tuned by changing the 
hybridisation of the nitrogens within the Arg mimetic integrin, altering their 
orientation and potentially allowing either single point or two point hydrogen 
bonding. 
The geometry of the cyclobutane proved not to be highly important for activity 
which contrasted with the initial molecular modelling which predicted much 
higher activity for the trans compounds. The trans compounds 65 were 
slightly more active in general over the cis 64 but the slight gain in activity is 
offset by the difficulty of synthesis as trans selective reduction proved to be 
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much less efficient. The length of the linker was shown to be fairly flexible in 
the aminopyrimidine series 58 with all compounds having similar activity 
although a 1 carbon shorter analogue of ICT9055 69, ICT9080 71 resulted in 
a large loss of activity. This may be explained by the greater flexibility in the 
amino pyrimidine sidechain being able to accommodate longer linker units. 
The Asp mimetic proved to be very important for high activity. As shown with 
Tirofiban 49 (Figure 13) the hydrophobic sidechain increased activity. When 
β-alanine 68a was used the compounds were almost inactive, and the 
unnatural enantiomers 67 were around 10 fold less active than the natural 
enantiomers 66. As the size of the side chains was increased so did the 
activity (Ph<tolyl<mesityl). The phenyl 68b and pyridyl 68c substituted β-
alanine sidechains gave highly insoluble compounds with little to no activity. 
 
Figure 19 SAR of the hit compound 
The aim of this project was to take the hit compound ICT9055 69 and further 
develop the SAR around it; particularly looking at the cyclobutane based 
linker, its length and orientation, and also the identity of the Arg and Asp 
mimetics. 
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2.4 Results and Discussion: Synthesis and 
Evaluation of RGD Mimetics 
A range of RGD mimetics were synthesised and initially screened for αvβ3 
antagonism in the fibronectin adhesion assay. Interesting compounds were 
then further screened in functional assays for αvβ3 antagonism; a spheroid 
invasion assay through collagen (U87 cell line) and a scratch assay to look at 
migration (M14 cell line). Compounds were also screened for αIIbβ3 binding 
fibrinogen inhibition using an ELISA assay with purified integrin αIIbβ3 binding 
fibrinogen. 
2.4.1 Cyclobutane Linker Unit 
From the original library, a minimum length of linker had been found as the 
hit compound ICT9055 69 proved to be considerably more active than its 
shorter counterpart ICT9080 71 but further investigation of the linker was 
planned; compound 73 to investigate extending the linker between the Arg 
and Asp mimetics, and compounds 72 and 74 to maintain approximately the 
same length linker as ICT9055 69 but with a different orientation of hydrogen 
bonding groups within the molecule. 
 
Figure 20 Linker length and orientation 
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The 2 differing length Arg-Gly mimetics 84a-b were synthesised in the same 
manner (Scheme 4) starting from ethyl levulinate 75a or ethyl-4-
acetylbutyrate 75b, firstly protecting the ketone as the cyclic acetal to allow 
reduction of the ester to give alcohols 77a-b, before oxidation and formation 
of the cyclobutenes 80a-b. The cyclobutenes 80a-b were hydrogenated 
using palladium on charcoal selectively gaining the cis substituted 
cyclobutanes 81a-b due to the steric bulk of the acetal side chain controlling 
which face of the ring was presented to the solid surface, confirmation of the 
relative stereochemistry was achieved via nOe spectroscopy. Deprotection of 
the cyclic acetal with acid gave ketones 81a-b which were subjected to the 
Friedlander synthesis to give naphthyridines 84a-b.  
 
Scheme 4 Synthesis of naphthyridine Arg-Gly mimetics 
The Asp mimetics 88a-b were synthesised from glutamine, first by formation 
of the sulfonamides 86a-b, followed by Hofmann rearrangements to give the 
primary amines 87a-b and then esterification using thionyl chloride and 
methanol. 
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Scheme 5 Synthesis of Asp mimetics 
Naphthyridine RGD mimetics 89a-b and 90a-b were then synthesised via an 
EDCI catalysed amide formation from cyclobutanes 84a-b (after ester 
hydrolysis) and Asp mimetics 88a-b. The terminal naphthyridine ring was 
then selectively reduced (no reduction of the other ring was ever seen) with 
hydrogen/platinum oxide to give the target tetrahydronaphthyridine RGD 
mimetics 72a-b and 73a-b. From the reduction to 73b a small amount of the 
trans substituted cyclobutane 73b’ was also isolated, which presumably 
formed as a minor product during the cyclobutene hydrogenation and only 
became separable at this stage. 
Scheme 6 Synthesis of RGD mimetics 
The ‘reversed amide’ compounds 74a-b required cyclobutylamine 91 which 
was formed from cyclobutane 84b via hydrolysis of the ester followed by 
Curtius rearrangement. At first this conversion proceeded in poor yield, but 
after optimisation (Table 4) quantitative yield was achieved. The initial poor 
yield appeared to be partially due to decomposition in the reaction mixture 
during longer reaction times but also poor recovery due to low solubility in 
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diethyl ether with many extractions (>10) required to remove all 
cyclobutylamine 91 from the aqueous layer. 
 
Scheme 7 Curtius rearrangement to give cyclobutamine 91 
 
Entry 
84b (mmol):H2SO4 
(ml):CHCl3 (ml) 
Time 
at 45 
°C 
Time 
at RT 
Work Up 
Yield 
91 
1 1:1:2 5.5 h 17 h 
aq→pH 13, 
extract Et2O 
19% 
2 1:2:4 5 h 17 h 
evaporate, 
aq→pH 14, 
extract Et2O 
41% 
3 1:2:4 5 h 45 min 
evaporate, 
aq→pH 14, 
extract DCM 
71% 
4 1:2:4 5 h 0  
aq→pH 14, 
extract DCM 
100% 
Table 4 Curtius rearrangement optimisation 
Asp mimetics 93a-b were synthesised from Asp-(OMe) 92 and the 
appropriate sulfonyl chloride. These were then coupled with cyclobutamine 
91 using EDCI to give the desired naphthyridine RGD mimetics 94a-b. In 
both cases an undesired side reaction occurred. The side product was shown 
to be succinimide 95a-b; 1H NMR spectroscopy showed a loss of the 
methoxy signal from the methyl ester and an NH peak, and mass 
spectrometry showed a loss of 32 amu (MeOH). COSY NMR then showed 
the cyclobutamine NH which had been lost not the Asp mimetic sulfonamide 
NH. 
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Scheme 8 Synthesis of Asp mimetics 93a/b 
 
 
Scheme 9 Synthesis of RGD mimetics 
When using DMF as solvent, the desired RGD mimetics 94a-b and 
succinimides 95a-b were formed in similar yields. Switching the reaction 
solvent to DCM gave better ratios of desired to undesired compounds in both 
cases. 
Entry Starting Material 
 
 
Solvent Yield 
 
 
1 Ar = Ph (93a) DMF 34% (94a) 22% (95a) 
2 Ar = Ph (93a) DCM 44% (94a) 18% (95a) 
3 Ar = Mes (93b) DMF 44% (94b) 46% (95b) 
4 Ar = Mes (93b) DCM 43% (94b) 10% (95b) 
Table 5 Effect of solvent on the amide formation 
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The desired naphthyridine RGD mimetics 94a-b were hydrogenated to give 
the target tetrahydronaphthyridine RGD mimetics 74a-b. From the reduction 
of 94a, a small amount of the trans isomer 74a’ was isolated (trans 
orientation of sidechains confirmed by NOESY) which had not been seen 
during the previous steps but presumably formed during the Curtius 
rearrangement. Succinimide compounds 95a-b were also reduced to their 
corresponding tetrahydronaphthyridines and, in the case of 
phenylsulfonamide 95a, a small amount of 74a was formed from opening of 
the succinamide ring during the reduction. 
2.4.2 Results: Cyclobutane linker 
The synthesised RGD mimetics (Table 6) (the unexpected succinamide 
containing analogues 95/96 will be discussed in the following section on Asp 
mimetics) were screened using an MTT assay for cytotoxicity against the 
melanoma cell line, SK-Mel-2 (Figure 22). The MTT assay is a colourmetric 
assay which relies on the ability of living cells to reduce the MTT to its 
formazan salt which is purple. Therefore the absorbance as of sample 
prepared from this directly correlates to the number of living cells. All 
compounds were shown to be largely non-toxic (>80% cell survival) at 5 μM 
with some compounds ICT9082 94a and ICT9084 94b being non-toxic at 
even higher concentrations (100 μM and 50 μM respectively). All the 
compounds were also shown to be less cytotoxic than hit compound ICT9055 
69 and control compound cRGDfV 54. 
A selection of compounds was then screened for αvβ3 antagonism in the 
fibronectin adhesion assay at non-toxic doses to ensure any decrease in 
adherent cell count was from loss of adhesion not cell death. The cells are 
plated on fibronectin coated plates and incubated, any unadhered cells 
(caused by antagonism of αvβ3) are then washed away and the remaining 
cells are quantified using MTT in the same manner as the cytotoxicity assay. 
Some of the SAR developed in the original library screen was further 
reinforced. Naphthyridine compounds were considerably less active than 
their tetrahydronaphthyridine counterparts, mesityl sulfonamides were more 
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active than the phenyl sulfonamides and the trans analogues were slightly 
more active than the cis. 
Unfortunately none of the new series were more active than ICT9055 69 
although ICT9092 72b, ICT9094 73b ICT9095 73b’ had good activity and 
were also considerably less cytotoxic. It is worth noting due to the variability 
of cell based assays (~±10%) that some of these compounds, particularly 
ICT9092 72b remain of interest for potential further development. This series 
has further developed the SAR around the linker, showing that hit compound 
ICT9055 69 is the appropriate length for αvβ3 antagonism with the previously 
synthesised shorter compound ICT9080 71 and longer compound ICT9094 
73b resulting in a loss of activity although extending the linker appears to 
bebetter tolerated presumably due to an amount of flexibility in the molecule 
allowing it to bend into an appropriate configuration to fit the binding site. 
Changing the orientation of linker also results in a loss of activity, shortening 
the Arg mimetic and lengthening the Asp (ICT9092 72b) resulted in small 
drop of activity and ‘reversing’ the amide (ICT9087 74b) caused a greater 
loss of activity (IC50 1.2 ± 0.9 μM cf. 0.34 ± 0.3 μM). 
 
Figure 21 Linker unit SAR 
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 Structure 
ICT 
Number 
 Structure 
ICT 
Number 
89a 
 
ICT9097 72a 
 
ICT9091 
89b 
 
ICT9096 72b 
 
ICT9092 
90a 
 
ICT9100 73a 
 
ICT9101 
90b 
 
ICT9093 73b 
 
ICT9094 
   73b’ 
 
ICT9095 
94a 
 
ICT9082 74a 
 
ICT9085 
   74a’ 
 
ICT9086 
94b 
 
ICT9084 74b 
 
ICT9087 
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Table 6 RGD mimetics (modified linker) 
 
Figure 22 Cytotoxicity assay Sk-Mel-2: RGD mimetics (modified linker) 
 
Figure 23 Adhesion assay Sk-Mel-2: RGD mimetics (modified linker) 
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2.4.3 Aspartic Acid Mimetic 
The Asp mimetic and particularly a hydrophobic sidechain had been shown 
to be very important for β3 binding, both in the literature (as shown with 
Tirobiban 49)64 and also within the in house library. The original library had 
shown that sulfonamides at the α position with S stereochemistry (and not R) 
were active and simple phenyl or pyridyl sidechains at the β position were 
highly insoluble and generally inactive but sulfonamides at the β position had 
not been investigated. The succinimides 95/96 formed as a side product 
above proved to be surprisingly active (Figure 28). The RGD sequence and 
mimetics of it have been shown to interact with the MIDAS in the β3 subunit 
via a carboxylate group therefore compounds lacking this were not expected 
to be active. This led us to believe the succinimide ring may have been 
opening in the assay conditions (Figure 24) to give either the α sulfonamide 
74 or the β sulfonamide 97 which was then the active antagonist. The 
succinimides 96 appeared considerably more active than the α sulfonamide 
74, therefore the β sulfonamides 97 were targeted for synthesis as it was 
believed this could be the active antagonist derived from 96. 
Figure 24 α sulfonamide, succinimide and β sulfonamide 
The β phenyl sulfonamide 47a was synthesised in the same manner as the α 
sulfonamides 93 but several attempts to form the mesityl analogue 99b 
failed. It is believed this unreactivity was due to the steric bulk of the tert-butyl 
ester and mesityl groups stopping the reaction. 
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Scheme 10 Synthesis of Asp mimetic 
The RGD mimetics were then synthesised by coupling Asp mimetic 99a with 
cyclobutamine 91 using EDCI to give naphthyridine RGD mimetic 100 which 
was then hyrodgenated to tetrahydronaphthyridine RGD mimetic 101. The 
carboxylic acid analogues 102/97a were also synthesised by treatment with 
TFA as it was unlikely that the tert-butyl esters would be efficiently cleaved in 
the adhesion assay. 
 Scheme 11 Synthesis of Arg-Gly-Asp mimetic 
2.4.4 Results: Aspartic Acid Mimetic 
The β phenyl sulfonamides were synthesised and along with the 
succinimides were screened for cytotoxicity. All were seen to be non-toxic at 
the screening concentration and were less toxic than hit compound ICT9055 
69 and control compound cRGDfV 54. The compounds were then screened 
for αvβ3 antagonism in the fibronectin adhesion assay. As the β mesityl 
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sulfonamide was not synthesised, ICT9057 103 the phenyl sulfonamide 
analogue of ICT9055 69 has been included for comparison. 
The succinimide compounds ICT9088 96a and ICT9089 96b were active, 
more active than the targeted ‘reversed’ amide analogues 74a/b at a single 
concentration (although the IC50 was calculated to be similar; ICT9089 1.8 ± 
1.0 μM cf. ICT9087 1.2 ± 0.9 μM). They were also as active as hit compound 
ICT9055 69 and its phenyl analogue ICT9057 103 at 5 μM. 
 
Figure 25 Comparison of 'reversed' amide, succinimide and hit compounds 
The β sulfonamides were screened as the tert-butyl esters 100/101 and the 
carboxylic acid 102/97a with each having similar activities (although the 
esters appeared slightly more active) suggesting the esters were efficiently 
cleaved in the assay conditions. The tetrahydronaphthyridine compound 
ICT9099 101 had slightly improved but similar activity to the succinimide 
analogue ICT9088 96a and ICT9057 103. This suggests that the 
hypothesised succinimide ring opening to an active form was occurring 
although further investigation is needed to confirm this. This would involve 
collaboration with the ICT PKPD group to identify and profile the metabolites 
obtained when compounds are incubated with Sk-Mel-2 cells. It also makes 
the mesityl analogue 97b worth revisiting after failed attempts to synthesise 
it. 
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Figure 26 Comparison of succinimide 96a, β sulfonamide and ICT9057 69 
Table 7 RGD mimetics (modified Asp mimetic) 
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ICT9103 
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Figure 27 Cytotoxicity assay Sk-Mel-2: RGD mimetics (modified Asp mimetic) 
 
Figure 28 Adhesion assay Sk-Mel-2: RGD mimetics (modified Asp mimetic) 
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2.4.5 Arginine Mimetic 
In an effort to lower the molecular weight and probe what is necessary for 
activity in the Arg mimetic, aminopyridine RGD mimetics 104a/b were 
targeted for synthesis.  
 
Figure 29 Modification to the Arg mimetic 
Firstly Boc protection followed by methylation of methyl aminopyridine 105 
gave 106. The planned alkylation of methyl pyridine 106 with allyl bromide 
10796 proved very capricious. Original attempts gave the desired alkene 108 
in modest yield along with some recovered starting material 106. Attempts to 
optimise this reaction proved fruitless; increasing reactions times from 75 to 
130 minutes appeared to improve this although further increasing them to 
150 minutes led to a drastic drop in yield and decomposition (Table 8 
Entries1-3). Attempts to then repeat this reaction yielded little or no product 
and varying amounts of recovered starting material (Table 8 Entries 4-6). 
Although attempts to optimise this reaction failed enough material of alkene 
108 was synthesised to allow continuation of the synthesis. Hydroboration of 
the alkene 108 followed by oxidation and [2+2] cyclisation gave cyclobutene 
111, before hydrogenation gave cis cyclobutane 112. 
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Scheme 12 Synthesis of aminopyridine Arg-Gly mimetic 
 
 
Entry Deprotonation 
of 106 at -78 °C 
(min) 
Reaction with allyl 
bromide 107 
Result 
Time 
(min) 
Temp. 
(°C) 
SM 106 Product 
108 
1 30 75 -78 22% 55% 
2 40 130 -78 - 68% 
3 50 150 -78 - 23% 
4 40 130 -78 94% - 
5 60 140 -78 69% - 
6 50 180 -78 → -30 57% 29% 
Table 8 Alkylation of aminopyridine 106 
The Asp mimetics 116a/b were synthesised from asparagine 113 in the same 
manner as Asp mimetics 88a/b (Scheme 5). 
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Scheme 13 Synthesis of Asp mimetic 
Ester hydrolysis of cyclobutane 112 followed by EDCI mediated coupling with 
Asp mimetics 116a/b gave Boc protected RGD mimetics 117a/b which were 
deprotected using TFA to yield amino pyridine RGD mimetics 104a/b. 
 
Scheme 14 Synthesis of Arg-Gly-Asp mimetic 
2.4.6 Results: Arginine Mimetic 
The amino pyridine RGD mimetics 104a/b were screened for cytotoxicity 
(Figure 31), they were slightly more toxic than the other compounds prepared 
but still reasonably non-toxic and less toxic than hit compound ICT9055 69. 
In the adhesion assay both compounds performed well with high activity. This 
was unexpected as the mesityl sulfonamides are usually much higher in 
activity than their phenyl analogues. 
Mesityl sulfonamide ICT9073 104b (IC50 0.6 ± 0.7 μM) was essentially 
equipotent (within the variability of the assay) with hit compound ICT9055 69 
(IC50 0.34 ± 0.3 μM) and phenyl sulfonamide ICT9072 104a was more active 
than its tetrahydronaphthyridine equivalent ICT9057 103 at single 
concentration. This made ICT9072 104a (IC50 1.8 μM) a very interesting 
compound as switching to the amino pyridine Arg mimetic appeared to 
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significantly boost the phenyl sulfonamides activity but not the mesityl. This 
would allow a reduction in molecular weight and a large increase in atom 
efficiency compared with the hit compound ICT9055 69. 
 
Figure 30 Comparison of tetrahydronaphthyridine and amino pyridine Arg mimetics 
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 Structure 
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Number 
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ICT9072 104b 
 
ICT9073 
Table 9 RGD mimetics (modified Arg mimetic) 
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Figure 31 Cytotoxicity assay Sk-Mel-2: RGD mimetics (modified Arg mimetic) 
 
Figure 32 Adhesion assay Sk-Mel-2: RGD mimetics (modified Arg mimetic) 
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2.4.7 Spheroid Invasion Assay (αvβ3 antagonism) 
An in house assay had been developed to look at cancer cell invasion in 3-D, 
by implanting spheroids (small clusters of cells, as compared to a monolayer 
of cells) into a collegen matrix tumour invasion into surrounding tissues can 
be simulated, a process mediated by the RGD binding integrins and 
compounds can be screened for inhibition of invasion. U87MG glioblastoma 
cells were selected for the assay as they express high levels of αvβ3 and can 
be grown into spheroids. The spheroids were grown using a hanging drop 
method before being implanted into a collagen matrix. A selection of 
interesting compounds showing activity in the adhesion assay were applied 
to the implanted spheroids and their activity against cell invasion into the 
collagen matrix measured as compared with the control.  
The RGD mimetics were screened for cytotoxicity against the new cell line 
and were all shown to be reasonably non-toxic at 100 μM (10 times the 
screening concentration). 
Hit compound ICT9055 69 had been shown to have good activity in this 
assay also, with 60% inhibition of invasion at 10 μM and being more active 
than control antagonist cRGDfV 54.  
The aminopyridine RGD mimetics ICT9072 and ICT9073 104a/b were both 
shown to be active in this assay with the phenyl sulfonamide ICT9072 104a 
being slightly more active which again was surprising as mentioned above. 
Unfortunately there was a shortage of material to test ICT9089 96b (the most 
active compound from the adhesion assay) but its less active phenyl 
sulfonamide analogue ICT9088 96a showed good activity being more active 
than hit compound ICT9055 69 further suggesting the succinimide ring Asp 
mimetic requires further investigation. 
Compounds with an altered cyclobutane linker did not show much 
improvement on ICT9055 69 in this assay. Although the longer trans 
substituted cyclobutane linker compound ICT9095 73b’ showed the same 
activity as the hit compound. 
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Table 10 RGD mimetics screened in the invasion assay 
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Figure 33 Cytotoxicity assay: U87MG 
 
Figure 34 Invasion assay: U87MG 
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2.4.8 Scratch Assay (αvβ3 antagonism) 
After showing promise in the adhesion and invasion assays the 
aminopyridine RGD mimetics ICT9072 and ICT9073 104a/b were tested in a 
scratch assay for inhibition of migration.  
M14 Cells (highly expressing αvβ3) were plated and grown into a mono layer. 
A physical scratch is made using a pasture pipette and drug solution at 
differing concentrations or controls were added. After 24 h the closing of the 
scratch was measured, and by comparison to control, gives a measurement 
of the amount inhibition of cell migration. 
Both compounds ICT9072 and ICT9073 104a/b showed good inhibition of 
cell migration, preventing the scratch from closing. Hit compound ICT9055 69 
had been shown to have an IC50 of less than 0.1 μM, (this was the lowest 
concentration screened while the assay was still available). Phenyl 
sulfonamide ICT9072 104a (IC50 0.15 ± 0.04 μM) was less active than 
ICT9055 69 but more active than its phenyl analogue (the direct comparison) 
ICT9057 103 (IC50 1.0 ± 0.09 μM). ICT9073 104b was also more active than 
ICT9055 69 and again IC50 was below the lowest concentration tested. 
These results again show promise for the aminopyridine Arg mimetic as both 
compounds had ~10 fold decrease in IC50 compared to their 
tetrahydronaphthyridine counterparts in this assay.  
T = 0 T = 24 hrs 
 Control ICT9072 
104a 
ICT9073 
104b 
  10 μM 10 μM 
Figure 35 Scratch assay: M14 Cells. At T = 0 a physical scratch is made to the monolayer of 
cells and allowed to close over 24 h. Drug is added and the inhibition of wound closing 
quantified as compared to control scratch. 
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Figure 36 Scratch assay: IC50 values 
2.4.9 ELISA Assay (αIIbβ3 binding) 
A selection of compounds was selected for screening for αIIbβ3 binding, the 
lengthened linker compounds were chosen as the αIIbβ3 binding site is longer 
than that of αvβ3. Before screening, the methyl esters were hydrolysed using 
aqueous HCl as the esters have proved to be inactive in the ELISA since the 
assay contains no cellular esterases which cleave them to the active acids 
(ICT numbers and their precursor ester numbers are included in the table 
below in brackets). ICT9102 102 and ICT9103 97a were also screened as 
they were already possessed in their carboxylic acid form. 
 
 Structure 
ICT 
Number 
 Structure 
ICT 
Number 
118a 
(90a) 
 
ICT9104 
(ICT9100) 
119a 
(73a) 
 
ICT9105 
(ICT9101) 
118b 
(90b) 
 
ICT9106 
(ICT9093) 
119b 
(73b) 
 
ICT90107 
(ICT9094) 
102 
 
ICT9102 97a 
 
ICT9103 
Table 11 Compounds submitted to the αIIbβ3 ELISA assay 
 57 
 
 
None of the compounds screened showed good activity, and therefore simply 
increasing the length of hit compound ICT9055 69 (or acid analogue ICT9064 
70) does not appear to increase its affinity for αIIbβ3. It may be that the linker 
adopts an unfavourable conformation under assay conditions, or the 
orientation of H-bonds is sub-optimal. The assay again showed the trend that 
the hydridisation of the terminal nitrogen in the Arg mimetic was less 
important for αIIbβ3 binding than in the case of αvβ3 suggesting single point 
binding is less sensitive. Further work is required to optimise the length and 
orientation of the Arg mimetic sidechain to increase αIIbβ3 activity. 
 
Figure 37 ELISA binding assay: αIIbβ3 
2.4.10 Scratch Assay (αvβ5 Antagonism) 
Along with the β3 integrins our group has become interested in other RGD 
binding integrins, including αvβ5 due to its roles in adhesion, migration and 
invasion. A selection of compounds along with hit compound ICT9055 69 that 
had shown activity in the other assays has been tested against this integrin. 
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DLD-1 cells were chosen since they have been shown to rely on αvβ3 and 
αvβ5 for migration with an emphasis on αvβ5.97 
Compounds were screened for cytotoxicity against DLD-1 cells and an IC20 
value calculated. Compounds were then screened for inhibition of migration 
in a scratch assay at this concentration to ensure any lack of migration was 
not due to cell death. 
At this concentration only ICT9072 104a showed any inhibition of migration 
and was slightly less active than hit compound ICT9055 69. As the other 
compounds had already been shown to be active at antagonising αvβ3 but 
were inactive in this assay and DLD-1 cells express αvβ5 as well it suggested 
that ICT9055 69 and ICT9072 104a can antagonise αvβ5 thus explaining their 
ability to inhibit migration. 
In an attempt to test the ability of the compounds to antagonise αvβ5 
specifically they were screened in combination with LM609, an anti-αvβ3 
antibody which was used to block αvβ3. The combination treatment gave 
higher inhibition of migration for ICT9072 104a as seen with hit compound 
ICT9055 69 also. This may suggest ICT9072 104a is a dual αvβ3/αvβ5 
antagonist or it could potentially be an additive effect with both LM609 and 
ICT9072 104a antagonising αvβ3 and requires further investigation. As 
ICT9073 104b was inactive in this assay it also suggests interesting SAR 
with selectivity between the αv integrins can be tuned by the size of the 
sulfonamide with β5 having a smaller exosite next to the MIDAS as shown 
with homology modelling98 and thus not allowing binding of larger 
sulfonamides.  
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 Structure 
ICT 
Number 
 Structure 
ICT 
Number 
104a 
 
ICT9072 104b 
 
ICT9073 
74a 
 
ICT9085 74b 
 
ICT9087 
73b 
 
 
ICT9094 96a 
 
ICT9088 
Compound Cytotoxicity: DLD-1 IC20 (µM) 
ICT9055 (69) 5 
ICT9072 (104a) 10 
ICT9073 (104b) 1 
ICT9085 (74a) 10 
ICT9087 (74b) 1 
ICT9094 (73b) 1 
ICT9088 (96a) 10 
Table 13 Cytotoxicity: DLD-1 
 Table 12 RGD mimetics screened against DLD-1 
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Figure 38 Scratch Assay: DLD-1 
 
Figure 39 Scratch assay: combination treatment 
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2.5 Conclusion 
The SAR surrounding hit compound ICT9055 69 has been further developed 
for αvβ3 antagonism. The length and orientation of groups within the linker 
have been confirmed to be optimised for anti-αvβ3 activity in ICT9055 69 
although certain modifications can be tolerated; for example, the longer 
linkers and ‘reversing’ the amide.  
The succinimide Asp mimetic and potentially its opening to a β sulfonamide 
have been highlighted for further investigation to confirm how this confers 
such good activity to the antagonists. Whether this is due to ring opening in 
the assay conditions to the Asp mimetic or whether it remains intact but holds 
the sulfonamide in a preferential orientation for binding. To investigate this 
mesityl analogue 50b should be synthesised and also replacement of the 
succinimide with either pyrollidine or pyrollidinone rings as this would change 
the ability to ring open in the assay. 
 
Figure 40 Asp acid analogues to be synthesised 
The aminopyridine Arg mimetic has shown good activity while reducing the 
molecular weight and has potential for adding αvβ5 antagonism to these 
molecules making these interesting compounds for further investigation. The 
combination of antagonising both αv integrins showing a greater effect on 
cancer cell migration also highlights the utility of being able to tune these 
compounds to target different combinations of integrins as different cell types 
have been shown to rely on different integrins or combinations of them for 
adhesion and migration. Therefore further analogues of these should by 
synthesised as has been done with the tetrahydronaphyridine compounds to 
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look at the length and orientation of the linkers along with the Asp mimetic. 
These can then be screened for both β3 and αvβ5 antagonism and begin to 
build up an SAR picture for these receptors. 
 
Figure 41 Modifications to aminopyridine compound 104a/b 
Further testing of the compounds synthesised here for αIIbβ3 antagonism 
using the ELISA is required as limited data was attained and the SAR around 
its antagonism had not been developed beyond showing the longer 
cyclobutane linker unit leads to a drop in activity. 
With all this SAR information in hand it would allow the design of an 
optimised dual β3 or multi integrin antagonist scaffold for further decoration 
and elaboration to increase activity and tune the PK characteristics to give a 
lead compound for further development. 
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3. Providencin 
3.1 Introduction 
3.1.1 Isolation and Structure 
 
Figure 42 Structure of providencin 120 
Providencin 120 is a diterpene belonging to a family of furanocembranoids 
including the bipinnatins, lophotoxins and pukalides isolated from gorgonian 
corals; their structures, biosynthesis, activities and total syntheses have been 
reviewed in detail by Roethle and Trauner,99 and Berrue and Kerr.100 
Providencin 120 was first isolated by Raptis et al.101 from Pseudopterogorgia 
Kallos found in the Caribbean near the island Providencia from which it is 
named. Raptis et al. were only able to isolate 20 mg of pure material (0.012% 
yield) from which they were able to determine the structure through NMR, IR, 
mass spectrometry and single crystal x-ray diffraction. It was shown 
providencin 120 contained a unique and previously undescribed trans-fused 
bicyclo[12.2.0]hexadecane ring system termed providenciane 121 (Figure 
43).  
 
Figure 43 Providenciane ring system 121 
It is believed providencin 120 shares the same biosynthetic pathways as that 
of the bipinnatins, firstly cyclisation of geranylgeranyl diphosphate 122 to give 
the macrocycle 124 (Scheme 15) followed by varying oxygenation patterns 
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and in some cases ring contractions and photochemical rearrangements 
leads to the diverse family of furanocembranoids.99 It has been suggested 
that bipinnatin E 125 is the biological precursor to providencin 120 with a 
Norrish type II radical cyclisation occurring to form the cyclobutane ring 
(Scheme 16).102 
 
Scheme 15 Biosynthetic macrocycle formation 
 
Scheme 16 Proposed biosynthesis of Providencin 120 
3.1.2 Biological Activity 
The providencin family of natural products is not only of interest synthetically 
due to their complex structures; several members have been shown to have 
interesting biological activity, meaning they are of interest for drug discovery. 
For example (Figure 44); Lophotoxin 127 has been heavily studied due to its 
ability to irreversibly bind the nicotine acetylcholine receptor and act as a 
potent neurotoxin.103 Bielschowskysin 128 a highly oxygenated and 
rearranged furanocembanoid has been shown to be highly active against 
drug resistant parasites that can cause malaria.104 Bielschowskysin 128 and 
Pinnatin A 129 have also shown cytotoxicity against cancers cell lines 
including lung, renal, ovarian and breast cancers.99,105 
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Figure 44 Related natural products with interesting biological activity 
Providencin 120 was screened against the NCI tumour bank showing some 
in vitro activity. It inhibited the growth of NCI-H460 non-small cell lung cancer 
(61%), MCF7 breast cancer (43%) and SF-268 CNS cancer (6%), although 
further work on this has been hampered by its low abundance.101 
3.1.3 Synthesis 
Related Natural Products and Analogues 
Considering the large size of this related family, only a small number of 
natural product or analogue syntheses have been completed and currently 
no total synthesis has been reported for providencin 120, although several 
related structures and natural products have been synthesised (Figure 45).  
Paquette was the first to synthesise any of this family first completing 
gorgiacerone 130106 and then acerosolide 131107the following year. Marshall 
then synthesised the unnatural enantiomer of kallolide B 132108 and rubifolide 
133109 to develop the chemistry but starting from a cheaper chiral pool 
reagent. More recently Pattenden and Trauner have been working in this 
area with both groups completing several targets. In 2006 both groups 
published syntheses of bipinnnatin J 136105, 110 with Trauner going on to 
convert this into first rubifolide 133 and then converting that to 
isoepilophodione B 137 and both groups converting bipinnatin J 136 into 
intricarene 138 thus both supporting the hypothesis of interconnected 
biosynthetic relationships within this family of natural products. The 
biosynthetic relationships between the different macrocycles in the family 
were further supported when Mulzer synthesised gorgiacerol111 via a 
Pattenden-Rodriguez photochemical ring contraction from a cembrane type 
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macrocycle seen in rubifolide 133 and the bipinnatins to the pseudopterane 
macrocycle present in gorgiacerol 139. 
 
Figure 45 Synthesised natural products and analogues 
Synthesis Towards Providencin 
Synthetic work towards providencin 120 has focussed upon the 
furylcyclobutane fragment as chemistry to synthesise the ‘left hand side’ has 
already been developed through efforts towards other members of the family 
sharing similar features shown above (e.g. acerolide 131 and bis-
deoxylophotoxin 135). 
Pattenden’s Biomimetic Synthesis of the Furylcyclobutane Fragment 
Pattenden et al.102 were the first to publish work towards providencin 120 
synthesising model substrate 143 to investigate the proposed biosynthesis of 
the cyclobutane ring from bipinnatin E 125 (Scheme 17). They were able to 
enact a light mediated Norrish type II radical cyclisation forming 
furylcyclobutane 144 in low yield. The relative stereochemistry of the alcohol 
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is also incorrect compared to that of providencin 120 although this was 
rationalised suggesting the intact macrocycle could constrain the molecule in 
such a way to lead to the correct diastereomer. This work therefore 
somewhat supported the biosynthesis of providencin 120 from bipinnatin E 
125. 
 
Scheme 17 Pattenden’s biomimetic synthesis of the furylcyclobutane fragment of providencin 
120 
White’s Synthesis of the Furylcyclobutane fragment 
White et al.112 were able to synthesise the required cyclobutane 148 via a 
zirconium mediated ring contraction, installing the 3 required stereocentres 
round the ring by utilising the chiral pool and starting from D-glucose 145 
transforming it to known tetrahydrofuran 146 in 4 steps before installing the 
alkene and methoxy group forming 147. Although this ring contraction 
methodology was successful with a high yield and forming the required 
cyclobutane 148 with relative ease it again highlights the lack of robust, 
convenient and generally applicable routes to highly-functionalised 
cyclobutanes, having to rely on appropriately functionalised tetrahydrofurans  
 
Scheme 18 White’s cyclobutane synthesis via ring contraction 
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being synthesised first. The group was then able to install the furan moiety to 
give furylcyclobutane 153 and had begun elaborating this structure towards 
providencin 120.  
 
Scheme 19 White's revised synthesis towards providencin 120 
Following this work, White et al.113 published a revised route to providencin 
120 (Scheme 19) again utilising the zirconium ring contraction to form 
cyclobutane 138 followed by some protecting group manipulation and 
oxidation to give aldehyde 154 which was used to install the furan moiety and 
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give furylcyclobutane 157 followed by deprotection and oxidation followed by 
Wittig reaction to install the exocyclic double bond. The ‘left hand side’ 
fragment 162 was then synthesised from epoxide 159, by alkyne addition, 
iodination and then formation of the lactone. 
With the 2 fragments in hand White had then planned to close the 
macrocycle via a Stille cross coupling to form the alkene-furan bond, and 
selenium aldol reaction to attach the lactone. They were able to either 
perform the Stille coupling or aldol addition to give intermediates 163 or 164 
but were then unable to close the macrocycle in both cases to give 165. 
Although unsuccessful this work led to advanced intermediates containing all 
the carbon atoms and appropriate functionality required for a total synthesis. 
Wood’s Synthesis of the Furylcyclobutane Fragment 
Wood’s synthesis114 began with a [2+2] cycloaddition using enol ether 166 
and diethyl fumarate 167 followed by reduction of the esters, benzyl 
protection and then hydrolysis of the acetal to give racemic cyclobutanone 
169. They were then able to brominate the silyl enol ether of 169 to give 
bromocyclobutanone 170. They then intended to directly displace the 
bromine with furoic acid 171 but interestingly found this added to the carbonyl 
first giving furylcyclobutanol 172 as an intermediate which they were able to 
isolate if quenched at low temperature, but in the final sequence they formed  
 
Scheme 20 Wood's synthesis of the furylcyclobutane fragment 
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the methyl ester in situ followed by warming and treatment with base to enact 
the furyl migration followed by epimerisation to give the required 
furylcyclobutanone 173 for further elaboration towards providencin 120. 
Mulzer’s Synthesis of 17-deoxyprovidencin 180 
Mulzer has come closest to a total synthesis, synthesising 17-
deoxyprovidencin 180115 lacking the cyclobutane alcohol group. Again this 
synthesis highlights the need for better methods for cyclobutane synthesis as 
the choice of starting material did not allow inclusion of a second oxygen on 
the cyclobutane. The synthesis began from known enantiopure fused 
cyclobutane 174, with the 5-membered ring being cleaved via ozonolysis, 
followed by selective protection of the least hindered alcohol and oxidation to 
aldehyde 175. Elaboration of aldehyde 175 led to cyclobutane 176, 
cyclisation to the furan and then alcohol deprotection and oxidation to give 
the furylcyclobutane 177. The macrocycle was then formed via aldol addition 
and then ring closing metathesis. This gave the undesired Z isomer which 
they were able to convert photochemically to the E isomer; interestingly they 
saw no Pattenden-Rodriguez ring contraction when performing this. The 
synthesis was then finished to give 17-deoxyprovidencin 180 through 
epoxidation of the alkenes and deprotection of the cyclobutanol, oxidation to 
cyclobutanone and then Wittig reaction to install the terminal alkene. 
 
Scheme 21 Mulzer’s synthesis of 17-deoxyprovidencin 180 
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This body of work has made progress towards the total synthesis of 
providencin 120 but still a full synthesis has not been completed. This also 
again highlights the need for improved cyclobutane synthesis methodology, 
particularly towards enantiospecific synthesis, with both White and Mulzer 
relying on very specific starting materials to be able to form the required 
cyclobutane enantiomer for their syntheses. 
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3.2 Results and Discussion: Providencin 
Retrosynthesis 
Pattenden’s retrosynthetic strategy for deoxypukolide 134 (Scheme 22) relied 
upon formation of known epoxide 181 and ‘right hand side’ fragment 182. To 
connect these two fragments the group employed first a selenium enolate 
epoxide ring opening, with the resulting alcohol cyclising to form the lactone 
ring, followed by Stille coupling to close the macrocycle. 
 
Scheme 22 Pattenden's retrosynthesis of deoxypulolide 134 
It was envisaged that similar disconnections could be employed for the 
synthesis of providencin 120 (Scheme 23), thus requiring known epoxide 181 
and cyclobutanol 183. This can be disconnected to give furan 185 and 
cyclobutene 186 which can be synthesised using our enamine [2+2] 
cyclisation methodology allowing further investigation of this reaction and 
expansion of the methodology. 
 
Scheme 23 Retrosynthesis of providencin 120 
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As previously stated, attempts to synthesise cyclobutanes enantioselectively 
have proved problematic but it was noticed that cyclobutene 186 would lend 
itself to an intramolecular cyclisation, by tethering the fumarate 187 and 
aldehyde 188 via one of the alcohols and ester of the fumarate, 
simultaneously forming the cyclobutene ring and a lactone. It was 
hypothesised that these intramolecular cyclisations would proceed though a 
constrained transition state and therefore allow for diastereocontrol via the 
side chain within the tether controlling how the molecule can fold into a 
reactive conformation therefore controlling the stereochemistry of the ring 
junctions, and gaining enantiocontrol through cyclising enantiopure 
precursors 190/193. 
 
Scheme 24 Intramolecular cyclisation retrosynthesis 
 74 
 
Once the stereochemistry of the butandiol sidechain-cyclobutane is set by 
the intramolecular cyclisation this would then allow control of the furan-
cyclobutane stereocentre via favoured furan addition to the cyclobutene trans 
to the sidechain, or alternatively via epimerisation after furan addition leading 
to the more stable trans arrangement. The final stereocentre, that of the 
alcohol, could be set through selective reduction of a cyclobutanone to give 
the desired enantiomer. 
 
Figure 46 Origins of stereochemistry 
3.2.1 Intramolecular Enamine [2+2] Cyclisations 
Intramolecular enamine [2+2] cyclisations were previously unknown in the 
literature therefore it was decided to first explore the scope of this reaction; 
investigating ring size, tether and then sidechains and diastereocontrol 
before applying this to synthesis towards providencin 120. 
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Ring size 
For the synthesis of providencin 120 the formation of a 6 or 8 membered 
lactone fused to the cyclobutane was required. The 5 and 7 membered 
lactones were also targeted to explore what ring sizes could also be 
synthesised. 
 
Scheme 25 Intramolecular enamine [2+2] cyclisations 
Diols 195a-d were mono-protected with TBS, relying on the solubility 
difference between the mono and dianion to gain selective mono-protection 
to give alcohols 196a-d in excellent yields. The fumarate esters were then 
formed and the TBS groups removed before oxidation with TEMPO and BAIB 
to give aldehydes 199a-d. Cyclisation with aldehyde 199b gave the 
bicyclo[4.2.0]octane 200b in reasonable yield over the 3 steps with the other 
cyclisations proving unsuccessful. The failure of the other cyclisations were 
most likely due to the tether being too short (200a) not allowing overlap of the 
required orbitals, or too long (200c/d) causing entropic issues, for an efficient 
reaction. Interestingly no starting material was observed after the initial 
cyclisation step suggesting a reaction had taken place but no pure 
compounds were ever isolated from these reactions suggesting a possibility 
of polymerisation. 
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Entry Precursor 199 Product 200 Yield 
1 
 
a 
- - 
2 
 
b 
 
41% 
3 
 
c 
- - 
4 
 
d 
- - 
Table 14 Intramolecular enamine [2+2] cyclisations 
The intramolecular cyclisation giving fused cyclobutene 200b proved to be 
much quicker than similar intermolecular variants as might be expected due 
to the tether holding the two reactive groups in close proximity to one 
another. The initial cyclisation to the cyclobutane 202 was complete in 24 
hours compared with a more typical 60 hours for an intermolecular reaction. 
The quaternisation of the amine then proved to be considerably slower taking 
around 90 hours rather than 18 hours, presumably due to increased steric 
hindrance of the nitrogen by the lactone ring. 
The rings were shown to be cis fused by nOe spectra as would be expected 
for 2 small fused rings and it is believed this cyclisation would proceed 
through a chair like transition state (Scheme 26). It has not been possible to 
isolate cyclobutane 202 to confirm which diastereomer is present; with the 
starting enamine and fumarate both being trans it may be expected that the 
amine and ester would be cis to one another and trans to the lactone ring in 
cyclobutane 202 but it has been shown in previous work on enamine [2+2] 
cyclisations that there is some scrambling of these relationships (Scheme 
27), with malonates giving predominantly trans substituted cyclobutenes 205 
and fumarate 187 in some instances giving a small proportion of cis 
substituted cyclobutenes.4 This happens after the initial enamine conjugate 
addition; when the iminium/enolate intermediate 206 can be present for long 
enough for rotation of bonds into a different ‘all trans’ configuration 206’ or 
alternatively as the enamine 203 addition to the malonate is essentially 
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reversible it is possible for this to reverse to form fumarate 187 in the reaction 
which can then go on to form the all trans cyclobutane. 
 
Scheme 26 Intramolecular cyclisation transition state 
 
 
Scheme 27 Route to 'unexpected' diastereomer 
After the positive result with the fused 6 membered lactone 200b, the tert-
butyl ester analogue was synthesised (Scheme 28) to allow for easier 
differentiation of the lactone and acyclic esters in the cyclobutene product. 
The synthesis was conducted by forming ethyl tert-butyl fumarate from ethyl 
hydrogen fumarate 197 followed by selective hydrolysis of the ethyl ester with 
LiOH to give tert-butyl hydrogen fumarate 207 which was taken through the 
same synthetic route as shown in Scheme 25 to give fused cyclobutene 209 
in poor yield, presumably from the increased steric hindrance created by the 
large ester. This also considerably increased reaction times. 
 
Scheme 28 Intramolecular cyclisation using tert-butyl ester 
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Amide Tether 
Expansion of this methodology to the preparation of lactam fused 
cyclobutenes was also investigated. Unprotected, Boc protected and benzyl 
protected cyclisation precusors were synthesised. 
Unprotected Amide 
Cyclisation substrate 213 was prepared from amino alcohol 210 through the 
same route as diols 195a-d although with poorer yields (Scheme 29). No 
cyclobutene was formed after attempted cyclisation. It was unclear as to why 
this reaction failed, whether it was due to the amide NH being present or 
ineffiecient ring closure, therefore Boc and benzyl protected amides were 
investigated. Thus changing the electronics of the micheal acceptor and also 
the increased steric bulk may help the molecule to fold into a reactive 
conformation. 
 
Scheme 29 Attempted intramolecular cyclisation with unprotected amide 
Boc Protected Amide 
Amide 212 was Boc protected before TBS deprotection and oxidation to 
aldehyde 216, which was cyclised to lactam fused cyclobutene 96 in 
reasonable yield over the 3 steps. 
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Scheme 30 Intramolecular cyclisation with Boc protected amide 
Benzyl Protected Amide 
Protected diol 196b was oxidised using the Swern oxidation before reductive 
amination using benzylamine to give protected amino alcohol 220. The 
fumarate amide was then formed followed by TBS deprotection, oxidation to 
aldehyde 222 and then cyclisation giving the lactam fused cyclobutene 223 in 
moderate yield over the 3 steps. 
 
Scheme 31 Intramolecular cyclisation with benzyl protected amide 
The intramolecular enamine [2+2] cyclisations were applicable to amide 
linked substrates, although with the unprotected amide being unreactive and 
the Boc and benzyl protected amides cyclising in lower yield than ester-linked 
substrates. The Boc protected amide cyclised in a higher yield than the 
benzyl. This could result from the Boc group being more electron withdrawing 
than the benzyl group, therefore making the fumarate more reactive to the 
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enamine addition, or it could have been due to the Boc group being more 
sterically demanding and thus making the molecule more likely to fold into a 
reactive conformation. 
Diasteroselective Intramolecular Enamine [2+2] Cyclisations 
To investigate whether side chains could control the diastereoselectivity of 
the intramolecular cyclisations, a range of secondary alcohols 224a-d was 
synthesised from aldehyde 218 via addition of an organolithium or Grignard 
reagent. These side chains were selected to investigate how the size of the 
side chain would affect diastereoselectivity, and along with the benzyl 
protected alcohol substituted side chain 191 (Scheme 24) required for the 
synthesis of providencin 120, would investigate the  tolerance of cyclisation 
to different functionality. 
The methyl 224a, vinyl 224b, and iso-propyl 224c substituted alcohols were 
then taken through to the appropriate aldehydes 226a-c in the usual manner. 
Repeated attempts to form the ester 225d with the phenyl substituted alcohol 
224d failed with the alcohol decomposing in the reaction mixture. 
 
Scheme 32 Diastereoselective intramolecular cyclisations 
The 3 substituted lactone fused cyclobutenes 227a-c were formed in good 
yield over 3 steps. The cyclisations appear to proceed completely 
diastereoselectively with the all cis compounds being isolated. Unfortunately 
the crude cyclobutene NMR spectra are too complex to identify if there is any 
other diastereomer present but after column chromatography only the all cis 
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diastereomer is isolated in each case. The all cis configuration was assigned 
via nOe spectroscopy, with correlations between H1 and H6 at the ring 
junction and H4 adjacent to the side chain (Figure 47). 
 R = Me 
 
 
R = vinyl R = iPr 
  
Figure 47 nOe correlations H1-H4-H6 of cyclobutenes 106a-c 
This high diastereoselectivity is believed to arise from a chair like transition 
state (Scheme 33) with the side chain sitting in a pseudo-equatorial position 
in the favoured conformation 228 cis leading to the cis product 227 cis. 
These levels of diastereoselectivity are quite high particularly for the methyl 
substituted fused cyclobutene 227a which bears a relatively small sidechain. 
This could be due to cyclobutane 230 trans being unstable or the iminium 
and enolate being too far from one another to close the cyclobutane ring, so 
the reversibility of the cyclisation to form the cyclobutane intermediate leads 
to a single stable thermodynamic product therefore explaining the high level 
of diastereoselectivity. 
H4                        H1                H6 H4     H1                          H6 
H4                H1                      H6 
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Scheme 33 Source of the high diastereoselectivity in the intramolecular cyclisation 
After the success with the lactone fused cyclobutenes 227a-c, the 
investigation expanded to the lactam fused system. It was decided to conduct 
this cyclisation only with the methyl sidechain as if high levels of 
diastereoselectivity were seen with the smallest group, then it is likely that 
larger side chains would also give high selectivity. Secondary amine 232 was 
synthesised from alcohol 224a via mesylate formation and substitution by 
sodium azide followed by reduction. Fumarate amide 233 was then 
synthesised and the amide Boc protected as this had given higher yields than 
benzyl protected substrates in the cyclisation of unsubstituted systems. 
Protected amide 234 was then taken through the remainder of the synthesis 
to give again the all cis lactam fused cyclobutene 236 in reasonable yield and 
excellent diastereoselectivity as confirmed by nOe spectra. 
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Scheme 34 Amide tethered diaseteroselective intramolecular cyclisations 
As the substituted lactones had cyclised in higher yield than the 
unsubstituted it was decided to attempt the 8 membered lactone 192, 
required for the synthesis of providencin 120 (Scheme 24:Route 2) as it was 
hoped the steric bulk of the side chains would make the folding into a 
reactive confirmation more favourable.  
Ally alcohol 224b was benzyl protected before hydroboration to install the 
primary alcohol required for ester formation. Fumarate 238 was deprotected 
and oxidised to give aldehyde 193. Unfortunately like the unsubstituted 8 
membered tether 199d, this too did not cyclise also. 
 
 
Scheme 35 Attempted intramolecular cyclisation to form 8 membered lactone 
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Chiral Synthesis of the Providencin Cyclobutene via Diastereoselective 
Intramolecular Enamine [2+2] Cyclisation of a Enantiopure Substrate 
After demonstrating that side chains within the tether gave diasterocontrol in 
the cyclisation reaction, it was planned to harness this to synthesise the 
cyclobutene 186 required for the synthesis of the furylcyclobutene fragment 
184 of providencin 120. Unfortunately the stereochemistry of the alcohol at 
C4 in fused cyclobutene 189 is the incorrect configuration for providencin 1 
as the intramolecular cyclisation gives the all cis compound whereas 
providencin requires the alcohol to be ‘trans’ to the ring junction. However, 
this could easily be inverted after the cyclisation. 
 
Scheme 36 Retrosynthetic analysis for the enantiopure cyclisation precursor for the synthesis 
of providencin 120 
Diol 240 was synthesised in 8 steps starting from (+)-malic acid 244 via 
known procedures.116 Selective protection of the primary alcohol with TBS 
followed by ester coupling to give fumarate 239 which was deprotected and 
oxidised to give aldehyde 190. This was cyclised in good yield to give 
enantiopure fused cyclobutene 189, again with excellent diastereoselectivity, 
ready for incorporation in to the synthesis of the furylcyclobutane fragment 
186 of providencin 120. The stereochemistry was assigned based upon the 
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known stereochemistry of the starting (+)-malic acid 244 which will have 
been retained throughout the synthesis and nOe spectroscopy showing an all 
cis arrangement as seen in the other intramolecular cyclisations. 
 
Scheme 37 Synthesis of the enantiopure fused cyclobutene 189 required for the synthesis of 
providencin 120 
3.2.2 Summary: Intramolecular Enamine [2+2] Cyclisation 
A previously unknown intramolecular variant of the enamine [2+2] cyclisation 
methodology has been developed. It has been shown that this reaction works 
to form 6-membered fused lactones and lactams. It is hypothesised to 
proceed via a chair-like transition state, and the steric demands of a 
sidechain within the tether can control the diastereoselectivity of this 
cyclisation by adopting a pseudo-equatorial position in the transition state. 
The utility of this reaction has been demonstrated by synthesising an 
enantiopure cyclobutene 189 ready for the incorporation into the synthesis of 
providencin 120. 
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 Aldehyde  Product Yield d.e. 
1 199a 
 
n = 1 - - - - 
2 199b n = 2 200b 
 
41% 
>95% 
(C1-C6) 
3 199c n = 3 - - - - 
4 199d n = 4 - - - - 
5 208 
 
 209 
 
20% 
>95% 
(C1-C6) 
6 226a 
 
R = Me 227a 
 
54% 
>95% 
(C1-C4-
C6) 
7 226b R = vinyl 227 48% 
>95% 
(C1-C4-
C6) 
8 226c R = iPr 227c 47% 
>95% 
(C1-C4-
C6) 
9 190 
R = 
(CH2)2OBn 
189 60% 
>95% 
(C1-C4-
C6) 
10 193 
 
 - - - - 
11 213 
 
R = H - 
 
- - 
12 216 R = Boc 217 35% 
>95% 
(C1-C6) 
13 222 R = Bn 223 25% 
>95% 
(C1-C6) 
14 235 
 
 236 
 
30% 
>95% 
(C1-C4-
C6) 
Table 15 Summary of intramolecular enamine [2+2] cyclisations 
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3.2.3 Model System for the Conversion of Cyclobutene 189 to 
Furylcyclobutane 184 
To investigate the conversion of fused cyclobutene 189 to furylcyclobutane 
184 a model system was used; the simplified cyclobutene 246 was selected 
as an appropriate model and synthesised (Scheme 38). The key steps 
requiring investigation were differentiation of the 2 esters and addition of the 
furan. 
 
Scheme 38 Simplified model system for synthetic investigation 
Retrosynthesis 1 
 
Scheme 39 Retrosynthesis 1: reduction and epoxidation 
The first potential method for furan addition and ester differentiation was via 
ring opening of epoxide 250, as this would allow introduction of the furan and 
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also produce a 1,2-diol which could be selectively oxidised to form 
cyclobutanone 248. 
The synthesis would require reduction of cyclobutene 246 which could then 
either be protected to give 252 followed by epoxidation to give cyclobutane 
epoxide 250, or epoxide 253 could be formed followed by protection to give 
cyclobutane epoxide 250 (Scheme 39). 
 
Scheme 40 Routes to cyclobutane epoxide 128 
Reduction of Cyclobutene 246 to Cyclobutene Diol 251 
Reduction of diester 246 to cyclobutene diol 251 proved highly problematic. A 
range of reducing agents was screened with both DIBAL-H and LiAlH4 
producing the desired diol in low yield but TLC showing that all the starting 
material 246 was being consumed. 
Increasing reaction times with DIBAL-H (Table 16 Entries 4&5) lowered the 
yield suggesting that the product or more likely the intermediates were 
unstable in the reaction mixture. Changing the solvent to THF (Table 16 
Entry 6) appeared to attenuate this problem and improve the yield. 
Attempting to speed up the reaction to minimise decomposition by performing 
it at RT led to complete decomposition (Table 16 Entry 7). Altering the 
quenching step in the LiAlH4 reductions improved the yield but leaving this 
step longer to ensure all diol is released from the aluminium complexes did 
not improve the yield further. Again attempts to speed up the reaction by 
conducting it at RT to minimise decomposition did not improve the yield 
further (Table 16 Entries 12&13). 
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Table 16 Reduction of cyclobutene 124 
It was decided to proceed with the LiAlH4 reductions (Table 16 Entry 10) as 
these produced a workable amount of diol 251. 
Protection and Epoxidation of the Diol 251 
TBS protection 
Attempts to protect diol 251 using TBS gave a mixture of mono-protected 
diols 254a-b, with repeated treatment with TBSCl not yielding any di-
protected diol 252a. Epoxidation of diol 251 proceeded in good yield but 
attempts to protect epoxide diol 253 were unsuccessful. It was concluded 
that the TBS groups were too bulky to allow di-protection as mono-protection 
appeared straightforward, but the TBS group must then sterically block the 
second alcohol from reacting. 
 
Entry Reagent Eq Solvent Time Temp Yield 
1 DMS∙BH3 3 THF 24 hrs 0 °C→RT decomposed 
2 BH3∙THF 3 THF 2 hrs 0 °C - 
3 Super Hydride™ 6 THF 80 hrs 0 °C→RT decomposed 
4 DIBAL-H 6 DCM 3 hrs -78 °C 15% 
5 DIBAL-H  6+6 DCM 6.5 + 3 hrs -78 °C 6% 
6 DIBAL-H 12 THF 7 hrs -78 °C 21% 
7 DIBAL-H 6 THF 3 hrs 20 mins RT decomposed 
8 LiAlH4 2 Et2O 50 mins 0 °C 15% 
9 LiAlH4 1+0.5 Et2O 2 hrs 40 mins 0 °C 23% 
10 LiAlH4 2 Et2O 1 hr * 0 °C 35% 
11 LiAlH4 2 Et2O 1 hr ** 0 °C 30% 
12 LiAlH4 2 Et2O 45 mins* RT 30% 
13 LiAlH4 2 Et2O 2 hrs* RT 30% 
*The ratio of reagents in the quench step was altered: NaOH (1 ml): water (1 ml): LiAlH4 (1 g). **The quench step was left for 
16 hours 
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Scheme 41 TBS protection and epoxidation 
TMS protection 
The smaller TMS groups were selected as protecting group to overcome the 
steric issues associated with the bulky TBS group. As TMS groups can be 
quite labile, epoxide 253 was protected rather than protecting diol 251 
followed by epoxidation. This gave di-protected epoxide 250b in reasonable 
yield. 
 
Scheme 42 TMS protection 
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Acetonide protection 
Treatment of diol 251 with 2,2-dimethoxy propane did not lead to expected 
acetonide 252b but instead led to di-acetal 252c in reasonable yield. This 
suggests the two alcohols are too far away from one another to allow for the 
formation of a 7 membered ring, but the acetals do not seem to suffer from 
the steric blocking as the TBS groups did. 
Unfortunately compound 252c proved to be fairly unstable and attempts to 
repeat this reaction failed. It was believed the epoxidation would change the 
conformation of the molecule and may allow for acetonide formation but 
attempts to protect the epoxide 253 as the acetonide/di-acetal also failed. 
 
Scheme 43 Acetonide protection and epoxidation 
MOM protection  
Initial attempts to MOM protect the diol 251 using MOMCl with TBAI as 
catalyst to form MOMI in situ gave a mixture of the two mono-protected 
alcohols 255a-b and di-protected product 252e. Retreatment of this mixture 
with MOMCl gave a slightly higher but still poor conversion to the desired di-
protected product 252e. When switching to stoichiometric NaI and heating to 
reflux the desired di-protected product 252e was formed in excellent yield.  
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Scheme 44 MOM protection and epoxidation 
 
Protected diol 252e was then epoxidised in good yield using mCPBA to form 
MOM protected epoxide 250d. 
Introduction of the Furan via Epoxide Ring Opening 
Simple furan 256 was used as test nucleophile for epoxide ring opening as it 
is more reactive than furoic acid 171 due to the carboxylate of the desired 
furoic acid 171 being electron withdrawing and therefore reducing 
nucleophilicity. 
The TMS protected epoxide 250b proved to be unstable to reaction with 
furan cuprate; part of this instability was the removal of the TMS groups 
forming diol 253 along with decomposition (Table 17 Entry 1). 
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Entry 
Epoxide 
250 
Furan Reagent Conditions Result 
R1 = R2 = eq  eq Temp/°C Time/hrs SM 250 257 
1 
TMS H 2 BuLi  
CuI 
1.1 
0.1 
-78 1 
0% x 0 2.5  
RT 20 
2 
MOM H 2 BuLi 2 -78 2  
70% x 0 4  
RT 15.5 
3 
MOM H 
 
4 BuLi 
TMEDA 
4 
4 
-15 0.25 
30% x 0 3.5 
RT 24  
4 
MOM CO2H 2 BuLi 4 -78 3.5 
100% x 
0 4  
Table 17 Epoxide ring opening 
The MOM protected epoxide 250d proved to be more stable to reaction 
conditions, although when trying to force the reaction using higher 
equivalents of furan and adding TMEDA in attempt to make the furyl lithium 
species more reactive, 250d also mainly decomposed (Table 17 Entries 
2&3). 
Furoic acid 171 was then used as it was believed the simple furan maybe too 
reactive and causing decomposition, this resulted in no decomposition but 
also no reaction occurred (Table 17 Entry 4). 
Summary: Retrosynthesis 1 
Model cyclobutene 246 was synthesised and reduced to diol 251 in poor 
yield; efforts to optimise this reaction proved unsuccessful. Protection of the 
diol proved difficult with the MOM protection being the most successful as it 
was readily formed and proved to be most stable to following reaction 
conditions. Attempts to ring open the epoxides with furan nucleophiles failed. 
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Retrosynthesis 2 
After difficulties with the reduction to the diol 251 and then epoxide opening, 
a reordering of the synthetic steps was envisaged; direct epoxidation of 
cyclobutene 246, followed by furan addition and then reduction of the esters 
and 1,2-diol oxidation to give cyclobutanone 248. 
 
Scheme 45 Retrosynthesis 2: epoxidation and furan addition 
Epoxidation of cyclobutene 246 
Epoxidation of cyclobutene 246 proved problematic; treatment with hydrogen 
peroxide and sodium hydroxide led to diol 260 from in situ epoxide ring 
opening by hydroxide. To overcome this, tert-butylhydroperoxide and 
potassium tert-butoxide were used as the tert-butoxide anion should be less 
nucleophilic than simple hydroxide due to its steric bulk. This gave epoxide 
259 in very low yield, with cyclobutanol 261 being formed, again from in situ  
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Scheme 46 Epoxidation of cyclobutene 246 
 
epoxide opening in the reaction mixture. Reducing the reaction time did not 
decrease this unwanted side reaction substantially, suggesting it was a very 
rapid process. 
As epoxide 259 was proving to be reactive and hard to isolate, a telescoping 
procedure was attempted, using the anion of furoic acid 171 (formed by 
treatment with BuLi) as the base for the reaction or adding it after treatment 
with tert-butylhydroperoxide to investigate whether it could outcompete the 
ring opening with tert-butoxide and lead straight to furylcyclobutane 262. 
Unfortunately both of these attempts failed and led to decomposition of the 
starting material. 
 
Scheme 47 Epoxidation and in situ furan addition 
To overcome the issue of in situ epoxide ring opening, the use of peroxy-
acids was investigated as reaction with these would lead to the formation of a 
carboxylate anion which should not be nucleophilic. mCPBA and potassium 
carbonate proved to be unreactive with unreacted cyclobutene 246 being 
isolated. Reaction with benzoyl peroxide 263 gave an inseparable mixture of 
 96 
 
epoxide 246 and starting material and attempts to push this reaction to 
completion were unsuccessful. Rather than deprotonating a peroxyacid to 
gain the peroxy anion,  the reaction with benzoyl peroxide works by sodium 
methoxide reacting with the ester to form methyl benzoate 265 and the 
peroxybenzoic acid anion 264 being the ‘leaving group’ of the trans-
esterification reaction. 
 
Scheme 48 Epoxidation using peroxy-acids 
Epoxide Ring Opening 
The small amount of epoxide 259 that was isolable from the attempted 
epoxidation reactions hindered full investigation of the epoxide ring opening. 
 
Scheme 49 Epoxide ring opening 
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Lewis acids have been shown to potentiate nucleophilic addition of furan 
therefore epoxide 259 was treated with TiCl4 and simple furan 256 but no 
reaction occurred with starting material being isolated. Epoxide 259 was also 
shown to be unreactive to hard nucleophiles as treatment with the di-anion of 
furoic acid 171 also failed with starting material being isolated again. 
Summary: Retrosynthesis 2 
Cyclobutane epoxide 259 proved difficult to form and was only formed in very 
low yield. It appeared to be much more reactive than its protected alcohol 
counterpart 250 as epoxide ring opening proceeded rapidly as an unwanted 
side reaction within the epoxidation reaction with hydrogen peroxide and tert-
butylhydroperoxide. Attempts to telescope this reaction using furoic acid as 
the base, and form the epoxide and open it in situ to lead straight to desired 
furylcyclobutane 258 failed. Attempts to open the isolated epoxide also failed 
with it appearing to be unreactive. 
Retrosynthesis 3 
After failure to open epoxides to introduce the furan moiety, direct addition to 
the cyclobutene was considered. Reduction of cyclobutene 246 followed by 
selective allylic alcohol oxidation would give cyclobutene 269 and allow for  
 
Scheme 50 Retrosynthesis 3: Furan addition into cyclobutene 
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differentiation of the 2 esters followed by furan addition to furyl cyclobutane 
268. Reduction of the ester and elimination of the subsequent alcohol would 
give alkene 267 which could be oxidised to cyclobutanone 248. 
As reduction of the esters of cyclobutene 246 was proving problematic, 
cyclobutene 246 itself was used for initial screening of addition of the furan 
moiety rather than desired cyclobutene 269. 
Organometallic Conjugate Additions 
The di-anion of furoic acid 171 was unreactive in the conjugate addition 
reaction to cyclobutene 246 (Table 18 Entry 1). Furan 256 should have been 
more nucleophilic, but ‘over reacted’ with an inseparable mixture of desired 
 
Entry 
Furan  
Reagent 
Conditions 
Result 
R = eq Temp/°C Time/hr 
1 CO2H 1.2 BuLi 
-78  1  
x 
0 °C 4 
2 H 15  BuLi -78 °C  1.5  
Inseperable 
mixture >10% 
yield 
3 CO2H 2.4 
BuLi, TMSCl, 
TMEDA 
-78 °C  1  
Decomposed 
0 °C 4 
4 H 1  
CuI, TMSCl, 
TMEDA 
0 °C 22 hrs x 
5 H 2  ZnCl2, TMSCl 
-78 °C  3 
x 
0 °C 19 
Table 18 Organometallic conjugate addition reactions 
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furyl cyclobutane 270a in low yield and furan addition to the 2 esters (Table 
18 Entry 2). Attempts to increase the reactivity of furoic acid 171 by adding 
TMSCl and TMEDA led to the decomposition of cyclobutane 246 (Table 18 
Entry 3). The softer nucleophiles, the cuprate and organozinc furans also 
proved unreactive with the cyclobutane 246 (Table 18 Entries 4&5). 
Lewis Acid Mediated Furan Addition 
Lewis acid mediated conjugate addition of furan had been reported in the 
literature117 to be catalysed by both BF3∙Et2O and TiCl4. Boron trifluoride was 
unable to catalyse addition to 246 (Table 19 Entry 1). Surprisingly TiCl4 did 
not catalyse the conjugate addition reaction as expected but instead led to 
Diels-Alder product 271a with the addition of TMSCl improving the yield 
(Table 19 Entries 2&3). Furoic acid 171 proved unreactive, not undergoing a 
Diels-Alder or conjugate addition reaction (Table 19 Entry 4). 
 
Transition metal catalysed furan addition 
Several furan species were synthesised to investigate transition metal 
catalysed additions to the cyclobutene 246 (Scheme 51). Iodo and boronic 
acid furyl species 273 and 274 were synthesised by treatment of furoic acid 
171 with LDA followed by iodide or boronic ester. Furoic acid methyl esters 
272 and 275 were synthesised simply by acid-catalysed esterification.  
 
Entry 
Furan  
Reagent 
Conditions 
Result 
R1 = eq Temp/°C Time/hr 
1 H 17 BF3∙Et2O RT  16 x 
2 H 20 TiCl4 RT  23  50% 
3 H 20 TiCl4, TMSCl RT 23 75% 
4 CO2H 10 TiCl4, TMSCl RT 24 x 
Table 19 Lewis acid mediated furan addition 
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Scheme 51 Formation of furan coupling partners 
 
Entry 
Furan  
Reagent 
Conditions 
Result 
R1 = R2 = eq Temp/°C Time/hr 
1 H CO2Me 1 
Pd(OAc)2, 
PPh3, K2CO3 
75  24 - x 
2 I CO2H 1 
Pd(OAc)2, 
Cu(OAc)2, 
NaOAc 
75 30 - x 
3 B(OH)2 CO2H 5 
[Rh(COD)Cl]2, 
NEt3 
RT 66 - x 
4 B(OH)2 CO2Me 5 
[Rh(COD)Cl]2, 
NEt3 
RT 21.5 270c 40% 
Table 20 Transition metal catalysed furan addition 
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C-H activation using palladium did not mediate addition of the furan species, 
with unreacted cyclobutene 246 being isolated along with a furan dimer. 
Palladium coupling with the iodofuroic acid 273 was also unsuccessful (Table 
20 Entries 1&2).Rhodium catalysed addition of aromatic boronic acids to a 
similar cyclobutene was a key step in the synthesis of pipercyclobutanamide 
A.118 Rhodium catalysed addition with the furoic acid 274 proved to be 
unsuccessful, but the addition yielded the desired furyl cyclobutane 270c in 
reasonable yield when using the furoic methyl ester 275 (Table 20 Entries 
3&4). 
Summary: Retrosynthesis 3 
Formation of a furyl cyclobutane 270c has been achieved through rhodium 
catalysed addition into cyclobutene 246. This still leaves an issue of 
differentiation of the esters and then conversion into the desired 
cyclobutanone 248 but as stated earlier, reduction of the esters followed by 
selective allylic oxidation before addition of the furan species would allow for 
differentiation of the 2 cyclobutene esters. 
3.2.4 Providencin Future Work 
Intramolecular Cyclisation 
Enamine [2+2] cyclisations have been shown to work with ketones along with 
esters and amides and therefore it should be possible to conduct 
intramolecular variants with ketones. Expansion of the intramolecular [2+2] 
cyclisation to carbon-linked tethers forming cyclohexanone fused to 
cyclobutenes would be a very useful expansion of this methodology.  
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Scheme 52 Intramolecular [2+2] cylisations with carbon linked tethers 
 
This cyclohexanone fused to cyclobutane motif is present in several natural 
products such as the penitrem family and fused cyclobutane 281 is an 
important intermediate in the Smith et al.119 synthesis of penitrem D 283 and 
should be easily synthesised using our methodology (Scheme 53). 
 
Scheme 53 Smith's synthesis of penitrem D 283 
 
Synthesis Towards Providencin 
After successfully introducing the furyl species to form furyl cyclobutane 270c 
from cyclobutene 246 further work needs to be conducted to convert 
cyclobutene 246 into cyclobutene 269 where the esters have been 
differentiated and one has been reduced. The rhodium catalysed furan 
addition must then be attempted on this new substrate. 
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Scheme 54 Proposed furan addition into cyclobutene 269 
After this, the rest of the steps detailed in retrosynthesis 3 (Scheme 50) will 
be attempted and then these transformations applied to the enantiopure 
fused cyclobutene 189 synthesised through the diastereoselective 
intramolecular [2+2] cyclisation to give advanced intermediate 184 before 
completion of the synthesis as detailed in Scheme 23. 
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4. Experimental 
4.1 Materials and Instrumentation 
Commercially available reagents and solvents were purchased from Sigma-
Aldrich®, Tokyo Chemistry Industry (TCI®), Alfa Aesar®, VWR® Fisher® and 
Merck®, and were used as received without additional purification unless 
otherwise stated.  
Products were purified by column chromatography where stated using Merck 
9385 silica gel 60 (40-63 μm). Analytical thin layer chromatography (TLC) 
was conducted on Merck silica gel 60 F254 aluminium backed plates. TLCs 
were visualised under short wavelength (254 nm) ultraviolet light and 
potassium permanganate (KMnO4) stain, vanillin stain or nihydrin stain. 
Proton Nuclear Magnetic Resonance (1H NMR) spectra were recorded using 
Bruker AMX400 (400 MHz) spectrometer. Carbon Nuclear Magnetic 
Resonance (13C) were performed on the same instruments operating at 101 
MHz. Chemical shifts are reported in parts per million (δ, ppm). 1H NMR 
chemical shifts are reported relative to an internal reference 
(tetramethylsilane) or residual proton signals of the solvent. Coupling 
constants (J) are expressed in Hertz (Hz). 13C NMR chemical shifts are 
reported relative to the signal of the solvent.  
Routine mass spectra were carried out by Andrew Healey and were run on a 
Micromass Quattro Ultima spectrometer in the electron impact (EI), chemical 
ionisation (AP) or electrospray (ES) mode as stated. High resolution mass 
spectrometry (HRMS) was carried out by the ESPRC National mass 
spectrometry service centre, Swansea University. 
Optical rotations where carried out on a Perkin Elmer polarimeter, model 341.  
All moisture sensitive reactions were carried out under an inert atmosphere 
using dry argon or nitrogen.  
LCMS analysis was performed on a Waters e2695 Seperation module using 
a HICHROM column (3.5RPB, 15cm × 2.1mm), with a flow rate of 0.25 
ml/min and mobile phase of water:MeOH:formic acid (5:5:0.1 at T=O 
mins,→1:9:0.1 at T=7mins, →5:5:0.1 at T=13 mins), eluting compounds were 
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analysed by Waters 2998 PDA Detector (uv spectroscopy 210-400 nm) and 
QDA Detector (mass spectrometry). 
4.2 Biological Assays 
All assays were run by members of the Sheldrake lab: adhesion assay (Dr 
Mark Sutherland, Andrew Gordon), scratch assay (M14 cells: Dr Fatemah 
Alshammari. DLD-1 cells: Dr Hanadi Ahmedah), spheroid invasion assay (Dr 
Manar Zraikat) and ELISA (Dr Mark Sutherland). For further details see 
reference 97 and 149 (a) and (b).  
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4.3 Development of Integrin Antagonists as 
Anticancer Therapeutics 
Ethyl 4-(2-methyl-1,3-dioxolan-2-yl)butanoate (76b) 
 
Ethylene glycol (1.41 ml, 1.57 g, 25.28 mmol) and pTSA∙H2O (289 mg, 1.52 
mmol) were added to a stirred solution of ethyl4-acetylbutyrate 75b (2.00 g, 
12.64 mmol) in benzene (40 ml) heated at reflux under Dean-Stark conditions 
under a blanket of N2 for 23 hours. The reaction mixture was allowed to cool 
to RT, washed with water (40 ml), dried (MgSO4) and concentrated in vacuo 
to yield the title compound 76b as a yellow oil (2.156 g, 10.67 mmol, 84% 
yield) ); Rf0.48 (3:7,EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 4.26 – 4.08 (m, 
2H, OCH2CH3), 3.99 – 3.88 (m, 4H, OCH2CH2O), 2.41 – 2.31 (m, 2H, H2), 
1.78 – 1.63 (m, 4H, H3+H4), 1.32 (s, 3H, CH3), 1.25 (t, J = 7.1 Hz, 3H, 
OCH2CH3). Consistent with literature.120 
4-(2-Methyl-1,3-dioxolan-2-yl)butan-1-ol (77b) 
 
Ethyl 4-(2-methyl-1,3-dioxolan-2-yl)butanoate 76b (1.39 g, 6.88 mmol) in 
Et2O (2 ml) was added dropwise to a stirred solution of LiAlH4 (261 mg, 6.88 
mmol) in Et2O (21 ml) at 0  °C under a blanket of N2 and the reaction mixture 
stirred at RT for 1 hour. The reaction mixture was then cooled to 0 °C and 
quenched by the slow addition of water (0.3 ml). A 5% aqueous solution of 
NaOH (0.78 ml) and water (1 ml) were then added and the mixture stirred for 
25 minutes, dried (MgSO4) and concentrated in vacuo to yield the title 
compound 77b as clear oil (904 mg, 5.65 mmol, 82% yield) ); Rf0.09 
(3:7,EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 3.89 – 3.82 (m, 4H, 
OCH2CH2O), 3.57 (dd, J = 11.8, 6.0 Hz, 2H, CH2OH), 1.63 – 1.56 (m, 2H), 
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1.54 – 1.46 (m, 2H), 1.44 – 1.35 (m, 2H), 1.24 (s, 3H, CH3). Consistent with 
literature.121 
4-(2-Methyl-1,3-dioxolan-2-yl)butanal (78b) 
 
MgSO4 (10 g) and PCC (13.6 g, 63.06 mmol) were added to a stirred solution 
of 4-(2-methyl-1,3-dioxolan-2-yl)butan-1-ol 77b (3.363 g, 21.02 mmol) in 
DCM (80 ml) and the reaction mixture was stirred at RT for 1.5 hours. The 
reaction mixture was filtered through Celite® and concentrated in vacuo. The 
crude residue was purified via column chromatography (3:7, EtOAc:PE) to 
yield the title compound 78b as a clear oil (1.60 g, 10.13 mmol, 48% yield); 
Rf0.45 (1:1,EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.78 (t, J = 1.5 Hz, 1H, 
CHO), 4.00 – 3.86 (m, 4H, OCH2CH2O), 2.48 (td, J = 7.1, 1.5 Hz, 2H, H2), 
1.83 – 1.60 (m, 4H, H3+H4), 1.33 (s, 3H, CH3).Consistent with literature.120 
Methyl 3-(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)cyclobut-1-enecarboxylate 
(80b) 
 
Diethylamine (0.54 ml, 384 mg, 5.26 mmol) was added to a stirred solution of 
4-(2-methyl-1,3-dioxolan-2-yl)butanal 78b (411 mg, 2.60 mmol) and K2CO3 
(725 mg, 5.26 mmol) in MeCN (11 ml) under a blanket of N2 and the reaction 
mixture stirred at RT for 5 hours. Methyl acrylate 79 (0.48 ml, 452 mg, 5.26 
mmol) was added and the reaction mixture stirred for a further 74 hours. The 
mixture was then filtered through Celite® and concentrated in vacuo. The 
crude cyclobutane was redissolved in MeCN (10 ml) and MeI (0.81 ml, 1.84 
g, 13 mmol) added and the reaction mixture stirred for 65 hours at RT under 
a blanket of N2. The reaction mixture was then concentrated in vacuo, 
redissolved in CHCl3 (10 ml), DBU (0.39 ml, 395 mg, 2.6 mmol) added and 
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the reaction mixture heated at reflux for 23.5 hours under a blanket of N2. 
The reaction mixture was concentrated in vacuo and the crude residue was 
purified via column chromatography (3:7, EtOAc:PE) to give the title 
compound 80b as a yellow oil (357 mg, 1.58 mmol, 61% yield); Rf 0.42 (3:7, 
EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 6.85 (s, 1H, H2), 3.99 – 3.86 (m, 
4H, OCH2CH2O), 3.73 (s, 3H, OCH3), 2.83 (dd, J = 13.3, 4.3 Hz, 1H, H4), 
2.71 (app dd, J = 11.5, 7.1 Hz, 1H, H3), 2.26 (dd, J = 13.3, 1.4 Hz, 1H, H4), 
1.72 – 1.65 (m, 2H), 1.64 – 1.56 (m, 2H), 1.31 (s, 3H, CH3); 13C NMR (101 
MHz, CDCl3) δ 163.1 (C), 145.0 (CH), 137.1 (C), 109.8 (C), 64.7 (CH2), 51.3 
(CH3), 39.9 (CH), 37.1 (CH2), 34.6 (CH2), 27.6 (CH2), 23.8 (CH3); m/z (AP+) 
226.8 ([M+H]+, 100%); HRMS Found ([M+H]+) 227.1278. C12H19O4 req. 
227.1278. 
Methyl (1r*,3s*)-3-(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)cyclobutane 
carboxylate (81b) 
 
10% Pd/C (27 mg) was added to a stirred solution of methyl 3-(2-(2-methyl-
1,3-dioxolan-2-yl)ethyl)cyclobut-1-enecarboxylate 80b (274 mg, 1.21 mmol) 
in EtOAc (20 ml) and the reaction mixture stirred under 1 atm of H2 for 23 
hours. The reaction mixture was then filtered through Celite® and 
concentrated in vacuo to give the title compound 81b as a clear oil (276 mg, 
1.21 mmol, 100% yield); Rf0.43 (3:7, EtOAc:PE); 1H NMR (400 MHz, CDCl3) 
δ 3.88 – 3.81 (m, 4H, OCH2CH2O), 3.59 (s, 3H, OCH3), 2.96 – 2.82 (m, 1H, 
H1), 2.22 (ddd, J = 16.7, 8.2, 2.5 Hz, 2H, H2+H4), 2.15 – 2.04 (m, 1H, H3), 
1.80 (qd, J = 9.3, 2.5 Hz, 2H, H2’+H4’), 1.50 – 1.37 (m, 4H, CH2CH2), 1.23 
(s, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 175. 7 (C), 109.9 (C), 64.6 (CH2), 
51.5 (CH3), 36.2 (CH2), 34.2 (CH/CH3), 31.7 (CH/CH3), 31.4 (CH2), 31.0 
(CH2), 23.7 (CH/CH3); m/z (AP+) 228.9 (MH+, 100%); HRMS Found 
([M+H]+) 229.1437. C12H21O4 req. 229.1434. 
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 Methyl (1r*,3s*)-3-(3-oxobutyl)cyclobutanecarboxylate (82b) 
 
Methyl (1r*,3s*)-3-(2-(2-methyl-1,3-dioxolan-2-yl)ethyl)cyclobutane 
carboxylate  81b (175 mg, 0.77 mmol) was dissolved in MeOH (7 ml) and 5% 
aqueous HCl (1.5 ml) and stirred at RT for 1 hour 20 minutes. The reaction 
mixture was concentrated in vacuo and the crude residue was purified via 
column chromatography (3:7, EtOAc:PE) to give the title compound 82b as a 
clear oil (101 mg, 0.55 mmol, 71% yield); Rf 0.40 (3:7, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 3.68 (s, 3H, OCH3), 3.02 – 2.90 (m, 1H, H1), 2.38 – 2.26 
(m, 4H, H2+H4+COCH2), 2.25 – 2.17 (m, 1H, H3), 2.14 (s, 3H, CH3), 1.88 
(qd, J = 9.2, 2.5 Hz, 2H, H2’+H4’), 1.68 (dd, J = 14.9, 7.4 Hz, 2H, 
COCH2CH2); 13C NMR (101 MHz, CDCl3) δ 208.7 (C), 175.5 (C), 51.6 (CH3), 
40.9 (CH2), 34.1 (CH/CH3), 31.1 (CH2), 31.0 (CH/CH3), 30.5 (CH2), 29.8 
(CH/CH3). m/z (AP+) 185.0 ([M+H]+, 100%); HRMS Found ([M+H]+) 
185.1174. C10H17O3 req. 185.1172. 
Methyl (1r*,3s*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutanecarboxylate 
(84b) 
 
2-Aminonicotinaldehyde 83 (108 mg, 0.89 mmol) and pyrrolidine (0.05 ml, 43 
mg, 0.61 mmol) were added to a stirred solution of methyl (1r*,3s*)-3-(3-
oxobutyl)cyclobutanecarboxylate 82b  (101 mg, 0.55 mmol) in MeOH (8 ml) 
followed by 1 drop concentrated H2SO4 and the reaction mixture stirred at RT 
for 23.5 hours. The reaction mixture was concentrated in vacuo and the 
crude residue was purified via column chromatography (EtOAc) to yield the 
title compound 84b as a yellow oil (120 mg, 0.44 mmol, 80% yield); Rf 0.06 
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(1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.05 (dd, J = 4.2, 1.9 Hz, 1H, 
Ar H7), 8.12 (dd, J = 8.1, 1.9 Hz, 1H, Ar H5), 8.06 (d, J = 8.4 Hz, 1H, Ar H4), 
7.41 (dd, J = 8.1, 4.3 Hz, 1H, Ar H6), 7.34 (d, J = 8.3 Hz, 1H, Ar H3), 3.63 (s, 
3H, OCH3), 2.97 – 2.89 (m, 3H, H1+ArCH2), 2.32 – 2.26 (m, 3H, H2+H3+H4), 
2.02 – 1.85 (m, 4H, H2’+H4’+ArCH2CH2); 13C NMR (101 MHz, CDCl3) δ 
175.6 (C), 166.4 (C), 156.0 (C), 153.3 (CH), 136.9 (CH), 136.7 (CH), 122.5 
(CH), 121.4 (CH), 121.0 (C), 51.5 (CH3), 36.6 (CH2), 36.1 (CH2), 34.2 (CH), 
32.0 (CH), 31.4 (CH2); m/z (AP+) 271.1 ([M+H]+, 100%); HRMS Found 
([M+H]+) 271.1447. C16H19O2N2 req. 271.1441. 
(S)-5-Amino-5-oxo-2-(phenylsulfonamido)pentanoic acid (86a) 
 
Method of Duggan.122 
A solution of benzenesulfonyl chloride (4.08 ml, 5.65 g, 31.97 mmol) in 
dioxane (25 ml), and a solution of NaOH (1.81 g, 45.16 mmol) in H2O (25 ml) 
were added to a stirred solution of (S)-glutamine 85 (5.83 g, 39.96 mmol) and 
NaOH (1.81 g, 45.16 mmol) in dioxane:H2O (1:1, 50 ml) and stirred for 4 hour 
45 minutes. The dioxane was removed in vacuo and the aqueous solution 
was extracted with EtOAc (2 × 30 ml). The aqueous layer was then acidified 
to pH 1 with concentrated HCl and cooled to 0 °C for 20 minutes, the 
resulting white precipitate was collected via filtration and dried in a desiccator 
to give the title compound 86a as white crystals (7.16 g, 25.03 mmol, 78% 
yield); mp 175-177 °C; [α]D +0.187 (c 0.97, MeOH);1H NMR (400 MHz, 
DMSO) δ 8.17 (d, J = 8.7 Hz, 1H, NH), 7.76 (dd, J = 7.0, 1.5 Hz, 2H, Ph), 
7.64 – 7.59 (m, 1H, Ph), 7.55 (t, J = 7.3 Hz, 2H, Ph), 7.27 (s, 1H, NHH’), 6.76 
(s, 1H, NHH’), 3.71 (dd, J = 13.8, 8.3 Hz, 1H, CH), 2.07 (t, J = 7.7 Hz, 2H, 
H2NCOCH2), 1.89 – 1.77 (m, 1H, CHCHH’), 1.72 – 1.58 (m, 1H, CHCHH’); 
13C NMR (101 MHz, DMSO) δ 173.1 (C), 172.5 (C), 141.1 (C), 132.3 (CH), 
128.9 (CH), 126.4 (CH), 55.2 (CH), 30.7 (CH2), 27.9 (CH2); m/z (AP+) 269.9 
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([M-OH]+ 100%), 287.0 ([M+H]+, 20%); HRMS Found ([M+H]+) 287.0697. 
C11H15O5N2S req. 287.0696. 
(S)-5-Amino-5-oxo-2-(2,4,6-trimethylphenylsulfonamido)pentanoic acid 
(86b) 
 
Method of Duggan.122 
A solution of 2-mesitylenesulfonyl chloride (3.5 g, 16 mmol) in dioxane (25 
ml), and a solution of NaOH (904 mg, 22.6 mmol) in H2O (25 ml) were added 
to a stirred solution of (S)-glutamine 85 (2.92 g, 20.0 mmol) and NaOH (904 
mg, 22.6 mmol) in dioxane:H2O (1:1, 50 ml) and stirred for 4.5 hours. The 
dioxane was removed in vacuo and the aqueous solution was extracted with 
EtOAc (2 × 30 ml). The aqueous layer was then acidified to pH 1 with 
concentrated aqueous HCl and cooled to 0 °C for 30 minutes. The solution 
was concentrated to ~15 ml and the resulting white precipitate was collected 
via filtration and dried in a desiccator to give the title compound 86b as white 
crystals (713 mg, 2.17 mmol, 14% yield); mp 156-159 °C; [α]D +0.400 (c 0.05, 
MeOH);1H NMR (400 MHz, DMSO) δ 8.01 (d, J = 9.4 Hz, 1H, NH), 7.25 (s, 
1H, NH), 6.98 (s, 2H, Mes H3+H5), 6.76 (s, 1H, NH), 3.59 (td, J = 9.1, 5.2 
Hz, 1H, CH), 2.54 (s, 6H, Mes (CH3)2), 2.24 (s, 3H, Mes CH3), 2.12 – 2.05 
(m, 2H, NCOCH2), 1.89 – 1.78 (m, 1H, CHH’CH), 1.73 – 1.62 (m, 1H, 
CHH’CH); 13C NMR (101 MHz, DMSO) δ 173.2 (C), 172.7 (C), 141.2 (C), 
138.4 (C), 134.6 (C), 131.4 (CH), 54.7 (CH), 30.8 (CH2), 27.8 (CH2), 22.6 
(CH3), 20.4 (CH3); m/z (AP+) 312.1 ([M-NH2]+, 100%), 329.1 ([M+H]+, 20%); 
HRMS Found ([M+H]+) 329.1167. C14H21O5N2S req. 329.1166. 
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(S)-4-Amino-2-(phenylsulfonamido)butanoic acid (87a) 
 
Method of Duggan.122 
Bromine (1.51 ml, 4.71 g, 29.46 mmol) was added to a stirred solution of 
NaOH (7.27 g, 181.7 mmol) in H2O (20 ml) at 0 °C and stirred for 5 minutes. 
A solution of (S)-5-amino-5-oxo-2-(phenylsulfonamido)pentanoic acid 86a 
(7.02 g, 24.55 mmol) and NaOH (2.06 g, 51.6 mmol) in H2O (20 ml) was 
added and the resulting solution stirred for a further 20 minutes. The reaction 
mixture was then heated to 90 °C for 35 minutes. The reaction mixture was 
then cooled to 0 °C and carefully neutralised by dropwise addition of 
concentrated aqueous HCland left in ice for 2 hours, the resultant white 
precipitate was collected via filtration to give the title compound 87a as a 
white solid (6.28 g, 24.34 mmol, 99% yield); [α]D -0.034 (c 0.82, DMSO);1H 
NMR (400 MHz, D2O) δ 7.80 (d, J = 8.3 Hz, 2H, Ph), 7.63 (t, J = 7.3 Hz, 1H, 
Ph), 7.53 (t, J = 7.7 Hz, 2H, Ph), 4.02 (dd, J = 9.5, 4.6 Hz, 1H, CH), 3.02 (dd, 
J = 15.3, 7.5 Hz, 2H, NCH2), 2.10 (ddd, J = 14.4, 10.3, 5.5 Hz, 1H, CHH’CH), 
1.90 (ddd, J = 14.5, 12.4, 7.7 Hz, 1H, CHH’CH); 13C NMR (101 MHz, D2O) δ 
173.2 (C), 137.9 (C), 133.7 (CH), 129.4 (CH), 126.7 (CH), 53.3 (CH), 36.1 
(CH2), 29.6 (CH2); m/z (ES+) 259.1 ([M+H]+, 100%); HRMS Found ([M+H]+) 
259.0750. C10H15O4N2S req. 259.0747. 
(S)-4-Amino-2-(2,4,6-trimethylphenylsulfonamido)butanoic acid (87b) 
 
Method of Duggan.122 
Bromine (0.13 ml, 401 mg, 2.51 mmol) was added to a stirred solution of 
NaOH (619 mg, 15.47 mmol) in H2O (3 ml) at 0 °C and stirred for 5 minutes. 
A solution of (S)-5-amino-5-oxo-2-(2,4,6-trimethylphenylsulfonamido) 
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pentanoic acid 86b (684 mg, 2.09 mmol) and NaOH (176 mg, 4.39 mmol) in 
H2O (3 ml) was added and the resulting solution stirred for a further 20 
minutes. The reaction mixture was then heated to 90 °C for 35 minutes. The 
reaction mixture was then cooled to 0 °C and carefully neutralised by 
dropwise addition of concentrated aqueous HCland left in ice for 20 minutes. 
The resultant white precipitate was collected via filtration to give the title 
compound 87b as a white solid (287 mg, 0.96 mmol, 46% yield); [α]D +0.24 
(c 0.25, MeOH);1H NMR (400 MHz, D2O) δ 7.00 (s, 2H, Mes H3+H5), 3.84 
(dd, J = 9.7, 4.8 Hz, 1H, CH), 3.09 – 2.87 (m, 2H, NCH2), 2.48 (s, 6H, Mes 
(CH3)2), 2.19 (s, 3H, Mes CH3), 2.07 (ddd, J = 15.0, 10.5, 5.3 Hz, 1H, 
CHH’CH), 1.99 – 1.83 (m, 1H, CHH’CH);13C NMR (101 MHz, D2O) δ 170.4 
(C), 144.3 (C), 139.4 (C), 131.9 (CH), 131.5 (C), 52.9 (CH), 36.1 (CH2), 29.4 
(CH2), 22.0 (CH3), 20.0 (CH3); m/z (ES+) 301.1 ([M+H]+, 100%); HRMS 
Found ([M+H]+) 301.1212. C13H21O4N2S req. 301.1217. 
Methyl (S)-3-amino-2-(phenylsulfonamido)butanoate (88a) 
 
Thionyl chloride (0.19 ml, 2.73 mmol) was added to a stirred solution of (S)-3-
amino-2-(phenylsulfonamido)butanoic acid 87a (640 mg, 2.48 mmol) in 
MeOH (25 ml) and the reaction mixture stirred for 26 hours at RT. The 
reaction mixture was concentrated in vacuo and the residue partitioned 
between DCM (30 ml)  and saturated aqueous sodium bicarbonate solution 
(20 ml), the aqueous layer was further extracted with DCM (3 × 30 ml) and 
the combined organic phase dried (MgSO4) and concentrated in vacuo to 
give the title compound 88a as a clear oil (543 mg, 2.12 mmol, 86 % yield); 
1H NMR (400 MHz, CDCl3) δ 7.97 – 7.67 (m, 2H, Ph), 7.62 – 7.34 (m, 3H, 
Ph), 3.68 – 3.59 (m, 1H, CH), 3.41 (s, 3H, OCH3), 2.55 – 2.41 (m, 2H, NCH2), 
2.12 – 1.98 (m, 2H, CH2CH);13C NMR (101 MHz, CDCl3) δ 173.8 (C), 133.0 
(C), 129.2 (CH), 129.0 (CH), 127.3 (CH), 53.4 (CH), 50.8 (CH3), 39.1 (CH2), 
30.5 (CH2); m/z (AP+) 241.2 ([M-OMe]+, 100%), 273.2 ([M+H]+, 90%); 
HRMS Found ([M+H]+) 273.0901. C11H17O4N2S req. 273.0904. 
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 Methyl (S)-4-amino-2-(2,4,6-trimethylphenylsulfonamido)butanoate 
(88b) 
 
Thionyl chloride (0.07 ml, 119 mg, 1.0 mmol) was added to a stirred solution 
of (S)-4-amino-2-(2,4,6-trimethylphenylsulfonamido)butanoic acid 87b (272 
mg, 0.91 mmol) in MeOH (9 ml) and the reaction mixture stirred for  27 hours. 
The reaction mixture was concentrated in vacuo, partitioned between DCM 
(20 ml) and saturated aqueous sodium bicarbonate (20 ml). The aqueous 
layer was further extracted with DCM (20 ml) and the combined organic 
layers were dried (MgSO4) and concentrated in vacuo to give the title 
compound 88b as a clear oil (131 mg, 0.42 mmol, 46%);[α]D -0.614 (c 0.44, 
CHCl3);1H NMR (400 MHz, CDCl3) δ 6.87 (s, 2H, Mes H3+H5), 3.96 (dd, J = 
7.1, 5.0 Hz, 1H, CH), 3.40 (s, 3H, OCH3), 2.75 (t, J = 5.2 Hz, 2H, NCH2), 2.57 
(s, 6H, Mes (CH3)2), 2.22 (s, 3H, Mes CH3), 1.83 – 1.61 (m, J = 18.9, 13.4, 
6.7 Hz, 2H, CH2CH); 13C NMR (101 MHz, CDCl3) δ 172.4 (C), 142.3 (C), 
139.2 (C), 133.6 (C), 131.9 (CH), 54.1 (CH), 52.3 (CH3), 38.1 (CH2), 35.1 
(CH2), 23.0 (CH3), 21.0 (CH3); m/z (ES+) 304.9 (100%), 315.1([M+H]+, 10%); 
HRMS Found ([M+H]+) 315.1377. C14H23O4N2S req. 315.1373. 
Methyl 4-((1s*,3R*)-3-((1,8-naphthyridin-2-yl)methyl)cyclobutane 
carboxamido)-(S)-2-(phenylsulfonamido)butanoate (89a)   
 
Methyl (1s*,3s*)-3-((1,8-naphthyridin-2-yl)methyl)cyclobutanecarboxylate 84a 
(82 mg, 0.32 mmol)was dissolved in 6 M aqueous HCl (2 ml) and stirred at 
RT for 18 hours. The reaction mixture was concentrated in vacuo to give the 
crude acid. The acid was dissolved in DMF (10 ml) and (S)-methyl 4-amino-
2-(phenylsulfonamido)butanoate 88a (82 mg, 0.32 mmol), EDCI (258 mg, 
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1.16 mmol), HOBt (150 mg, 1.16 mmol) and DIPEA (0.34 ml, mg, 1.95 mmol) 
were added and the reaction mixture stirred at RT under a blanket of N2 for 
16 hours. The reaction mixture was diluted with H2O (10 ml), extracted with 
DCM (3 × 10 ml) and the combined organic layers washed with saturated 
ammonium chloride solution (2 × 10 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via PTLC (95:5, DCM:MeOH) to give 
the title compound 89a as a clear oil (50 mg, 0.10 mmol, 31% yield); Rf 0.32 
(95:5, DCM:MeOH); [α]D +0.12 (c 0.78, CHCl3); IR 3337.2 cm-1 (NH), 2930.5 
cm-1 (CH Sp3), 1701.1 cm-1 (C=O ester), 1640.6 cm-1 (C=O amide);1H NMR 
(400 MHz, CDCl3) δ 9.11 (dd, J = 4.1, 1.7 Hz, 1H, Ar H7), 8.18 (dd, J = 8.1, 
1.8 Hz, 1H, Ar H5), 8.11 (d, J = 8.3 Hz, 1H, Ar H4), 7.85 (d, J = 7.4 Hz, 2H, 
Ph), 7.59 (t, J = 7.4 Hz, 1H, Ph), 7.52 (t, J = 7.5 Hz, 2H, Ph), 7.47 (dd, J = 
8.1, 4.3 Hz, 1H, Ar H6), 7.37 (d, J = 8.2 Hz, 1H, Ar H3), 6.18 (t, J = 5.7 Hz, 
1H, NH), 5.76 (d, J = 8.8 Hz, 1H, NH), 3.99 – 3.89 (m, 1H, CH), 3.66 (dt, J = 
12.2, 5.3 Hz, 1H, H1), 3.47 (s, 3H, OCH3), 3.34 – 3.23 (m, 1H, H3), 3.18 (d, J 
= 7.4 Hz, 2H, ArCH2), 3.01 – 2.82 (m, 2H, CONHCH2), 2.44 – 2.32 (m, 2H, 
H2+H4), 2.22 – 2.05 (m, 3H, H2’+H4’+CHH’CH), 1.74 (ddd, J = 14.3, 9.8, 4.9 
Hz, 1H, CHH’CH); 13C NMR (101 MHz, CDCl3) δ 175.1 (C), 171.9 (C), 164.9 
(C), 156.0 (C), 153.3 (CH), 139.3 (C), 137.0 (CH), 136.8 (CH), 133.0 (CH), 
129.2 (CH), 127.2 (CH), 122.9 (CH), 121.5 (CH), 121.1 (C), 53.5 (CH), 52.6 
(CH3), 45.5 (CH2), 36.6 (CH), 35.3 (CH2), 32.6 (CH2), 31.6 (CH2), 31.5 (CH2), 
31.1 (CH); m/z (AP+) 125.0 (100%), 497.2 ([M+H]+, 15%); HRMS found 
([M+H]+) 497.1852 C25H29O5N4S req. 497.1853. 
Methyl 4-((1s*,3R*)-3-((1,8-naphthyridin-2-yl)methyl)cyclobutane 
carboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate (89b) 
 
Methyl (1s*,3s*)-3-((1,8-naphthyridin-2-yl)methyl)cyclobutanecarboxylate 84a 
(82 mg, 0.32 mmol)was dissolved in 6 M aqueous HCl (2 ml) and stirred at 
RT for 18 hours. The reaction mixture was concentrated in vacuo to give the 
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crude acid. The acid was dissolved in DMF (10 ml) and methyl (S)-4-amino-
2-(2,4,6-trimethylphenylsulfonamido)butanoate 88b (96 mg, 0.32 mmol), 
EDCI (258 mg, 1.16 mmol), HOBt (150 mg, 1.16 mmol) and DIPEA (0.34 ml, 
mg, 1.95 mmol) were added and the reaction mixture stirred at RT under a 
blanket of N2 for 16 hours. The reaction mixture was diluted with H2O (10 ml), 
extracted with DCM (3 × 10 ml) and the combined organic layers washed 
with saturated ammonium chloride solution (2 × 10 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via PTLC (95:5, 
DCM:MeOH) to give the title compound 89b as a clear oil (37 mg, 0.068 
mmol, 21% yield); Rf 0.36 (95:5, DCM:MeOH); [α]D +0.14 (c 0.92, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 9.02 (dd, J = 4.2, 1.9 Hz, 1H, Ar H7), 8.09 (dd, J = 
8.1, 1.9 Hz, 1H, Ar H5), 8.02 (d, J = 8.3 Hz, 1H, Ar H4), 7.38 (dd, J = 8.0, 4.2 
Hz, 1H, Ar H6), 7.28 (d, J = 8.2 Hz, 1H, Ar H3), 6.87 (s, 2H, Mes H3+H5), 
5.98 (t, J = 5.9 Hz, 1H, NH), 5.56 (d, J = 9.0 Hz, 1H, NH), 3.74 (dd, J = 11.2, 
7.0 Hz, 1H, H1), 3.58 (dt, J = 12.3, 5.2 Hz, 1H, CH), 3.39 (s, 3H, OCH3), 3.18 
– 3.11 (m, 1H, H3), 3.09 (d, J = 7.4 Hz, 2H, ArCH2), 2.89 – 2.82 (m, 1H, 
CONHCHH’), 2.76 (t, J = 8.5 Hz, 1H, CONHCHH’), 2.56 (s, 6H, Mes (CH3)2), 
2.27 (dt, J = 11.6, 8.1 Hz, 2H, CH2CH), 2.21 (s, 3H, Mes CH3), 2.08 – 1.88 
(m, 2H, H2+H4), 1.74 – 1.57 (m, 2H, H2’+H4’); 13C NMR (101 MHz, CDCl3) δ 
175.0 (C), 172.1 (C), 164.9 (C), 156.1 (C), 153.3 (CH), 142.6 (C), 139.2 (C), 
137.0 (CH), 136.8 (CH), 133.1 (C), 132.0 (CH), 122.9 (CH), 121.5 (CH), 
121.1 (C), 52.9 (CH), 52.6 (CH), 45.5 (CH2), 36.5 (CH), 35.2 (CH2), 32.5 
(CH2), 31.6 (CH2), 31.5 (CH2), 31.0 (CH3), 23.0 (CH3), 20.9 (CH3); m/z (AP+) 
539.3 ([M+H]+, 80%), 91.1 (100%); HRMS found ([M+H]+) 539.2314, 
C28H35N4S req. 539.2323. 
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Methyl 4-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(phenylsulfonamido)butanoate (90a) 
 
Methyl (1r*,3s*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutanecarboxylate 84b 
(68 mg, 0.25 mmol)was dissolved in 6 M aqueous HCl (2.5 ml) and stirred at 
RT for 17 hours. The reaction mixture was concentrated in vacuo to give the 
crude acid.The acid was dissolved in DCM (6 ml) and (S)-methyl 4-amino-2-
(phenylsulfonamido)butanoate 88a (67 mg, 0.25 mmol), EDCI (143 mg, 0.75 
mmol), HOBt (101 mg, 0.75 mmol) and DIPEA (0.22 ml, 161 mg, 1.25 mmol) 
were added and the reaction mixture stirred at RT under a blanket of N2 for 
24 hours. The reaction mixture was diluted with H2O (10 ml), extracted with 
DCM (2 × 10 ml) and the combined organic layers washed with saturated 
ammonium chloride solution (10 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via PTLC (95:5, DCM:MeOH) to give 
the title compound 90a as a clear oil (59 mg, 0.116 mmol, 46% yield); Rf 0.27 
(95:5, DCM:MeOH); IR 3333.2 cm-1(NH), 2936.2 cm-1 (CH Sp3), 1703.1 cm-1 
(C=O ester), 1639.2 cm-1 (C=O amide); 1H NMR (400 MHz, CDCl3) δ 9.01 
(dd, J = 4.3, 2.0 Hz, 1H, Ar H7), 8.09 (dd, J = 8.1, 2.0 Hz, 1H, Ar H5), 8.03 (d, 
J = 8.3 Hz, 1H, Ar H4), 7.79 – 7.72 (m, 2H, Ph), 7.56 – 7.41 (m, 3H, Ph), 7.38 
(dd, J = 8.1, 4.3 Hz, 1H, Ar H6), 7.32 (d, J = 8.4 Hz, 1H, Ar H3), 6.05 – 5.94 
(m, 1H), 5.62 (d, J = 9.2 Hz, 1H), 3.83 (td, J = 9.6, 4.3 Hz, 1H), 3.67 – 3.51 
(m, 1H), 3.38 (s, 3H, CH3), 3.20 – 3.08 (m, 1H), 2.91 (t, J = 7.6 Hz,  2H), 2.81 
– 2.68 (m, 1H), 2.29 – 2.17 (m, 3H), 2.07 – 1.97 (m, 1H), 1.93 (dd, J = 14.9, 
6.9 Hz, 2H), 1.87 – 1.79 (m, 2H), 1.67 – 1.56 (m, 1H); 13C NMR (101 MHz, 
CDCl3) δ 175.2 (C), 172.0 (C), 166.5 (C), 155.9 (C), 153.3 (CH), 139.1 (C), 
137.0 (CH), 136.8 (CH), 133.1 (CH), 129.2 (CH), 127.1 (CH), 122.6 (CH), 
121.5 (CH), 121.1 (C), 53.4 (CH), 52.7 (CH3), 39.1 (CH2), 36.7 (CH2), 36.2 
(CH), 36.1 (CH2), 35.1 (CH2), 32.5 (CH2), 31.5 (CH2), 31.2 (CH); m/z (AP-) 
509.31 ([M-H]-, 10%), 140.86 (100%); HRMS found ([M-H]-) 509.1854. 
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C26H29O5N4S req. 509.1864; LCMS rt 3.56, m/z (ES+) 511.3 ([M+H]+, 100%), 
>95%. 
Methyl 4-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate (90b) 
 
Methyl (1r*,3s*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutanecarboxylate 84b 
(45 mg, 0.17 mmol)was dissolved in 6 M aqueous HCl (2 ml) and stirred at 
RT for 18 hours. The reaction mixture was concentrated in vacuo to give the 
crude acid. The acid was dissolved in DCM (5 ml) and (S)-methyl 4-amino-2-
(2,4,6-trimethylphenylsulfonamido)butanoate 88b (53 mg, 0.17 mmol), EDCI 
(97 mg, 0.51 mmol), HOBt (69 mg, 0.51 mmol) and DIPEA (0.15 ml, 110 mg, 
0.85 mmol) were added and the reaction mixture stirred at RT under a 
blanket of N2 for 29 hours. The reaction mixture was diluted with H2O (10 ml), 
extracted with DCM (3 × 10 ml) and the combined organic layers washed 
with saturated ammonium chloride solution (2 × 10 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via PTLC (97:3, 
DCM:MeOH) to give the title compound 90b as a clear oil (76 mg, 0.13 mmol, 
76% yield); Rf 0.31 (95:5, DCM:MeOH); [α]D -0.057 (c 0.3, CHCl3); IR 3329.5 
cm-1 (NH), 2931.2 cm-1 (CH sp3), 1706.1 cm-1 (C=O ester), 1632.9 cm-1 (C=O 
amide);1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H, Ar H7), 8.10 (d, J = 7.2 Hz, 
1H, Ar H5), 8.03 (d, J = 8.3 Hz, 1H, Ar H4), 7.39 (app s, 1H, Ar H6), 7.32 (d, 
J = 8.3 Hz, 1H, Ar H3), 6.88 (s, 2H, Mes H3+H5), 5.93 (s, 1H), 5.52 (d, J = 
9.4 Hz, 1H), 3.72 (td, J = 9.7, 4.3 Hz, 1H), 3.59 (dt, J = 12.1, 5.1 Hz, 1H), 
3.38 (s, 3H, CH3), 3.11 (ddd, J = 19.1, 9.7, 4.9 Hz, 1H), 2.90 (s, 2H), 2.70 (dt, 
J = 17.9, 9.0 Hz, 1H), 2.57 (s, 6H, Mes (CH3)2), 2.22 (app s, 4H, Mes (CH3) + 
?), 2.04 – 1.72 (m, 7H), 1.59 (qd, J = 9.6, 4.6 Hz, 1H); 13C NMR (101 MHz, 
CDCl3) δ 175.05 (C), 172.16 (C), 166.54 (C), 155.83 (C), 153.30 (CH), 
142.68 (C), 139.12 (C), 137.00 (CH+CH), 132.99 (C), 132.05 (CH), 122.59 
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(CH), 121.47 (CH), 121.06 (C), 52.78 (CH), 52.63 (CH3), 36.68 (CH2), 36.20 
(CH), 36.00 (CH2), 35.09 (CH2), 32.50 (CH2), 31.47 (CH2), 31.40 (CH2), 
31.13 (CH), 23.01 (CH3), 20.96 (CH3); m/z (AP+) 553.23 ([M+H]+, 10%), 
239.02 (100%); HRMS found ([M+H]+) 553.2469. C29H37O5N4S req. 
553.2479; LCMS rt 7.81, m/z (ES+) 553.4 ([M+H]+, 100%), >95%. 
Methyl (S)-2-(phenylsulfonamido)-4-((1s*,3R*)-3-((5,6,7,8-tetrahydro-1,8-
naphthyridin-2-yl)methyl)cyclobutanecarboxamido)butanoate (72a) 
 
Methyl 4-((1s*,3R*)-3-((1,8-naphthyridin-2-yl)methyl)cyclobutane 
carboxamido)-(S)-2-(phenylsulfonamido)butanoate 89a (50 mg, 0.10 mmol) 
was dissolved in MeOH (5 ml), PtO2 (5 mg) was added and the reaction 
mixture stirred under 1 atm of H2 for 23 hours. The reaction mixture was 
filtered through Celite® and concentrated in vacuo. The crude residue was 
purified via PTLC (95:5, DCM:MeOH) to give the title compound 72a as a 
clear oil (8 mg, 0.016 mmol, 16% yield); Rf 0.29 (95:5, DCM:MeOH); [α]D 
+0.11 (c 0.44, CHCl3); IR 3318.6 cm-1 (NH), 3284.8 cm-1 (NH), 2928.6 cm-1 
(CH Sp3), 1733.5 cm-1 (C=O ester), 1650.6 cm-1 (C=O amide);1H NMR (400 
MHz, CDCl3) δ 7.81 – 7.71 (m, 2H, Ph), 7.55 – 7.47 (m, 1H, Ph), 7.44 (t, J = 
7.5 Hz, 2H, Ph), 7.01 (d, J = 7.1 Hz, 1H, Ar), 6.24 (d, J = 7.3 Hz, 1H, Ar), 
6.00 (s, 1H, NH), 3.84 (dd, J = 9.8, 4.2 Hz, 1H, H1), 3.56 (dt, J = 12.1, 5.4 
Hz, 1H, CH), 3.39 (s, 3H, OCH3), 3.33 (t, J = 4.6 Hz, 2H, THN), 3.23 – 3.10 
(m, 1H, H3), 2.75 (dt, J = 17.8, 9.0 Hz, 1H), 2.69 – 2.48 (m, 5H, 
THN+CONHCH2), 2.27 – 2.18 (m, 2H), 2.02 (ddd, J = 12.2, 8.6, 4.1 Hz, 1H), 
1.92 (dd, J = 20.5, 9.8 Hz, 2H, H2+H4), 1.87 – 1.79 (m, 2H, THN), 1.68 – 
1.56 (m, 2H, H2’+H4’); 13C NMR (101 MHz, CDCl3) δ 175.1 (C), 171.9 (C), 
158.5 (C), 155.2 (C), 139.2 (C), 137.3 (CH), 133.0 (CH), 129.2 (CH), 127.2 
(CH), 114.3 (C), 111.3 (CH), 53.5 (CH), 52.7 (CH3), 41.5 (CH2), 36.3 (CH), 
35.3 (CH2), 32.6 (CH2), 31.5 (CH2), 31.5 (CH2), 31.3 (CH), 26.2 (CH2), 21.1 
(CH2); m/z (AP+) 501.2 ([M+H]+, 100%); HRMS found ([M+H]+) 501.2161 
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C25H33O5N4S req. 501.2166; LCMS rt 2.01, m/z (ES+) 501.3 ([M+H]+, 100%), 
>95%. 
Methyl 4-((1s*,3R*)-3-((5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl) 
methyl)cyclobutanecarboxamido)-(S)-2-(2,4,6-
trimethylphenylsulfonamido)butanoate (72b) 
 
Methyl 4-((1s*,3R*)-3-((1,8-naphthyridin-2-yl)methyl)cyclobutane 
carboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate 89b (30 
mg, 0.056 mmol) was dissolved in MeOH (3 ml), PtO2 (3 mg) was added and 
the reaction mixture stirred under 1 atm of H2 for 23 hours. The reaction 
mixture was filtered through Celite® and concentrated in vacuo. The crude 
residue was purified via PTLC (95:5, DCM:MeOH) to give the title compound 
72b as a clear oil (7 mg, 0.0138 mmol, 25% yield); Rf 0.34 (95:5, 
DCM:MeOH); [α]D +0.09 (c 0.375, CHCl3); IR 3274.8 cm-1 (NH), 2932.8 cm-1 
(CH Sp3), 1737.5 cm-1 (C=O ester), 1655.8 cm-1 (C=O amide);1H NMR (400 
MHz, CDCl3) δ 7.00 (d, J = 7.2 Hz, 1H, Ar), 6.88 (s, 2H, Mes H3,5), 6.23 (d, J 
= 7.3 Hz, 1H, Ar), 5.90 (t, J = 6.1 Hz, 1H, NH), 3.73 (dd, J = 9.8, 4.3 Hz, 1H, 
H1), 3.57 (dt, J = 12.2, 5.2 Hz, 1H, CH), 3.39 (s, 3H, OCH3), 3.37 – 3.31 (m, 
2H, THN), 3.11 (ddd, J = 14.2, 9.8, 5.0 Hz, 1H, H3), 2.76 – 2.65 (m, 2H, 
CONHCH2), 2.62 (t, J = 6.3 Hz, 2H, THN), 2.57 (s, 6H, Mes (CH3)2), 2.55 – 
2.47 (m, 1H), 2.22 (s, 3H, Mes CH3), 2.22 – 2.15 (m, 2H), 2.05 – 1.95 (m, 
1H), 1.94 – 1.87 (m, 2H, H2+H4), 1.87 – 1.79 (m, 2H, THN), 1.66 – 1.55 (m, 
2H, H2’+H4’); 13C NMR (101 MHz, CDCl3) δ 175.0 (C), 172.1 (C), 155.3 (C), 
142.7 (C), 139.2 (C), 137.1 (CH), 134.3 (C), 133.1 (C), 132.0 (CH), 114.1 (C), 
111.4 (CH), 52.9 (CH), 52.6 (CH3), 41.5 (CH2), 36.3 (CH2), 35.2 (CH), 32.5 
(CH2), 31.5 (CH2), 31.5 (CH2), 31.3 (CH), 29.7 (CH2), 26.2 (CH2), 23.0 (CH3), 
21.2 (CH2), 20.9 (CH3); m/z (AP+) 229.1 (100%), 543.2 ([M+H]+, 50%); 
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HRMS Found ([M+H]+) 543.2633. C28H39O5N4S req. 543.2636; LCMS rt 
3.47, m/z (ES+) 543.4 ([M+H]+, 100%), >95%. 
Methyl(S)-2-(phenylsulfonamido)-4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-
naphthyridin-2-yl)ethyl)cyclobutanecarboxamido)butanoate (73a) 
 
PtO2 (5 mg) was added to a solution of methyl 4-((1r*,3R*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutanecarboxamido)-(S)-2-(phenylsulfonamido) 
butanoate (46 mg, 0.09 mmol) 90a in MeOH (5 ml) and the reaction mixture 
stirred under 1 atm of H2 at RT for 23 hours. The reaction mixture was filtered 
through Celite® and concentrated in vacuo. The crude residue was purified 
via PTLC (95:5, DCM:MeOH) to give the title compound 73a as a yellow oil 
(15 mg, 0.029 mmol, 32% yield); Rf 0.23 (95:5, DCM:MeOH); [α]D +0.16 (c 
0.50, CHCl3); IR 3286.9 cm-1 (NH), 2933.5 cm-1 (CH Sp3), 1739.2 cm-1 (C=O 
ester), 1648.4 cm-1 (C=O amide);1H NMR (400 MHz, CDCl3) δ 7.79 – 7.73 
(m, 2H, Ph), 7.55 – 7.49 (m, 1H, Ph), 7.49 – 7.42 (m, 2H, Ph), 7.21 (d, J = 
7.4 Hz, 1H, Ar), 6.32 (d, J = 7.4 Hz, 1H, Ar), 6.14 (t, J = 5.9 Hz, 1H), 3.84 (dd, 
J = 9.4, 4.3 Hz, 1H), 3.57 – 3.47 (m, 1H), 3.38 (s, 3H, CH3), 3.22 – 3.12 (m, 
1H), 2.77 (p, J = 8.7 Hz, 1H), 2.67 (t, J = 6.1 Hz, 2H), 2.52 – 2.46 (m, 2H), 
2.29 – 2.13 (m, 3H), 2.03 – 1.95 (m, 1H), 1.91 – 1.77 (m, 5H), 1.77 – 1.60 (m, 
4H). 13C NMR (101 MHz, CDCl3) δ 175.2 (C), 171.9 (C), 152.7 (C), 151.7 (C), 
139.8 (CH), 139.2 (C), 133.0 (CH), 129.2 (CH), 127.2 (CH), 117.0 (C), 110.5 
(CH), 53.6 (CH), 52.7 (CH3), 41.4 (CH2), 36.1 (CH), 35.9 (CH2), 35.3 (CH2), 
32.4 (CH2), 32.0 (CH2), 31.2 (CH2), 31.2 (CH2), 30.71 (CH), 25.8 (CH2), 19.9 
(CH2); m/z (ES+) 515.4 ([M+H]+, 100%); LCMS rt 2.10, m/z (ES+) 515.4 
([M+H]+, 100%), >95%. 
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Methyl 4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
yl)ethyl)cyclobutanecarboxamido)-(S)-2-(2,4,6-
trimethylphenylsulfonamido)butanoate (73b)  
Methyl 4-((1s*,3S*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl) 
cyclobutanecarboxamido)-(S)-2-(2,4,6-
trimethylphenylsulfonamido)butanoate (73b’) 
 
PtO2 (6 mg) was added to a stirred solution of methyl 4-((1r*,3R*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutanecarboxamido)-(S)-2-(2,4,6-trimethylphenyl 
sulfonamido)butanoate 90b (60 mg, 0.106 mmol) in MeOH (7 ml) and the 
reaction mixture stirred under 1 atm of H2 at RT for 22 hours 30 minutes. The 
reaction mixture was filtered through Celite® and concentrated in vacuo. The 
crude residue was purified via PTLC (97:3, DCM:MeOH) to give the two title 
compounds: 
methyl 4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl) 
cyclobutanecarboxamido)-(S)-2-(2,4,6-
trimethylphenylsulfonamido)butanoate (73b):  
as a clear oil (32 mg, 0.056 mmol, 53% yield); Rf 0.25 (95:5, DCM:MeOH); 
[α]D +0.08 (c 0.8, CHCl3); IR 3382.7 cm-1 (NH), 3287.4 cm-1 (NH), 2930.7 cm-
1 (CH Sp3), 1727.8 cm-1 (C=O ester), 1640.7 cm-1 (C=O amide); 1H NMR 
(400 MHz, CDCl3) δ 7.07 (d, J = 7.3 Hz, 1H, Ar), 6.96 (s, 2H, Mes H3+H5), 
6.32 (d, J = 7.3 Hz, 1H, Ar), 5.99 (s, 1H, NH), 5.61 (s, 1H, NH), 5.04 (s, 1H, 
NH), 3.79 (dd, J = 9.8, 4.0 Hz, 1H), 3.72 – 3.60 (m, 1H), 3.45 (s, 3H, CH3), 
3.43 – 3.38 (m, 2H), 3.23 – 3.13 (m, 1H), 2.81 – 2.72 (m, 1H), 2.73 – 2.66 (m, 
3H), 2.65 (s, 6H, Mes (CH3)2), 2.50 – 2.42 (m, 2H), 2.30 (s, 3H, Mes CH3), 
2.29 – 2.17 (m, 3H), 1.90 (dt, J = 15.5, 7.5 Hz, 4H), 1.75 (dd, J = 15.3, 7.2 
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Hz, 2H), 1.70 – 1.61 (m, 1H); 13C NMR (101 MHz, CDCl3) δ 175.17 (C), 
172.19 (C), 157.57 (C), 155.44 (C), 142.68 (C), 139.14 (C), 136.89 (CH), 
133.00 (C), 132.05 (CH), 113.47 (C), 111.11 (CH), 52.77 (CH), 52.63 (CH3), 
41.58 (CH2), 36.57 (CH2), 36.28 (s), 35.08 (CH2), 34.91 (CH2), 32.50 (CH2), 
31.50 (CH2), 31.43 (CH2), 31.13 (CH), 26.30 (CH2), 23.01 (CH3), 21.39 
(CH2), 20.97 (CH3); m/z (AP+) 557.3 ([M+H]+, 40%), 373.3 ([M-SO2Mes]+, 
20%), 341.3 (100%); HRMS found ([M+H]+) 557.2781. C29H41O5N4S req. 
557.2792; LCMS rt 3.42, m/z (ES+) 557.4 ([M+H]+, 100%), >95%. 
methyl 4-((1s*,3S*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl) 
cyclobutanecarboxamido)-(S)-2-(2,4,6-
trimethylphenylsulfonamido)butanoate (73b’):  
as a clear oil (6 mg, 0.01 mmol, 9% yield); Rf 0.20 (95:5, DCM:MeOH); [α]D 
+0.04 (c 0.3, CHCl3); IR 3289.4 cm-1 (NH), 2931.2 cm-1 (CH Sp3), 1732.1 cm-
1 (C=O ester), 1632.1 cm-1 (C=O amide);1H NMR (400 MHz, CDCl3) δ 7.23 
(d, J = 7.4 Hz, 1H, Ar), 6.96 (s, 2H, Mes H3+H5), 6.37 – 6.32 (m, 1H, Ar), 
6.16 (s, 1H, NH), 5.71 (s, 1H, NH), 3.80 (d, J = 4.9 Hz, 1H), 3.68 – 3.57 (m, 
1H), 3.46 (app s, 5H, CH3+ ? ), 3.27 – 3.15 (m, 1H), 2.84 – 2.77 (m, 1H), 2.72 
(dd, J = 12.2, 6.0 Hz, 2H), 2.65 (s, 6H, Mes (CH3)2), 2.61 – 2.54 (m, 2H), 2.30 
(s, 3H, Mes CH3), 2.36 – 2.19 (m, 1H), 2.10 – 1.99 (m, 2H), 1.98 – 1.88 (m, 
3H), 1.84 (dd, J = 15.0, 7.0 Hz, 2H), 1.77 – 1.67 (m, 2H); 13C NMR (101 MHz, 
CDCl3) δ 175.05 (C), 172.13 (C), 156.60 (C), 153.38 (C), 142.64 (C), 139.14 
(C), 135.67 (CH), 133.08 (C), 132.03 (CH), 111.04 (C), 110.13 (CH), 52.90 
(CH), 52.59 (CH3), 41.21 (CH2), 36.19 (CH), 35.97 (CH2), 35.18 (CH2), 32.45 
(CH2), 31.27 (CH2), 31.16 (CH2), 30.74 (CH), 29.72 (CH2), 25.80 (CH2), 
23.03 (CH3), 20.97 (CH3), 20.15 (CH2); m/z (AP+) 557.3 ([M+H]+, 20%), 
373.3 ([M-SO2Mes]+, 50%), 341.3 (100%); HRMS found ([M+H]+) 557.2784. 
C29H41O5N4S req. 557.2792; LCMS rt 4.91, m/z (ES+) 557.4 ([M+H]+, 100%), 
>95%. 
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(1R*, 3S*)-3-(2-(1,8-Naphthyridin-2-yl)ethyl)cyclobutanamine (91) 
 
Method of Chang.123 
Methyl (1r*,3s*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutanecarboxylate 84b 
(292 mg, 1.08 mmol) was dissolved in 6 M aqueous HCl (10 ml) and stirred 
at RT for 24 hours. The reaction mixture was concentrated in vacuo to give 
the crude acid. This was dissolved in CHCl3 (4 ml) and conc. H2SO4 (2 ml) 
and heated to 45 °C. NaN3 (140 mg, 2.16 mmol) was then added portionwise 
and the reaction mixture stirred for 5 hours. It was then allowed to cool to RT 
and the reaction was quenched with water (2 ml), extracted with DCM (10 ml) 
and the aqueous phase adjusted to pH 14 with 50% aqueous NaOH. The 
aqueous layer was then extracted with DCM (4 × 15 ml), dried (MgSO4) and 
concentrated in vacuo to give the title compound 91 as a yellow oil (245 mg, 
1.08 mmol, 100% yield); 1H NMR (400 MHz, CDCl3) δ 9.00 (dd, J = 4.2, 1.9 
Hz, 1H, Ar, H7), 8.07 (dd, J = 8.1, 1.9 Hz, 1H, Ar H5), 8.01 (d, J = 8.3 Hz, 1H, 
Ar H4), 7.36 (dd, J = 8.1, 4.2 Hz, 1H, Ar H6), 7.29 (d, J = 8.4 Hz, 1H, Ar H3), 
3.19 – 3.07 (m, 1H, H1), 2.92 – 2.86 (m, 2H, ArCH2), 2.41 – 2.31 (m, 2H), 
1.90 (dd, J = 15.2, 7.5 Hz, 2H), 1.85 – 1.76 (m, 1H, H3), 1.43 (bs, 2H, NH2), 
1.22 (ddd, J = 18.0, 9.0, 2.8 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 166.7 
(C), 156.0 (C), 153.3 (CH), 136.8 (CH), 136.7 (CH), 122.6 (CH), 121.4 (CH), 
121.0 (C), 44.9 (CH), 40.5 (CH2), 37.3 (CH2), 36.8 (CH2), 27.4 (CH); m/z 
(AP+) 227.8 ([M+H]+, 100%); HRMS Found ([M+H]+) 228.1499. C14H18N3 
req. 228.1495. 
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(S)-4-Methoxy-4-oxo-3-(phenylsulfonamido)butanoic acid (93a) 
 
Method of Reich.124 
Sodium bicarbonate (53 mg, 0.63 mmol) was added to a stirred suspension 
of (S)-Asp-(OMe) 92  (74 mg, 0.5 mmol) in H2O:dioxane (1:1, 3 ml) and the 
mixture stirred for 30 minutes at RT. Phenylsulfonyl chloride (0.05 ml, 74 mg, 
0.42 mmol) was added and the mixture stirred for a further 22 hours. The 
dioxane was removed in vacuo, the reaction mixture acidified with 3 M 
aqueous HClresulting in a fine white precipitate and the mixture was 
extracted with DCM (5 x 20 ml). The combined organic layers were dried 
(MgSO4) and concentrated in vacuo to give the title compound 93a as a clear 
oil (75 mg, 0.26 mmol, 62% yield); 1H NMR (400 MHz, CDCl3) δ 7.83 – 7.78 
(m, 2H, Ph), 7.55 – 7.49 (m, 1H, Ph), 7.47 – 7.42 (m, 2H, Ph), 6.21 (d, J = 
8.4 Hz, 1H, NH), 4.17 – 4.06 (m, 1H, CH), 3.49 (s, 3H, OCH3), 3.00 (dd, J = 
17.5, 4.2 Hz, 1H, CHH’), 2.83 (dd, J = 17.5, 4.7 Hz, 1H, CHH’); 13C NMR 
(101 MHz, CDCl3) δ 174.7 (C), 170.3 (C), 139.6 (C), 133.0 (CH), 129.1 (CH), 
127.2 (CH), 53.0 (CH3), 51.9 (CH), 37.8 (C); m/z  (AP+) 288.0 ([M+H]+, 
100%); HRMS Found ([M+H]+) 288.0542. C11H14O6NS req. 288.0536. 
(S)-4-Methoxy-4-oxo-3-(2,4,6-trimethylphenylsulfonamido)butanoic acid 
(93b) 
 
Method of Reich.124 
Sodium bicarbonate (53 mg, 0.63 mmol) was added to a stirred suspension 
of (S)-Asp-(OMe) 92 (74 mg, 0.5 mmol) in H2O:dioxane (1:1, 3 ml) and the 
mixture stirred for 30 minutes at RT. 2,4,6-Trimethylphenylsulfonyl chloride 
(92 mg, 0.42 mmol) in dioxane (1.5 ml) was added and the mixture stirred for 
a further 16 hours. The dioxane was removed in vacuo. The reaction mixture 
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was acidified with 3 M aqueous HCl resulting in a fine white precipitate and 
the mixture was extracted with DCM (5 × 20 ml). The combined organic 
layers were dried (MgSO4) and concentrated under reduced pressure to give 
the crude product which was purified via PTLC (95:5, DCM:MeOH) to give 
the title compound 93b as a clear oil (36 mg, 0.11 mmol, 26% yield); 1H NMR 
(400 MHz, CDCl3) δ 6.88 (s, 2H, Mes H3+H5), 5.96 (d, J = 6.2 Hz, 1H, NH), 
4.04 – 3.96 (m, 1H, CH), 3.55 (s, 3H, OCH3), 2.94 (dd, J = 17.2, 2.6 Hz, 1H, 
CHH’), 2.81 (dd, J = 17.2, 3.7 Hz, 1H, CHH’), 2.57 (s, 6H, Mes (CH3)2), 2.22 
(s, 3H, Mes CH3); 13C NMR (101 MHz, CDCl3) δ 175.1 (C), 170.6 (C), 142.6 
(C), 139.32 (C), 133.3 (C), 132.0 (CH), 53.1 (CH3), 51.6 (CH), 37.6 (CH2), 
22.9 (CH3), 21.0 (CH3); m/z  (AP+) 330.1 ([M+H]+, 100%). 
Methyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-
4-oxo-(S)-2-(phenylsulfonamido)butanoate (94a) 
N-((S)-1-((1r*,3R*)-3-(2-(1,8-Naphthyridin-2-yl)ethyl)cyclobutyl)-2,5-
dioxopyrrolidin-3-yl)benzenesulfonamide (95a) 
EDCI (103 mg, 0.54 mmol), HOBt (73 mg, 0.54 mmol) and DIPEA (0.16 ml, 
116 mg, 0.90 mmol) were added to a stirred solution of (1r*,3s*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutanamine 91 (41 mg, 0.18 mmol) and (S)-4-
methoxy-4-oxo-3-(phenylsulfonamido)butanoic acid 93a (51 mg, 0.18 mmol) 
in DCM (4 ml) and stirred at RT under a blanket of N2 for 24 hours. The 
reaction mixture was diluted with water (10 ml) and extracted with DCM (3 x 
15 ml). The combined organic layers were washed with saturated aqueous 
ammonium chloride (10 ml), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via PTLC (95:5, DCM:MeOH) to give the two title 
compounds: 
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Methyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-
4-oxo-(S)-2-(phenylsulfonamido)butanoate (94a): 
 clear oil (39 mg, 0.079 mmol, 44% yield); Rf 0.17 (95:5, DCM:MeOH); [α]D 
+0.135 (c 1.1, CHCl3); IR 3260.6 cm-1 (NH), 2923.4 cm-1 (CH Sp3), 1735.0 
cm-1 (C=O ester), 1632.4 cm-1 (C=O amide); 1H NMR (400 MHz, CDCl3) δ 
9.08 (dd, J = 4.1, 1.9 Hz, 1H, Ar H7), 8.17 (dd, J = 8.1, 1.9 Hz, 1H, Ar H5), 
8.10 (d, J = 8.2 Hz, 1H, Ar H4), 7.86 (d, J = 7.2 Hz, 2H, Ph), 7.59 – 7.54 (m, 
1H, Ph), 7.52 – 7.44 (m, 3H, Ph+Ar H6), 7.37 (d, J = 8.2 Hz, 1H, Ar H3), 6.07 
(t, J = 7.0 Hz, 2H, (NH)2), 4.19 – 4.07 (m, 2H, H1+CH), 3.53 (s, 3H, OCH3), 
2.96 (t, J = 7.5 Hz, 2H, ArCH2), 2.87 (dd, J = 15.7, 4.4 Hz, 1H, CHH’), 2.64 
(dd, J = 15.7, 4.6 Hz, 1H, CHH’), 2.51 – 2.39 (m, 2H, ArCH2CH2), 2.09 – 1.94 
(m, 3H, H2+H3+H4), 1.48 (dd, J = 19.8, 9.3 Hz, 2H, H2’+H4’); 13C NMR (101 
MHz, CDCl3) δ 170.8 (C), 168.1 (C), 166.4 (C), 155.9 (C), 153.3 (CH), 140.0 
(C), 137.1 (CH), 136.9 (CH), 132.8 (CH), 129.0 (CH), 127.1 (CH), 122.7 
(CH), 121.6 (CH), 121.1 (C), 52.8 (CH3), 52.6 (CH), 41.2 (CH), 38.9 (CH2), 
37.0 (CH2), 36.9 (CH2), 36.9 (CH2), 36.2 (CH2), 28.7 (CH); m/z  (ES+) 497.0 
([M+H]+, 100%); HRMS Found ([M+H]+) 497.1848. C25H29O5N4S req. 
497.1853; LCMS rt 3.52, m/z (ES+) 497.3 ([M+H]+, 100%), >95%. 
N-((S)-1-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)-2,5-
dioxopyrrolidin-3-yl)benzenesulfonamide (95a):  
white solid (15 mg, 0.032 mmol, 18% yield); Rf 0.25 (95:5, DCM:MeOH); [α]D 
+0.150 (c 0.9, CHCl3); IR 3310.8 cm-1 (NH), 2928.1 cm-1 (CH Sp3), 1737.9 
cm-1 (C=O succinimide);1H NMR (400 MHz, CDCl3) δ 8.96 (dd, J = 4.2, 2.0 
Hz, 1H, Ar H7), 8.08 (dd, J = 8.1, 1.9 Hz, 1H, Ar H5), 8.01 (d, J = 8.3 Hz, 1H, 
Ar H4), 7.86 – 7.82 (m, 2H, Ph), 7.57 – 7.52 (m, 1H, Ph), 7.47 (t, J = 7.5 Hz, 
2H, Ph), 7.37 (dd, J = 8.1, 4.3 Hz, 1H, Ar H6), 7.29 (d, J = 8.3 Hz, 1H, Ar H3), 
6.20 (s, 1H, NH), 4.33 – 4.21 (m, 1H, H1), 4.03 (dd, J = 8.6, 6.1 Hz, 1H, CH), 
2.98 – 2.86 (m, 3H,CHH’+ArCH2), 2.78 (dd, J = 18.1, 6.1 Hz, 1H, CHH’), 2.34 
– 2.21 (m, 2H, H2,4), 2.18 – 2.07 (m, 2H, H2,4), 2.00 – 1.93 (m, 3H, H3+ 
ArCH2CH2); 13C NMR (101 MHz, CDCl3) δ 174.7 (C), 174.0 (C), 166.4 (C), 
155.8 (C), 153.2 (CH), 139.1 (C), 137.1 (CH), 136.8 (CH), 133.3 (CH), 129.4 
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(CH), 127.3 (CH), 122.6 (CH), 121.5 (CH), 121.0 (C), 51.3 (CH), 42.5 (CH), 
36.9 (CH2), 36.8 (CH2), 35.9 (CH2), 32.3 (CH2), 32.0 (CH2), 28.8 (CH); m/z  
(ES+) 465.0 ([M+H]+, 100%); HRMS Found ([M+H]+) 465.1587. 
C24H25O4N4S req. 465.1591; LCMS rt 3.56, m/z (ES+) 465.3 ([M+H]+, 100%), 
>95%. 
Methyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-
4-oxo-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate (94b) 
N-((S)-1-((1r*,3R*)-3-(2-(1,8-Naphthyridin-2-yl)ethyl)cyclobutyl)-2,5-
dioxopyrrolidin-3-yl)-2,4,6-trimethylbenzenesulfonamide (95b) 
EDCI (63 mg, 0.33 mmol), HOBt (45 mg, 0.33 mmol) and DIPEA (0.096 ml, 
71 mg, 0.55 mmol) were added to a stirred solution of (1r*,3s*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutanamine 91 (25 mg, 0.11 mmol) and (S)-4-
methoxy-4-oxo-3-(2,4,6-trimethylphenylsulfonamido)butanoic acid 93b (36 
mg, 0.11 mmol) in DMF (3 ml) and stirred at RT, under a blanket of N2 for 
24.5 hours. The reaction mixture was diluted with water (25 ml) and extracted 
with EtOAc (3 × 25 ml). The combined organic layers were washed with 
saturated aqueous ammonium chloride (2 × 25 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via PTLC (95:5, 
DCM:MeOH) to give the two title compounds: 
methyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-
4-oxo-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate (94b): 
yellow oil (26 mg, 0.048 mmol, 44% yield); Rf 0.17 (95:5, DCM:MeOH); [α]D 
+0.234 (c 0.87, CHCl3); IR 3274.2 cm-1 (NH), 2937.1 cm-1 (CH Sp3), 1742.6 
cm-1 (C=O ester), 1644.3 cm-1 (C=O amide);1H NMR (400 MHz, CDCl3) δ 
9.02 (dd, J = 4.2, 1.9 Hz, 1H, Ar H7), 8.09 (dd, J = 8.1, 1.9 Hz, 1H, Ar H5), 
8.03 (d, J = 8.2 Hz, 1H, Ar H4), 7.39 (dd, J = 8.1, 4.3 Hz, 1H, Ar H6), 7.29 (d, 
J = 8.3 Hz, 1H, Ar H3), 6.86 (s, 2H, Mes H3+H5), 5.99 (d, J = 7.7 Hz, 1H, 
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NH), 5.85 (d, J = 7.8 Hz, 1H, NH), 4.13 – 4.06 (m, 1H, H1), 4.00 – 3.93 (m, 
1H, CH), 3.50 (s, 3H, OCH3), 2.89 (t, J = 7.4 Hz, 2H, ArCH2), 2.76 (dd, J = 
15.6, 4.1 Hz, 1H, CHH’), 2.56 (s, 6H, Mes (CH3)2), 2.52 (dd, J = 15.8, 5.0 Hz, 
1H, CHH’), 2.43 – 2.35 (m, 2H, H2+H4), 2.21 (s, 3H, Mes CH3), 1.96 – 1.88 
(m, 3H, H3+ArCH2CH2), 1.39 (dd, J = 19.1, 9.7 Hz, 2H, H2’+H4’); 13C NMR 
(101 MHz, CDCl3) δ 171.1 (C), 168.2 (C), 166.3 (C), 155.9 (C), 153.4 (CH), 
142.3 (C), 139.1 (C), 137.1 (CH), 136.8 (CH), 133.9 (C), 131.9 (CH), 122.7 
(CH), 121.5 (CH), 121.1 (C), 52.8 (CH3), 52.3 (CH), 41.2 (CH), 38.7 (CH2), 
37.0 (CH2), 36.9 (CH2), 36.2 (CH2), 28.7 (CH), 22.9 (CH3), 21.0 (CH3); m/z 
(ES+) 539.0 ([M+H]+, 100%); HRMS Found ([M+H]+) 539.2318. 
C28H35O5N4S req. 539.2323; LCMS rt 7.48, m/z (ES+) 539.3 ([M+H]+, 100%), 
>95%. 
N-((S)-1-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)-2,5-
dioxopyrrolidin-3-yl)-2,4,6-trimethylbenzenesulfonamide (95b): 
yellow oil (26 mg, 0.051 mmol, 46% yield); Rf 0.22 (95:5, DCM:MeOH); [α]D 
+0.034 (c 0.87, CHCl3); IR 2923.1 cm-1 (CH Sp3), 1735.0 cm-1 (C=O 
succinimide); 1H NMR (400 MHz, CDCl3) δ 9.00 (d, J = 2.4 Hz, 1H, Ar H7), 
8.09 (dd, J = 8.1, 1.8 Hz, 1H, Ar H5), 8.03 (d, J = 8.3 Hz, 1H, Ar H4), 7.38 
(dd, J = 8.0, 4.2 Hz, 1H, Ar H6), 7.31 (d, J = 8.3 Hz, 1H, Ar H3), 6.92 (s, 2H, 
Mes H3+H5), 5.55 (s, 1H, NH), 4.28 (p, J = 9.5 Hz, 1H, H1), 3.87 (dd, J = 
8.5, 6.0 Hz, 1H, CH), 2.93 – 2.80 (m, 3H, ArCH2+CHH’), 2.62 (dd, J = 18.3, 
6.4 Hz, 1H, CHH’), 2.59 (s, 6H, Mes (CH3)2), 2.38 – 2.28 (m, 2H, H2+H4), 
2.24 (s, 3H, Mes CH3), 2.23 – 2.15 (m, 2H, H2’+H4’), 2.00 (app t, J = 5.8 Hz, 
3H, ArCH2CH2+H3); 13C NMR (101 MHz, CDCl3) δ 174.9 (C), 173.9 (C), 
166.3 (C), 155.9 (C), 153.3 (CH), 143.2 (C), 139.4 (C), 137.1 (CH), 136.8 
(CH), 132.3 (CH), 132.2 (C), 122.5 (CH), 121.5 (CH), 121.0 (C), 51.1 (CH), 
42.6 (CH), 36.9 (CH2), 36.8 (CH2), 35.8 (CH2), 32.4 (CH2), 32.0 (CH2), 28.8 
(CH), 22.9 (CH3), 21.0 (CH3); m/z  (ES+) 507.0 ([M+H]+, 100%); HRMS 
Found ([M+H]+) 507.2053. C27H31O4N4S req. 507.206; LCMS rt 8.12, m/z 
(ES+) 507.3 ([M+H]+, 100%), >95%. 
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Methyl (S)-4-oxo-2-(phenylsulfonamido)-4-(((1r*,3R*)-3-(2-(5,6,7,8-
tetrahydro-1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)butanoate (74a) 
Methyl (S)-4-oxo-2-(phenylsulfonamido)-4-(((1s*,3S*)-3-(2-(5,6,7,8-
tetrahydro-1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)butanoate 
(74a’) 
PtO2 (3 mg) was added to a solution of methyl 4-((3-(2-(1,8-naphthyridin-2-
yl)ethyl)cyclobutyl)amino)-4-oxo-(S)-2-(phenylsulfonamido)butanoate 94a (63 
mg, 0.13 mmol) in EtOH (5 ml) and the reaction mixture stirred under 1 atm 
of H2 at RT for 23.5 hours. The reaction mixture was filtered through Celite® 
and concentrated in vacuo. The crude residue was purified via PTLC (97:3, 
DCM:MeOH) to give the two title compounds: 
(cis)-methyl (S)-4-oxo-2-(phenylsulfonamido)-4-(((1r*,3R*)-3-(2-(5,6,7,8-
tetrahydro-1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)butanoate 
(74a): 
white solid (30 mg, 0.06 mmol, 46% yield); Rf 0.36 (95:5, DCM:MeOH); [α]D 
+0.170 (c 1.00, CHCl3); IR 3252.8 cm-1 (NH), 2923.8 cm-1 (CH Sp3), 1743.4 
cm-1 (C=O ester), 1644.8 cm-1 (C=O amide);1H NMR (400 MHz, CDCl3) δ 
7.79 (d, J = 7.3 Hz, 2H, Ph), 7.52 – 7.47 (m, 1H, Ph), 7.42 (t, J = 7.5 Hz, 2H, 
Ph), 7.01 (d, J = 7.2 Hz, 1H, Ar), 6.24 (d, J = 7.2 Hz, 1H, Ar), 5.92 (s, 1H, 
NH), 4.10 – 4.00 (m, 2H, H1+CH), 3.46 (s, 3H, OCH3), 3.33 (d, J = 4.1 Hz, 
2H, THN), 2.76 (dd, J = 15.6, 4.4 Hz, 1H, CHH’), 2.62 (t, J = 6.2 Hz, 2H, 
THN), 2.55 (dd, J = 15.6, 4.7 Hz, 1H, CHH’), 2.42 – 2.33 (m, 4H, 
ArCH2+H2+H4), 1.84 (dt, J = 11.4, 5.0 Hz, 3H, H2’+H3+H4’), 1.67 (dd, J = 
15.3, 7.5 Hz, 2H, THN), 1.42 – 1.31 (m, 2H, ArCH2CH2); 13C NMR (101 MHz, 
CDCl3) δ 170.8 (C), 168.1 (C), 156.8 (C), 155.3 (C), 140.0 (C), 137.2 (CH), 
132.7 (CH), 129.0 (CH), 127.1 (CH), 113.9 (C), 111.1 (CH), 52.8 (CH3), 52.7 
(CH), 41.5 (CH2), 41.4 (CH), 38.9 (CH2), 36.9 (CH2), 36.8 (CH2), 34.9 (CH2), 
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28.6 (CH), 26.2 (CH2), 21.2 (CH2); m/z (AP+) 501.3 ([M+H]+ 100%), 469.2 
([M-OMe]+ 20%); HRMS Found ([M+H]+) 501.2158. C25H33O5N4S req. 
501.2166; LCMS rt 1.88, m/z (ES+) 501.3 ([M+H]+, 100%), >95%. 
(trans)-methyl (S)-4-oxo-2-(phenylsulfonamido)-4-(((1s*,3S*)-3-(2-
(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
yl)ethyl)cyclobutyl)amino)butanoate (74a’): 
Clear oil (7 mg, 0.014 mmol, 11% yield); Rf 0.34 (95:5, DCM:MeOH); [α]D 
+0.234 (c 0.35, CHCl3); IR 3257.9 cm-1 (NH), 2925.5 cm-1 (CH Sp3), 1735.2 
cm-1 (C=O ester), 1647.6 cm-1 (C=O amide); 1H NMR (400 MHz, CDCl3) δ 
7.82 – 7.75 (m, 2H, Ph), 7.51 – 7.44 (m, 1H, Ph), 7.41 (t, J = 7.5 Hz, 2H, Ph), 
7.18 (d, J = 7.2 Hz, 1H, Ar), 6.65 (d, J = 7.0 Hz, 1H, NH), 6.27 (d, J = 7.2 Hz, 
1H, Ar), 4.09 (dt, J = 12.9, 6.5 Hz, 2H, H1+CH), 3.45 (s, 3H, OCH3), 3.48 – 
3.39 (m, 2H, THN), 2.81 (dd, J = 15.5, 5.1 Hz, 1H, CHH’), 2.67 (t, J = 6.2 Hz, 
2H, THN), 2.58 (dd, J = 15.6, 4.6 Hz, 1H, CHH’), 2.53 – 2.45 (m, 2H, 
H2+H4), 2.45 – 2.38 (m, 2H, ArCH2), 1.99 – 1.79 (m, 5H, THN+H2’+H3+H4’), 
1.54 (dd, J = 12.3, 4.8 Hz, 2H, ArCH2CH2); 13C NMR (101 MHz, CDCl3) δ 
170.9 (C), 168.3 (C), 153.2 (C), 151.2 (C), 140.3 (CH), 139.5 (C), 132.6 (CH), 
128.9 (CH), 127.1 (CH), 117.0 (C), 110.3 (CH), 52.9 (CH3), 52.6 (CH), 41.8 
(CH), 41.2 (CH2), 38.7 (CH2), 36.4 (CH2), 35.7 (CH2), 32.3 (CH2), 28.9 (CH), 
25.7 (CH2), 20.0 (CH2); m/z (AP+) 501.3 ([M+H]+ 100%), 469.2 ([M-OMe]+ 
20%); HRMS Found ([M+H]+) 501.2159. C25H33O5N4S req. 501.2166; LCMS 
rt 2.10, m/z (ES+) 501.3 ([M+H]+, 100%), >95%. 
Methyl 4-oxo-4-(((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
yl)ethyl)cyclobutyl)amino)-(S)-2-(2,4,6-
trimethylphenylsulfonamide)butanoate (74b) 
 
PtO2 (2 mg) was added to a solution of methyl 4-(((1r*,3R*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutyl)amino)-4-oxo-(S)-2-(2,4,6-
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trimethylphenylsulfonamido)butanoate 94b (35 mg, 0.065 mmol) in EtOH (4 
ml), and the reaction mixture stirred under 1 atm of H2 at RT for 25 hours. 
The reaction mixture was filtered through Celite® and concentrated in vacuo. 
The crude residue was purified via PTLC (95:5, DCM:MeOH) to give the title 
compound 74b as a pale yellow gummy solid (21 mg, 0.039 mmol, 60% 
yield): Rf 0.30 (95:5, DCM:MeOH); [α]D +0.202 (c 1.05, CHCl3); IR 3310.4 cm-
1 (NH), 2927.9 cm-1 (CH Sp3), 1737.8 cm-1 (C=O ester), 1639.1 cm-1 (C=O 
amide);1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 7.3 Hz, 1H, Ar), 6.86 (s, 2H, 
Mes H3,5), 6.24 (d, J = 7.3 Hz, 1H, Ar), 5.94 (d, J = 7.6 Hz, 1H, NH), 5.42 (s, 
1H, NH), 4.06 (dd, J = 16.1, 8.2 Hz, 1H, H1), 3.98 (t, J = 4.5 Hz, 1H, CH), 
3.50 (s, 3H, OCH3), 3.37 – 3.30 (m, 2H, THN), 2.74 (dd, J = 15.5, 4.3 Hz, 1H, 
CHH’), 2.62 (t, J = 6.2 Hz, 2H, THN), 2.56 (s, 6H, Mes (CH3)2), 2.52 (dd, J = 
15.7, 5.0 Hz, 1H, CHH’), 2.39 (dd, J = 15.4, 7.7 Hz, 4H, ArCH2+H2+H4), 2.21 
(s, 3H, Mes CH3), 1.85 (ddd, J = 17.6, 11.0, 6.8 Hz, 3H, THN+H3), 1.69 (dd, 
J = 15.4, 7.5 Hz, 2H, ArCH2CH2), 1.39 (dd, J = 17.6, 8.7 Hz, 2H, H2’+H4’); 
13C NMR (101 MHz, CDCl3) δ 171.1 (C), 168.2 (C), 156.1 (C), 155.0 (C), 
142.2 (C), 139.1 (C), 137.5 (CH), 134.0 (C), 131.9 (CH), 114.3 (C), 111.0 
(CH), 52.7 (CH3), 52.4 (CH), 41.5 (CH2), 41.4 (CH), 38.7 (CH2), 36.8 (CH2), 
36.8 (CH2), 34.6 (CH2), 28.6 (CH), 26.2 (CH2), 22.9 (CH3), 21.1 (CH2), 20.9 
(CH3); m/z (AP+) 543.2 ([M+H]+ 10%), 511.1 ([M-OMe]+ 80%); HRMS Found 
([M+H]+) 543.2629. C28H39O5N4S req. 543.2636; LCMS rt 3.46, m/z (ES+) 
543.4 ([M+H]+, 100%), >95%. 
N-((S)-2,5-dioxo-1-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
yl)ethyl)cyclobutyl)pyrrolidin-3-yl)benzenesulfonamide (96a) 
 
PtO2 (3 mg) was added to a solution of N-((S)-1-((1r*,3R*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutyl)-2,5-dioxopyrrolidin-3-
yl)benzenesulfonamide 95a (30 mg, 0.065 mmol) in MeOH (3 ml), and the 
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reaction mixture stirred under 1 atm of H2 at RT for 23.5 hours. The reaction 
mixture was filtered through Celite® and concentrated in vacuo. The crude 
residue was purified via PTLC (95:5, DCM:MeOH) to give the title compound 
96a as a white solid (15 mg, 0.032 mmol, 49% yield): Rf 0.33 (95:5, 
DCM:MeOH); [α]D +0.075 (c 0.735, CHCl3); IR 2937.4 cm-1 (CH Sp3), 1700.3 
cm-1 (C=O succinimide);1H NMR (400 MHz, CDCl3) δ 7.86 – 7.81 (m, 2H, 
Ph), 7.59 – 7.53 (m, 1H, Ph), 7.48 (t, J = 7.6 Hz, 2H, Ph), 6.98 (d, J = 7.3 Hz, 
1H, Ar), 6.22 (d, J = 7.3 Hz, 1H, Ar), 4.94 (s, 1H, NH), 4.33 – 4.19 (m, 1H, 
H1), 3.95 (dd, J = 8.7, 6.0 Hz, 1H, CH), 3.31 (t, J = 5.5 Hz, 2H, THN), 2.95 
(dd, J = 18.2, 8.7 Hz, 1H, CHH’), 2.68 (dd, J = 18.2, 6.0 Hz, 1H, CHH’), 2.61 
(t, J = 6.3 Hz, 2H, THN), 2.37 (t, J = 7.5 Hz, 2H, ArCH2), 2.31 – 2.23 (m, 2H, 
H2+H4), 2.21 – 2.13 (m, 2H, H2’+H4’), 1.95 – 1.87 (m, 1H, H3), 1.85 – 1.78 
(m, 2H, THN), 1.74 (dd, J = 15.3, 7.5 Hz, 2H, ArCH2CH2); 13C NMR (101 
MHz, CDCl3) δ 174.7 (C), 173.7 (C), 157.4 (C), 155.5 (C), 138.8 (C), 136.8 
(CH), 133.4 (CH), 129.4 (CH), 127.3 (CH), 113.5 (C), 111.1 (CH), 51.3 (CH), 
42.7 (CH), 41.6 (CH2), 37.0 (CH2), 36.3 (CH2), 35.1 (CH2), 32.4 (CH2), 32.1 
(CH2), 28.8 (CH), 26.3 (CH2), 21.4 (CH2); m/z (ES+) 469.0 ([M+H]+ 100%); 
HRMS Found ([M+H]+) 469.1900. C24H29O4N4S req. 469.1904; LCMS rt 
2.33, m/z (ES+) 469.3 ([M+H]+, 100%), >95%. 
N-((S)-2,5-Dioxo-1-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-
yl)ethyl)cyclobutyl)pyrrolidin-3-yl)-2,4,6-trimethylbenzenesulfonamide 
(96b)  
 
PtO2 (1 mg) was added to a solution of N-((S)-1-((1r*,3R*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutyl)-2,5-dioxopyrrolidin-3-yl)-2,4,6-
trimethylbenzenesulfonamide 95b (10 mg, 0.02 mmol) in MeOH (2 ml), and 
the reaction mixture stirred under 1 atm of H2 at RT for 23.5 hours. The 
reaction mixture was filtered through Celite® and concentrated in vacuo. The 
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crude residue was purified via PTLC (95:5, DCM:MeOH) to give the title 
compound 96b as a yellow oil (3 mg, 0.0065 mmol, 33% yield): Rf 0.30 (95:5, 
DCM:MeOH); [α]D +0.079 (c 0.165, CHCl3); IR 2939.9 cm-1 (CH Sp3), 1706.1 
cm-1 (C=O succinimide);1H NMR (400 MHz, CDCl3) δ 6.99 (d, J = 7.3 Hz, 1H, 
Ar), 6.92 (s, 2H, Mes H3,5), 6.24 (d, J = 7.3 Hz, 1H, Ar), 4.33 – 4.19 (m, 1H, 
H1), 3.83 (dd, J = 8.6, 6.0 Hz, 1H, CH), 3.36 – 3.29 (m, 2H, THN), 2.85 (dd, J 
= 18.2, 8.6 Hz, 1H, CHH’), 2.64 – 2.54 (m, 9H, Mes (CH3)2+THN+CHH’), 2.42 
– 2.37 (m, 2H, ArCH2), 2.33 – 2.25 (m, 2H, H2+H4), 2.24 (s, 3H, Mes CH3), 
2.18 (dt, J = 10.8, 7.4 Hz, 2H, H2’+H4’), 1.97 – 1.88 (m, 1H, H3), 1.86 – 1.79 
(m, 2H, THN), 1.76 (dd, J = 15.3, 7.5 Hz, 2H, ArCH2CH2); 13C NMR (101 
MHz, CDCl3) δ 175.0 (C), 174.0 (C), 156.2 (C), 155.2 (C), 143.3 (C), 139.6 
(C), 137.4 (CH), 132.4 (CH), 132.2 (C), 113.4 (C), 111.0 (CH), 51.2 (CH), 
42.8 (CH), 41.6 (CH2), 37.0 (CH2), 36.3 (CH2), 32.5 (CH2), 32.2 (CH2), 28.9 
(CH), 26.3 (CH2), 23.0 (CH3), 21.3 (CH2), 21.1 (CH3); m/z (ES+) 511.2 
([M+H]+ 100%); HRMS Found ([M+H]+) 511.2367. C27H35O4N4S req. 
511.2374. 
(S)-4-(tert-butoxy)-4-oxo-2-(phenylsulfonamido)butanoic acid (99a) 
 
Method.124 
NaHCO3 (105 mg, 1.25 mmol) was added to a stirred suspension of (S)-
Asp(OtBu)-OH 98 (189 mg, 1 mmol) in dioxane:water (1:1, 6 ml) and stirred 
at RT for 45 minutes. Benzenesulfonyl chloride (0.108 ml, 150 mg, 0.85 
mmol) was added and the reaction mixture stirred for a further 28 hours. The 
dioxane was removed in vacuo, the aqueous layer was acidified with 3 M 
HCl, extracted with DCM (4 × 20 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via PTLC (95:5, DCM:MeOH) to give 
the title compound 99a as a white foam (131 mg, 0.40 mmol, 40% yield); Rf 
0.26 (95:5, DCM:MeOH); [α]D +0.330 (c 0.63, CHCl3); 1H NMR (400 MHz, 
CDCl3) δ 7.80 (d, J = 7.4 Hz, 2H, Ph), 7.51 (t, J = 7.3 Hz, 1H, Ph), 7.43 (t, J = 
7.5 Hz, 2H, Ph), 5.74 (d, J = 8.2 Hz, 1H, NH), 4.13 – 4.06 (m, 1H, CH), 2.82 
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(dd, J = 17.1, 4.3 Hz, 1H, CHH’), 2.67 (dd, J = 17.1, 5.1 Hz, 1H, CHH’), 1.34 
(s, 9H, tBu); 13C NMR (101 MHz, CDCl3) δ 174.25 (C), 169.76 (C), 139.69 
(C), 133.00 (CH), 129.15 (CH), 127.14 (CH), 82.56 (C), 52.02 (CH), 38.76 
(CH2), 27.97 (CH3); m/z (ES-) 328.1 ([M-H]-, 100%); HRMS found 
([M+NH4]+) 347.1270 C14H23O6N2S req. 347.1271. 
tert-Butyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl) 
amino)-4-oxo-(S)-3-(phenylsulfonamido)butanoate (100) 
 
EDCI (172 mg, 0.9 mmol), HOBt (122 mg, 0.9 mmol) and DIPEA (0.26 ml, 
194 mg, 1.5 mmol) were added to a stirred solution of (1r*,3s*)-3-(2-(1,8-
naphthyridin-2-yl)ethyl)cyclobutanamine 91 (68 mg, 0.3 mmol) and (S)-4-
(tert-butoxy)-4-oxo-2-(phenylsulfonamido)butanoic acid 99a (100 mg, 0.3 
mmol) in DCM (8 ml) and stirred at RT, under a blanket of N2 for 22 hours 30 
minutes. The reaction mixture was diluted with water (15 ml) and extracted 
with DCM (3 × 15 ml). The combined organic layers were washed with 
saturated aqueous ammonium chloride (10 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via PTLC (97:3, 
DCM:MeOH) to give the title compound 100 as a yellow oil (80 mg, 0.15 
mmol, 50% yield); Rf 0.45 (95:5, DCM:MeOH); [α]D +0.21 (c 1.0, CHCl3); IR 
2973.2 cm-1 (CH Sp3), 1724.8 cm-1 (C=O ester), 1655.3 cm-1 (C=O amide);1H 
NMR (400 MHz, CDCl3) δ 9.03 (dd, J = 4.2, 2.0 Hz, 1H, Ar H7), 8.10 (dd, J = 
8.1, 2.0 Hz, 1H, Ar H5), 8.04 (d, J = 8.2 Hz, 1H, Ar H4), 7.79 (d, J = 7.4 Hz, 
2H, Ph), 7.57 – 7.50 (m, 1H, Ph), 7.45 (t, J = 7.6 Hz, 2H, Ph), 7.39 (dd, J = 
8.1, 4.2 Hz, 1H, Ar H6), 7.30 (d, J = 8.2 Hz, 1H, Ar H3), 6.59 (d, J = 7.9 Hz, 
1H, NH), 6.23 (d, J = 8.8 Hz, 1H, NH), 4.00 – 3.88 (m, 2H), 2.89 (t, J = 7.3 
Hz, 2H, ArCH2), 2.78 (dd, J = 17.2, 4.0 Hz, 1H), 2.37 – 2.27 (m, 2H), 2.19 
(dd, J = 17.2, 6.6 Hz, 1H), 2.02 – 1.86 (m, 5H), 1.32 (s, 9H, tBu); 13C NMR 
(101 MHz, CDCl3) δ 171.12 (C), 168.29 (C), 166.33 (C), 155.91 (C), 153.37 
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(CH), 139.78 (C), 137.06 (CH), 136.82 (CH), 133.16 (CH), 129.40 (CH), 
127.06 (CH), 122.60 (CH), 121.54 (CH), 121.06 (C), 82.30 (C), 52.94 (CH), 
41.30 (CH), 37.17 (CH2), 36.92 (CH2), 36.70 (CH2), 36.02 (CH2), 28.62 (CH), 
27.96 (CH3); m/z (AP+) 228.0 (100%), 539.3 ([M+H]+, 20%); HRMS Found 
[M+H]+ 539.2320. C28H35O5N4S req. 539.2323; LCMS rt 7.30, m/z (ES+) 
539.4 ([M+H]+, 100%), >95%. 
tert-Butyl (S)-4-oxo-3-(phenylsulfonamido)-4-(((1r*,3R*)-3-(2-(5,6,7,8-
tetrahydro-1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)butanoate (101) 
 
tert-Butyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-4-
oxo-(S)-3-(phenylsulfonamido)butanoate 100 (56 mg, 0.10 mmol) was 
dissolved in MeOH (6 ml), PtO2 (6 mg) was added and the reaction mixture 
stirred under 1 atm of H2 for 24 hours. The reaction mixture was filtered 
through Celite® and concentrated in vacuo. The crude residue was purified 
via PTLC (95:5, DCM:MeOH) to give the title compound 101 as a clear oil (48 
mg, 0.089 mmol, 89% yield); Rf 0.42 (95:5, DCM:MeOH); [α]D +0.177 (c 0.96, 
CHCl3); IR 3287.2 cm-1 (NH), 2927.7 cm-1 (CH Sp3), 1725.1 cm-1 (C=O 
ester), 1654.7 cm-1 (C=O amide);1H NMR (400 MHz, CDCl3) δ 7.79 (d, J = 
7.6 Hz, 2H, Ph), 7.54 (t, J = 7.4 Hz, 1H, Ph), 7.46 (t, J = 7.6 Hz, 2H, Ph), 7.00 
(d, J = 7.3 Hz, 1H, Ar), 6.50 (d, J = 7.8 Hz, 1H, NH), 6.23 (d, J = 7.3 Hz, 1H, 
Ar), 3.94 (dd, J = 16.6, 8.7 Hz, 1H), 3.88 (dd, J = 6.6, 3.8 Hz, 1H), 3.37 – 
3.30 (m, 2H), 2.79 (dd, J = 17.3, 3.9 Hz, 1H), 2.62 (t, J = 6.2 Hz, 3H), 2.40 – 
2.33 (m, 3H), 2.33 – 2.26 (m, 2H), 2.15 (dd, J = 17.2, 6.7 Hz, 1H), 1.88 – 
1.79 (m, 4H), 1.64 (dd, J = 15.4, 7.6 Hz, 2H), 1.31 (s, 9H, tBu); 13C NMR (101 
MHz, CDCl3) δ 171.18 (C), 168.20 (C), 157.36 (C), 155.46 (C), 139.74 (C), 
136.91 (CH), 133.18 (CH), 129.42 (CH), 127.06 (CH), 113.57 (C), 111.12 
(CH), 82.30 (C), 53.47 (CH2), 52.86 (CH), 41.58 (CH2), 41.37 (CH), 37.02 
(CH2), 36.81 (CH2), 35.24 (CH2), 28.52 (CH), 27.96 (CH3), 26.30 (CH2), 
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21.36 (CH2); m/z (AP+) 543.3 ([M+H]+, 100%); HRMS Found ([M+H]+) 
543.2629. C28H39O5N4S req. 543.2636; LCMS rt 2.94, m/z (ES+) 543.4 
([M+H]+, 100%), >95%. 
(S)-4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-4-
oxo-3-(phenylsulfonamido)butanoic acid (102) 
 
tert-Butyl 4-(((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)-4-
oxo-(S)-3-(phenylsulfonamido)butanoate 100 (21 mg, 0.039 mmol) was 
dissolved in DCM (2 ml) and TFA (0.3 ml) and the reaction mixture stirred for 
24 hours. The reaction mixture was concentrated in vacuo to give the title 
compound 102 as a yellow solid (26 mg, 0.039 mmol, 100% yield); Rf 0.24 
(95:5, DCM:MeOH); [α]D +0.24 (c 1.12, CHCl3); IR 3261.9 cm-1 (NH), 2919.7 
cm-1 (CH Sp3), 1731.1 cm-1 (C=O acid), 1637.3 cm-1 (C=O amide);1H NMR 
(400 MHz, MeOD) δ 9.16 (d, J = 4.7 Hz, 1H, Ar H7), 8.87 (dd, J = 8.3, 1.7 Hz, 
1H, Ar H5), 8.81 (d, J = 8.5 Hz, 1H, Ar H4), 7.96 – 7.85 (m, 2H, Ph), 7.79 – 
7.69 (m, 2H, Ph+Ar H6), 7.50 (dd, J = 16.2, 8.8 Hz, 1H, H3), 7.43 (t, J = 7.5 
Hz, 2H, Ph), 3.99 (t, J = 6.6 Hz, 1H), 3.77 (dt, J = 16.8, 8.4 Hz, 1H), 3.09 – 
3.02 (m, 2H, ArCH2), 2.45 (dd, J = 16.4, 6.7 Hz, 1H), 2.35 (dd, J = 16.4, 6.7 
Hz, 1H), 2.30 – 2.15 (m, 2H), 1.98 – 1.85 (m, 3H), 1.49 – 1.32 (m, 2H); m/z 
(ES+) 483.3 ([M+H]+, 100%). 13C-NMR was not obtained as the acid began 
reacting with MeOD to form methyl esters in situ; LCMS rt 2.92, m/z (ES+) 
483.3 ([M+H]+, 100%), >95%. 
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(S)-4-oxo-3-(phenylsulfonamido)-4-(((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-
1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)butanoic acid (97a) 
 
tert-Butyl 4-oxo-(S)-3-(phenylsulfonamido)-4-(((1r,3R)-3-(2-(5,6,7,8-tetra 
hydro-1,8-naphthyridin-2-yl)ethyl)cyclobutyl)amino)butanoate 101 (13 mg, 
0.024 mmol) was dissolved in DCM (1 ml) and TFA (0.2 ml) and the reaction 
mixture stirred for 2.5 hours. The reaction mixture was concentrated in vacuo 
to give the title 97a compound as a yellow solid (16 mg, 0.039 mmol, 100% 
yield); Rf 0.10 (95:5, DCM:MeOH); [α]D +0.102 (c 1.00, CHCl3); IR 3253.5 cm-
1 (NH), 2931.9 cm-1 (CH Sp3), 1725.0 cm-1 (C=O ester), 1636.4 cm-1 (C=O 
amide);1H NMR (400 MHz, MeOD) δ 7.82 – 7.72 (m, 2H, Ph), 7.58 – 7.40 (m, 
4H, Ph+Ar), 6.51 (d, J = 7.3 Hz, 1H, Ar), 4.01 (t, J = 6.6 Hz, 1H), 3.78 (dt, J = 
16.7, 8.3 Hz, 1H), 3.45 – 3.34 (m, 2H, ArCH2), 2.78 – 2.67 (m, 2H), 2.55 – 
2.48 (m, 2H), 2.45 (dd, J = 16.5, 6.6 Hz, 1H), 2.37 (dd, J = 16.5, 6.6 Hz, 1H), 
2.31 – 2.18 (m, 2H), 1.91 – 1.81 (m, 3H), 1.68 (dd, J = 15.2, 7.5 Hz, 2H), 
1.39 (dt, J = 19.6, 9.7 Hz, 2H); m/z (ES+) 487.3 ([M+H]+, 100%).13C-NMR 
was not obtained as the acid began reacting with MeOD to form methyl 
esters in situ; LCMS rt 2.01, m/z (ES+) 487.3 ([M+H]+, 100%), >95%. 
tert-Butyl methyl(6-methylpyridin-2-yl)carbamate (106) 
 
2-Aminopicoline 105 (1.20 g, 11.0 mmol) and Boc2O (2.66 g, 12.0 mmol) 
were stirred at 60 °C for 18 hours. The reaction mixture was then cooled, 
partitioned between saturated aqueous ammonium chloride (30 ml) and 
EtOAc (30 ml). The aqueous layer was extracted with EtOAc (30 ml), and the 
combined organic layers dried (MgSO4) and concentrated in vacuo to give 
the crude Boc protected amine, which was dissolved in DMF (15 ml) and 
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added slowly to a stirred suspension of NaH (60% dispersion in oil, 528 mg, 
13.2 mmol) in DMF (30 ml) at 0 °C under a blanket of N2. After 15 minutes 
the reaction mixture was allowed to warm to RT and stirred for a further 1 
hour. MeI (0.89 ml, 2.03 g, 14.3 mmol) was added and the reaction mixture 
stirred for 18 hours. The reaction mixture was partitioned between saturated 
aqueous ammonium chloride (30 ml) and EtOAc (30 ml), extracted with 
EtOAc (2 × 30 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:9→2:8, EtOAc:PE) to 
give the title compound 106 as a yellow oil (2.04 g, 9.18 mmol, 83% yield); Rf 
0.56 (3:7, EtOAc:PE);1H NMR (400 MHz, CDCl3) δ 7.58 – 7.47 (m, 1H, H3), 
7.43 – 7.34 (m, 1H, H4), 6.87 (d, J = 7.3 Hz, 1H, H5), 3.40 (s, 3H, NCH3), 
2.50 (s, 3H, CH3), 1.52 (s, 9H, tBu). Consistent with literature.125 
tert-Butyl (6-(but-3-en-1-yl)pyridin-2-yl)(methyl)carbamate (108) 
 
nBuLi (1.6 M in hexanes, 6.31 ml, 10.10 mmol) was added dropwise to a 
stirred solution of diisopropylamine (1.62 ml, 1.16 g, 11.50 mmol) in THF (10 
ml) at 0 °C under a blanket of N2. The solution was stirred for 30 minutes 
before being added dropwise to a stirred solution of tert-butyl methyl(6-
methylpyridin-2-yl)carbamate 106  (2.04 g, 9.18 mmol) in THF (15 ml) at −78 
°C under a blanket of N2 and stirred for 40 minutes. Allyl bromide 107 (0.99 
ml, 1.39 g, 11.50 mmol) was added and the reaction mixture stirred for a 
further 2 hours 10 minutes. The solution was allowed to warm to RT, 
quenched with saturated aqueous ammonium chloride (30 ml) extracted with 
ethyl acetate (2 × 40ml), and the combined organic layers dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column  
chromatography (1:9, EtOAc:PE) to give the title compound 108 as a yellow 
oil (1.637 g, 6.25 mmol, 68% yield); Rf 0.67 (3:7, EtOAc:PE);1H NMR (400 
MHz, CDCl3) δ 7.54 – 7.49 (m, 1H, Py H4), 7.44 (d, J = 8.2 Hz, 1H, Py H3), 
6.84 (d, J = 7.1 Hz, 1H, Py H5), 5.88 (ddt, J = 17.0, 10.2, 6.5 Hz, 1H, 
CH=CH2), 5.05 (ddd, J = 17.0, 3.3, 1.6 Hz, 1H, CH=CHH’), 4.97 (dd, J = 
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10.2, 1.6 Hz, 1H, CH=CHH’), 3.40 (s, 3H, NCH3), 2.79 (t, J = 7.6 Hz, 2 H, 
PyCH2), 2.54 – 2.45 (m, 2H, PyCH2CH2), 1.51 (s, 9H, tBu). Consistent with 
literature.96 
tert-Butyl (6-(4-hydroxybutyl)pyridin-2-yl)(methyl)carbamate (109) 
 
Method of Brown.126 
A solution of BH3∙THF (1 M in THF, 5.7 ml, 5.7 mmol) was added dropwise to 
a stirred solution of tert-butyl (6-(but-3-en-1-yl)pyridin-2-yl)(methyl)carbamate 
108 (1.00 g, 3.8 mmol) in THF (12 ml) at 0 °C and allowed to warm to RT 
while stirring for 2 hours 20 minutes under a blanket of N2. NaOH (1 M in 
water, 7.5 ml, 7.5 mmol) and 30% v/v aqueous H2O2 (2.5 ml) were added 
and the reaction mixture stirred for a further 3 hours. Saturated aqueous 
sodium potassium tartrate (20 ml) and water (20 ml) were added and the 
reaction mixture extracted with DCM (2 × 30 ml). The combined organic 
layers were dried (MgSO4) and concentrated in vacuo to give the title 
compound 109 as a clear oil (988 mg, 3.53 mmol, 93% yield); Rf 0.22 (3:7, 
EtOAc:PE);1H NMR (400 MHz, CDCl3) δ 7.45 (t, J = 7.8 Hz, 1H, Py H4), 7.35 
(d, J = 8.2 Hz, 1H, Py H3), 6.78 (d, J = 7.3 Hz, 1H, Py H5), 3.61 (t, J = 6.4 
Hz, 2H, CH2OH), 3.31 (s, 3H, NCH3), 2.70 (t, J = 7.5 Hz, 2H, PyCH2), 1.80 – 
1.67 (m, 3H, CH2+OH), 1.61 – 1.52 (m, 2H, CH2), 1.44 (s, 9H, tBu). 
Consistent with literature.96 
tert-Butyl methyl(6-(4-oxobutyl)pyridin-2-yl)carbamate (110) 
 
TEMPO (3 mg, 0.02 mmol) and BAIB (64 mg, 0.20 mmol) were added to a 
stirred solution of tert-butyl (6-(4-hydroxybutyl)pyridin-2-yl)(methyl)carbamate 
109 (50 mg, 0.18 mmol) in DCM (2 ml) and the reaction mixture stirred at RT 
for 4.5 hours. The reaction mixture was then diluted with DCM (10 ml), and 
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washed with saturated aqueous sodium thiosulfate (10 ml).  The aqueous 
layer was further extracted with DCM (15 ml) and the combined organic 
layers washed with saturated aqueous sodium bicarbonate (15 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (3:7, EtOAc:PE) to give the title compound 110 as a 
yellow oil (32 mg, 0.12 mmol, 66% yield).1H NMR (400 MHz, CDCl3) δ 9.71 
(t, J = 1.5 Hz, 1H, COH), 7.49 – 7.36 (m, 2H, Py H3+H4), 6.76 (d, J = 7.1 Hz, 
1H, Py H5), 3.31 (s, 3H, NCH3), 2.69 (t, J = 7.5 Hz, 2H, PyCH2), 2.43 (td, J = 
7.3, 1.5 Hz, 2H,CH2COH), 2.01 (dt, J = 15.1, 7.6 Hz, 2H, CH2), 1.44 (s, 9H, 
tBu); 13C NMR (101 MHz, CDCl3) δ 202.4 (CH), 158.8 (C), 154.7 (C), 154.5 
(C), 137.2 (CH), 118.1 (CH), 116.6 (CH), 81.0 (C), 43.2 (CH2), 36.8 (CH2), 
34.2 (CH3), 28.3 (CH3), 21.6 (CH2); m/z (AP+) 278.9 ([M+H]+, 60%), 223.0 
(100%); HRMS found ([M+H]+) 279.1711. C15H23O3N2 req. 279.1703. 
Methyl 3-(2-(6-((tert-butoxycarbonyl)(methyl)amino)pyridin-2-yl)ethyl) 
cyclobut-1-enecarboxylate (111) 
 
Diethylamine (0.24 ml, 170 mg, 2.30 mmol) was added to a stirred solution of 
tert-butyl methyl(6-(4-oxobutyl)pyridin-2-yl)carbamate 110 (316 mg, 1.14 ml) 
and K2CO3 (317 mg, 2.30 mmol) in MeCN (5 ml) and the reaction mixture 
stirred at RT for 2 hours 40 minutes under a blanket of N2. Methyl acrylate 
(0.21 ml, 200 mg, 2.30 mmol) was added and the reaction mixture stirred for 
64 hours. The reaction mixture was filtered through Celite® and concentrated 
in vacuo. The crude cyclobutane was dissolved in MeCN (6 ml) and MeI 
(0.36 ml, 809 mg, 5.70 mmol) was added and the reaction mixture stirred at 
RT under a blanket of N2 for 23 hours. The reaction mixture was 
concentrated in vacuo and the residue redissolved in CHCl3 (6 ml). DBU 
(0.17 ml, 173 mg, 1.14 mmol) was added and the reaction mixture heated at 
reflux for 22 hours. The reaction mixture was concentrated in vacuo and the 
crude residue was purified via column chromatography (2:8, EtOAc:PE) to 
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give the title compound 111 as a yellow oil (282 mg, 0.84 mmol, 74% yield); 
Rf 0.49 (3:7, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 7.47 – 7.42 (m, 1H, Py 
H4), 7.37 (d, J = 8.2 Hz, 1H, Py H3), 6.76 (d, J = 7.3 Hz, 1H, Py H5), 6.75 (d, 
J = 0.8 Hz, 1H, H2), 3.66 (s, 3H, OCH3), 3.31 (s, 3H, NCH3), 2.76 (dd, J = 
13.2, 4.3 Hz, 1H, H4), 2.70 (t+m, J = 7.7 Hz, 3H, PyCH2+H3), 2.21 (dd, J = 
13.2, 1.2 Hz, 1H, H4’), 1.91 – 1.79 (m, 2H, PyCH2CH2), 1.44 (s, 9H, tBu); 13C 
NMR (101 MHz, CDCl3) δ 172.0 (C), 163.1 (C), 159.5 (C), 154.7 (C), 154.5 
(C), 150.0 (CH), 137.2 (CH), 118.0 (CH), 116.5 (CH), 80.9 (C), 51.3 (CH3), 
39.7 (CH), 36.2 (CH2), 34.7 (CH2), 34.3 (CH3), 32.9 (CH2), 28.3 (CH3); m/z 
(AP+) 347.2 ([M+H]+ 100%); HRMS found (M+) 346.1885. C19H26O4N2 req. 
346.1887. 
Methyl (1r*,3s*)-3-(2-(6-((tert-butoxycarbonyl)(methyl)amino)pyridin-2-
yl)ethyl) cyclobutanecarboxylate (112) 
 
10% Pd/C (27 mg) was added to a solution of methyl 3-(2-(6-((tert-
butoxycarbonyl)(methyl)amino)pyridin-2-yl)ethyl)cyclobut-1-enecarboxylate 
111 (269 mg, 0.78 mmol) in EtOAc (25 ml) and the reaction mixture stirred 
under H2 (1 atm) for 24 hours. The reaction mixture was filtered through 
Celite® and concentrated in vacuo to give the title compound 112 as a clear 
oil (252 mg, 0.72 mmol, 92% yield);1H NMR (400 MHz, CDCl3) δ 7.47 – 7.40 
(m, 1H, Py H4), 7.35 (d, J = 8.2 Hz, 1H, Py H3), 6.74 (d, J = 7.3 Hz, 1H, Py 
H5), 3.59 (s, 3H, OCH3), 3.31 (s, 3H, NCH3), 2.91 – 2.83 (m, 1H, H1), 2.55 (t, 
J = 7.7 Hz, 2H, PyCH2), 2.26 – 2.14 (m, 3H, PyCH2CH2+H3), 1.88 – 1.79 (m, 
2H, H2,4), 1.74 (dd, J = 15.2, 7.2 Hz, 2H, H2,4), 1.44 (s, 9H, tBu); 13C NMR 
(101 MHz, CDCl3) δ 175.8 (C), 159.9 (C), 154.4 (C), 151.4 (C), 137.1 (CH), 
117.9 (CH), 116.4 (CH), 80.7 (C), 51.6 (CH3), 36.3 (CH2), 35.4 (CH2), 34.3 
(CH3), 34.3 (CH), 31.5 (CH2), 31.4 (CH), 28.3 (CH3); m/z (AP+) 349.2 
([M+H]+ 100%); HRMS found ([M+H]+) 349.2118. C19H29O4N2 req. 349.2122. 
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(S)-N-Benzenesulfonyl-asparagine (114a) 
 
A solution of benzenesulfonyl chloride (4.08 ml, 5.59 g, 31.97 mmol) in 
dioxane (25 ml), and a solution of NaOH (1.81 g, 45.16 mmol) in H2O (25 ml) 
were added to a stirred solution of (S)-asparagine 113 (5.28 g, 39.96 mmol) 
and NaOH (1.81 g, 45.16 mmol) in dioxane:H2O (1:1, 50 ml) and stirred for 1 
hour 10 minutes. The dioxane was removed in vacuo and the aqueous 
solution was extracted with EtOAc (2 × 30 ml). The aqueous layer was then 
acidified to pH 1 with concentrated HCl and cooled to 0 °C for 30 minutes, 
the resulting white precipitate was collected via filtration and dried in a 
desiccator to give the title compound 114a as white crystals (4.791 g, 17.61 
mmol, 44% yield); mp 159-160 °C (lit.122 163 °C); [α]D +0.100 (c 1.15, 
MeOH);1H NMR (400 MHz, DMSO) δ 8.07 (d, J = 8.8 Hz, 1H, NHSO2Ph), 
7.79 (d, J = 7.2 Hz, 2H, Ph), 7.68 – 7.47 (m, 3H, Ph), 6.90 (brs, 1H, OH), 
4.21 – 3.98 (m, 1H CH), 3.48 (brs, 2H, NH2), 2.55 – 2.39 (m, 1H, CHH’), 2.26 
(dd, J = 15.5, 6.1 Hz, 1H, CHH’). Consistent with literature.122 
(S)-N-2,4,6-trimethylphenylsulfonyl-asparagine (114b) 
 
A solution of 2-mesitylenesulfonyl chloride (6.99 g, 31.97 mmol) in dioxane 
(25 ml), and a solution of NaOH (1.81 g, 45.16 mmol) in H2O (25 ml) were 
added to a stirred solution of (S)-asparagine 113 (5.28 g, 39.96 mmol) and 
NaOH (1.81 g, 45.16 mmol) in dioxane:H2O (1:1, 50 ml) and stirred for 2 
hours. The dioxane was removed in vacuo and the aqueous solution was 
extracted with EtOAc (2 × 30 ml). The aqueous layer was then acidified to pH 
1 with concentrated aqueous HCl and cooled to 0 °C for 30 minutes. the 
resulting white precipitate was collected via filtration and dried in a desiccator 
to give the title compound 114b as off-white crystals (3.941 g, 12.55 mmol, 
39% yield); mp 189-191 °C (lit.127 195 °C); [α]D +0.090 (c 1.00, MeOH);1H 
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NMR (400 MHz, DMSO) δ 12.59 (s, 1H, NHSO2Mes), 7.83 (d, J = 9.1 Hz, 
1H), 7.34 (s, 1H), 6.99 (s, 2H, Mes H3+H5), 6.90 (s, 1H), 3.99 (dt, J = 9.0, 
6.7 Hz, 1H, CH), 2.54 (s, 6H, Mes (CH3)2), 2.48 – 2.42 (m, 1H, CHH’), 2.32 – 
2.26 (m, 1H, CHH’), 2.25 (s, 3H, Mes CH3). Consistent with literature.127 
(S)-3-Amino-2-(phenylsulfonamido)propanoic acid (115a) 
 
Bromine (0.47 ml, 1.47 g, 9.18 mmol) was added to a stirred solution of 
NaOH (2.176 g, 54.40 mmol) in H2O (8 ml) at 0 °C and stirred for 5 minutes. 
A solution of (S)-N-benzenesulfonyl-asparagine 114a (2.00 g, 7.35 mmol) 
and NaOH (616 mg, 15.40 mmol) in H2O (5 ml) was added and the resulting 
solution stirred for a further 20 minutes. The reaction mixture was then 
heated to 90 °C for 40 minutes. The reaction mixture was then cooled to 0 °C 
and carefully neutralised by dropwise addition of concentrated aqueous 
HCland the resultant white precipitate was collected via filtration to give the 
title compound 115a as white crystals (625 mg, 2.56 mmol, 35% yield); mp 
200-203 °C (lit.122 203-206 °C);1H NMR (400 MHz, DMSO) δ 7.87 – 7.83 (m, 
2H, Ph), 7.71 – 7.65 (m, 1H, Ph), 7.61 (t, J = 7.4 Hz, 2H, Ph), 3.14 (dd, J = 
9.8, 4.6 Hz, 1H, CH), 3.04 (dd, J = 11.9, 4.6 Hz, 1H, CHH’), 2.82 (dd, J = 
11.8, 9.9 Hz, 1H, CHH’). Consistent with literature.122 
(S)-3-Amino-2-(2,4,6-trimethylphenylsulfonamido)propanoic acid (115b) 
 
Bromine (0.40 ml, 1.25 g, 7.84 mmol) was added to a stirred solution of 
NaOH (1.856 g, 46.40 mmol) in H2O (8 ml) at 0 °C and stirred for 10 minutes. 
A solution of (S)-N-2,4,6-trimethylphenylsulfonyl-asparagine 114b (1.97 g, 
6.27 mmol) and NaOH (527 mg, 13.17 mmol) in H2O (10 ml) was added and 
the mixture stirred for a further 25 minutes. The reaction mixture was then 
heated to 90 °C for 40 minutes. The reaction mixture was then cooled to 0 °C 
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and carefully neutralised by dropwise addition of  concentrated aqueous HCl 
and the resultant white precipitate was collected via filtration to give the title 
compound 115b as an off white solid (824 mg, 2.88 mmol, 46% yield); [α]D 
+0.459 (c 1.0, MeOH);1H NMR (400 MHz, DMSO) δ 7.05 (s, 2H, Mes 
H3+H5), 3.03 (dd, J = 11.8, 4.1 Hz, 1H, CH), 2.93 (dd, J = 9.4, 4.3 Hz, 1H, 
CHH’), 2.81 – 2.73 (m, 1H, CHH’), 2.59 (s, 6H, Mes (CH3)2), 2.26 (s, 3H, Mes 
CH3). Consistent with literature.127 
Methyl 3-amino-(S)-2-(phenylsulfonamido)propanoate (116a) 
 
Thionyl chloride (0.20 ml, 332 mg, 2.79 mmol) was added to a stirred solution 
of (S)-3-amino-2-(phenylsulfonamido)propanoic acid 115a (620 mg, 2.54 
mmol) in MeOH (25 ml) and the reaction mixture stirred for 24 hours at RT. 
The reaction mixture was concentrated in vacuo and the residue partitioned 
between DCM (30 ml) and saturated aqueous sodium bicarbonate (30 ml), 
the aqueous layer was further extracted with DCM (3 × 20 ml) and the 
combined organic phases dried (MgSO4) and concentrated in vacuo to give 
the title compound 116a as a clear oil (258 mg, 1.00 mmol, 39% yield); 1H 
NMR (400 MHz, CDCl3) δ 7.80 (d, J = 7.3 Hz, 2H, Ph), 7.54 – 7.41 (m, 3H, 
Ph), 3.88 (s, 1H, CH), 3.47 (s, 3H, OCH3), 3.17 – 2.85 (m, 2H, CH2). 
Consistent with literature.128 
Methyl 3-amino-(S)-2-(2,4,6-trimethylphenylsulfonamido)propanoate 
(116b) 
 
Thionyl chloride (0.08 ml, 138 mg, 1.16 mmol) was added to a stirred solution 
of (S)-3-amino-2-(2,4,6-trimethylphenylsulfonamido)propanoic acid 115b 
(300 mg, 1.05 mmol) in MeOH (10 ml) and the reaction mixture stirred for  22 
hours. The reaction mixture was concentrated in vacuo, partitioned between 
DCM (30 ml) and saturated aqueous sodium bicarbonate. The aqueous layer 
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was further extracted with DCM (30 ml) and the combined organic layers 
were dried (MgSO4) and concentrated in vacuo to give the title compound 
116b as a clear oil (229 mg, 0.76 mmol, 72%); Rf 0.55 (1:1, EtOAc:PE);1H 
NMR (400 MHz, CDCl3) δ 6.88 (s, 2H, Mes H3+H5), 3.78 (s, 1H, CH), 3.50 
(s, 3H, OCH3), 2.94 (br s, 2H, CH2), 2.58 (s, 6H, Mes (CH3)2), 2.22 (s, 3H, 
Mes CH3). Consistent with literature.128 
Methyl 3-((1r*,3R*)-3-(2-(6-((tert-butoxycarbonyl)(methyl)amino) pyridin-
2-yl)ethyl)cyclobutanecarboxamido)-(S)-2-
(phenylsulfonamido)propanoate (117a) 
 
NaOH (1 M in water, 0.55 ml, 0.55 mmol) was added to a stirred solution of 
methyl (1r*,3s*)-3-(2-(6-((tert-butoxycarbonyl)(methyl)amino)pyridin-2-yl) 
ethyl)cyclobutane carboxylate 112 (40 mg, 0.11 mmol) in MeOH (5 ml) and 
the reaction mixture heated at reflux for 5 hours. The mixture was allowed to 
cool, quenched with HCl (4 M in dioxane, 0.14 ml, 0.55 mmol), diluted with 
EtOAc (5 ml), dried (MgSO4) and concentrated in vacuo to give the crude 
acid. The acid was dissolved in DMF (3 ml) and (S)-methyl 3-amino-2-
(phenylsulfonamido)propanoate 116a (28 mg, 0.11 mmol), EDCI (63 mg, 
0.33 mmol), HOBt (45 mg, 0.33 mmol) and DIPEA (0.096 ml, 71 mg, 0.55 
mmol) were added and the reaction mixture stirred at RT under a blanket of 
N2 for 18 hours. The reaction mixture was diluted with H2O (10 ml), extracted 
with EtOAc (3 × 15 ml) and the combined organic layers washed with H2O (2 
× 10 ml), followed by saturated aqueous ammonium chloride (10 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
PTLC (EtOAc) to give the title compound 117a as a clear oil (19 mg, 0.033 
mmol, 30% yield); Rf 0.55 (EtOAc); [α]D +0.28 (c 0.94, CHCl3); 1H NMR (400 
MHz, CDCl3) δ 7.80 – 7.75 (m, 2H, Ph), 7.55 – 7.49 (m, 1H, Ph), 7.47 – 7.41 
(m, 3H, Ph+Py H4), 7.34 (d, J = 8.2 Hz, 1H, Py H3), 6.74 (d, J = 7.3 Hz, 1H, 
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Py H5), 5.86 (t, J = 6.0 Hz, 1H, NH), 5.73 (d, J = 7.1 Hz, 1H, NH), 3.91 (d, J = 
4.3 Hz, 1H, CH), 3.60 – 3.40 (m, 2H), 3.50 (s, 3H, OCH3), 3.31 (s, 3H, 
NCH3), 2.70 (dd, J = 12.7, 4.5 Hz, 1H, H1), 2.58 – 2.50 (m, 2H, PyCH2), 2.24 
– 2.08 (m, 3H, H2+H3+H4), 1.84 – 1.66 (m, 4H PyCH2CH2+H2’+H4’), 1.43 
(s, 9H, tBu); 13C NMR (101 MHz, CDCl3) δ 175.7 (C), 170.0 (C), 159.9 (C), 
154.6 (C), 154.5 (C), 139.2 (C), 137.1 (CH), 133.1 (CH), 129.2 (CH), 127.2 
(CH), 117.9 (CH), 116.4 (CH), 80.8 (C), 55.8 (CH), 53.1 (CH3), 41.7 (CH2), 
36.2 (CH2), 36.0 (CH), 35.3 (CH2), 34.3 (CH3), 31.4 (CH2), 31.3 (CH2), 31.0 
(CH), 28.3 (CH3); m/z (AP+) 575.2 ([M+H]+ 10%), 475.1 ([M-Boc]+ 100%); 
HRMS found ([M+H]+) 575.2523. C28H39O7N4S req. 575.2534. 
Methyl 3-((1r*,3R*)-3-(2-(6-((tert-butoxycarbonyl)(methyl)amino) pyridin-
2-yl)ethyl)cyclobutanecarboxamido)-(S)-2-(2,4,6-
trimethylphenylsulfonamido) propanoate (117b) 
 
NaOH (1 M in water, 0.80 ml, 0.80 mmol) was added to a stirred solution of 
methyl (1r*,3s*)-3-(2-(6-((tert-butoxycarbonyl)(methyl)amino)pyridin-2-yl) 
ethyl)cyclobutane carboxylate 112 (56 mg, 0.16 mmol) in MeOH (6 ml) and 
the reaction mixture heated at reflux for 5 hours. The mixture was allowed to 
cool, quenched with HCl (4 M in dioxane, 0.20 ml, 0.80 mmol), diluted with 
EtOAc (5 ml), dried (MgSO4) and concentrated in vacuo to give the crude 
acid. The acid was dissolved in DMF (3 ml) and (S)-methyl 3-amino-2-(2,4,6-
trimethylphenylsulfonamido)propanoate 116b (48 mg, 0.16 mmol), EDCI (92 
mg, 0.48 mmol), HOBt (65 mg, 0.48 mmol) and DIPEA (0.14 ml, 0.80 mmol) 
were added and the reaction mixture stirred at RT under a blanket of N2 for 
17 hours. The reaction mixture was diluted with H2O (10ml), extracted with 
EtOAc (3 × 15 ml) and the combined organic layers washed with saturated 
aqueous ammonium chloride (2 × 10 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via PTLC (3:1, EtOAc:PE) to give the 
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title compound 117b as a clear oil (41 mg, 0.067 mmol, 42% yield); Rf 0.48 
(3:1, EtOAc:PE); [α]D +0.28 (c 1.03, CHCl3);1H NMR (400 MHz, CDCl3) δ 
7.47 – 7.39 (m, 1H, Py H4), 7.34 (d, J = 8.2 Hz, 1H, Py H3), 6.88 (s, 2H, Mes 
H3+H5), 6.75 (d, J = 7.3 Hz, 1H, Py H5), 5.85 (d, J = 5.9 Hz, 1H, NH), 5.73 
(d, J = 7.4 Hz, 1H, NH), 3.79 (td, J = 7.0, 4.1 Hz, 1H, CH), 3.59 – 3.49 (m, 
1H, H1), 3.51 (s, 3H, OCH3), 3.48 – 3.40 (m, 1H, CHH’), 3.31 (s, 3H, NCH3), 
2.75 – 2.64 (m, 1H, CHH’), 2.55 (app s, 8H, Mes (CH3)2+PyCH2), 2.20 – 2.09 
(m, 3H, H2+H3+H4), 1.98 (s, 3H, Mes CH3), 1.84 – 1.68 (m, 4H, 
PyCH2CH2+H2’+H4’), 1.44 (s, 9H, tBu); 13C NMR (101 MHz, CDCl3) δ 175.5 
(C), 170.3 (C), 159.9 (C), 154.5 (C), 154.5 (C), 142.7 (C), 139.2 (C), 137.1 
(CH), 133.1 (C), 132.1 (CH), 117.9 (CH), 116.4 (CH), 80.8 (C), 55.3 (CH), 
53.0 (CH3), 41.7 (CH2), 36.2 (CH2), 36.0 (CH), 35.3 (CH2), 34.3 (CH3), 31.4 
(CH2), 31.3 (CH2), 31.1 (CH), 28.3 (CH3), 22.9 (CH3), 21.0 (CH3); m/z (AP+) 
617.0 ([M+H]+ 100%); HRMS found ([M+H]+) 617.3000. C31H45O7N4S req. 
617.3003. 
Methyl 3-((1r*,3R*)-3-(2-(6-(methylamino)pyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(phenylsulfonamido)propanoate (104a) 
 
TFA (0.5 ml) was added to a stirred solution of methyl 3-((1r*,3R*)-3-(2-(6-
((tert-butoxycarbonyl)(methyl)amino)pyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(phenylsulfonamido)propanoate 117a (19 mg, 0.033 
mmol) in DCM (4 ml) and stirred for 23 hours. The reaction mixture was then 
concentrated in vacuo and the residue purified via PTLC (5:95, MeOH:DCM) 
to give the title compound 104a as a clear oil (14.5 mg, 0.031 mmol, 94% 
yield); Rf 0.22 (95:5 DCM:MeOH); [α]D +0.38 (c 0.73, CHCl3); IR 3319.9 cm-1 
(NH), 3248.9 cm-1 (NH), 2925.3 cm-1 (CH Sp3), 1743.0 cm-1 (C=O ester), 
1651.5 cm-1 (C=O amide); 1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 7.2 Hz, 
2H, Ph), 7.61 – 7.54 (m, 1H, Ph), 7.50 (t, J = 7.5 Hz, 2H, Ph), 7.39 (dd, J = 
8.1, 7.5 Hz, 1H, Py H4), 6.42 (d, J = 7.2 Hz, 1H, Py H3), 6.22 (d, J = 8.3 Hz, 
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1H, Py H5), 6.07 (t, J = 5.6 Hz, 1H, NH), 4.99 (s, 1H, NH), 4.00 (dd, J = 6.5, 
4.4 Hz, 1H), 3.65 – 3.50 (m, 2H), 3.57 (s, 3H, OCH3), 2.88 (s, 3H, NCH3), 
2.80 – 2.71 (m, 1H, H1), 2.54 – 2.47 (m, 2H, PyCH2), 2.28 – 2.14 (m, 3H, 
H2+H3+H4), 1.89 – 1.80 (m, 2H, PyCH2CH2), 1.76 (dd, J = 15.3, 7.2 Hz, 2H, 
H2’+H4’); 13C NMR (101 MHz, CDCl3) δ 175.8 (C), 170.2 (C), 159.9 (C), 
159.1 (C), 139.5 (C), 138.4 (CH), 133.0 (CH), 129.2 (CH), 127.1 (CH), 111.4 
(CH), 102.6 (CH), 55.8 (CH), 52.9 (CH3), 41.6 (CH2), 36.4 (CH2), 36.0 (CH), 
35.1 (CH2), 31.4 (CH2), 31.3 (CH2), 31.1 (CH), 29.3 (CH3); m/z (AP+) 475.2 
([M+H]+ 100%), 333.1 ([M-SO2Ph]+ 75%); HRMS found ([M+Na]+) 497.1816. 
C23H30O5N4SNa req. 497.1829; LCMS rt 1.83, m/z (ES+) 475.3 ([M+H]+, 
100%), >95%. 
Methyl 3-((1r*,3R*)-3-(2-(6-(methylamino)pyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)propanoate 
(104b) 
 
TFA (0.5 ml) was added to a stirred solution of methyl 3-((1r*,3R*)-3-(2-(6-
((tert-butoxycarbonyl)(methyl)amino)pyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)propanoate 117b (41 
mg, 0.067 mmol) in DCM (8 ml) and stirred for 23 hours. The reaction mixture 
was then concentrated in vacuo and the residue purified via PTLC (5:95, 
MeOH:DCM) to give the title compound 104b as a clear oil (25.4 mg, 0.049 
mmol, 73% yield); Rf 0.25 (95:5 DCM:MeOH); [α]D +0.28 (c 1.27, CHCl3); IR 
3300.9 cm-1 (NH), 2937.4 cm-1 (CH Sp3), 1740.9 cm-1 (C=O ester), 1653.5 
cm-1 (C=O amide); 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.26 (m, 1H, Py H4), 
6.87 (s, 2H, Mes H3+H5), 6.34 (d, J = 7.3 Hz, 1H, Py H3), 6.13 (d, J = 8.3 
Hz, 1H, Py H5), 5.92 (t, J = 5.5 Hz, 1H, NH), 4.67 (s, 1H, NH), 3.81 (dd, J = 
6.6, 4.2 Hz, 1H, CH), 3.58 – 3.41 (m, 2H, CH2), 3.50 (s, 3H, OCH3), 2.81 (d, J 
= 4.3 Hz, 3H, NCH3), 2.73 – 2.63 (m, 1H, H1), 2.55 (s, 6H, Mes (CH3)2), 2.45 
– 2.39 (m, 2H, PyCH2), 2.21 (s, 3H, Mes CH3), 2.27 – 2.06 (m, 3H, 
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H2+H3+H4), 1.82 – 1.72 (m, 2H, H2’+H4’), 1.69 (dd, J = 15.2, 7.1 Hz, 2H, 
PyCH2CH2); 13C NMR (101 MHz, CDCl3) δ 175.6 (C), 170.3 (C), 160.2 (C), 
159.2 (C), 142.6 (C), 139.2 (C), 138.1 (CH), 133.2 (C), 132.0 (CH), 111.5 
(CH), 102.5 (CH), 55.4 (CH), 52.9 (CH3), 41.7 (CH2), 36.3 (CH2), 36.1 (CH), 
35.3 (CH2), 31.4 (CH2), 31.3 (CH2), 31.2 (CH), 29.3 (CH3), 22.9 (CH3), 20.9 
(CH3); m/z (AP+) 517.0 ([M+H]+ 100%); HRMS found ([M+H]+) 517.2473. 
C26H37O5N4S req. 517.2479; LCMS rt 2.56, m/z (ES+) 517.4 ([M+H]+, 100%), 
>95%. 
 
The following carboxylic acids 118a-b and 119a-b were hydrolysed in small 
scale to be submitted directly for biological screening. Due to the small scale 
13C-NMR was not obtained as the samples were too weak thus they were 
analysed just by 1H-NMR and mass spectrometry.  
(S)-4-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutane 
carboxamido)-2-(phenylsulfonamido)butanoic acid (118a) 
 
Methyl 4-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(phenylsulfonamido)butanoate 90a (2.3 mg, 0.0045 
mmol) was stirred in 6 M aqueous HCl (0.5 ml) for 22 hours at room 
temperature. The reaction mixture was then concentrated in vacuo to give 
the title compound 118a as a yellow oil (2.2 mg, 0.0045 mmol, 100%); 1H 
NMR (400 MHz, D2O) δ 8.97 (d, J = 3.3 Hz, 1H, Ar H7), 8.77 (d, J = 8.6 Hz, 
1H, Ar H5), 8.64 (d, J = 8.2 Hz, 1H, Ar H4), 7.87 (d, J = 8.6 Hz, 1H, Ar H6), 
7.76 (d, J = 8.2 Hz, 1H, Ar H3), 7.58 (t, J = 6.5 Hz, 2H, Ph), 7.55 – 7.45 (m, 
1H, Ph), 7.41 (t, J = 7.8 Hz, 2H, Ph), 3.70 (dd, J = 9.0, 5.1 Hz, 1H), 3.06 (app 
t, J = 7.6 Hz, 4H), 2.81 – 2.70 (m, 1H), 2.25 – 2.15 (m, 1H), 2.14 – 2.05 (m, 
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2H), 1.91 – 1.78 (m, 3H), 1.67 – 1.48 (m, 3H); m/z (ES+) 497.5 ([M+H]+ 
100%); HRMS Found [M+H]+ 497.1844. C25H29O5N2S req. 497.1853. 
(S)-2-(phenylsulfonamido)-4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-
naphthyridin-2-yl)ethyl)cyclobutanecarboxamido)butanoic acid (119a) 
 
Methyl (S)-2-(phenylsulfonamido)-4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-
naphthyridin-2-yl)ethyl)cyclobutanecarboxamido)butanoate 73a (4.7 mg, 
0.0091 mmol) was stirred in 6 M aqueous HCl (0.5 ml) for 22 hours at room 
temperature. The reaction mixture was then concentrated in vacuo to give 
the title compound 119a as a yellow oil (4.5 mg, 0.0091 mmol, 100%); 1H 
NMR (400 MHz, D2O) δ 7.66 (d, J = 8.0 Hz, 2H, Ph), 7.59 – 7.48 (m, 1H, Ph), 
7.44 (t, J = 7.7 Hz, 2H, Ph), 7.35 (d, J = 7.4 Hz, 1H, Ar), 6.41 (d, J = 7.4 Hz, 
1H, Ar), 3.74 (dd, J = 9.0, 5.0 Hz, 1H), 3.27 – 3.21 (m, 2H, ArCH2), 3.12 – 
3.03 (m, 2H, NHCH2), 2.80 – 2.68 (m, 1H), 2.56 (t, J = 6.0 Hz, 2H), 2.45 (t, J 
= 7.4 Hz, 2H), 2.13 – 2.03 (m, 3H), 1.89 – 1.79 (m, 1H), 1.74 – 1.65 (m, 3H), 
1.64 – 1.50 (m, 4H); m/z (ES+) 501.5 ([M+H]+ 100%); HRMS Found 
([M+H]+) 501.2154. C25H33O5N4S req. 501.2166. 
(S)-4-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutane 
carboxamido)-2-(2,4,6-trimethylphenylsulfonamido)butanoic acid (118b) 
 
Methyl 4-((1r*,3R*)-3-(2-(1,8-naphthyridin-2-yl)ethyl)cyclobutane 
carboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate 90b (3.3 
mg, 0.0060 mmol) was stirred in 6 M aqueous HCl (0.5 ml) for 22 hours at 
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room temperature. The reaction mixture was then concentrated in vacuo to 
give the title compound 118b as a yellow oil (3.2 mg, 0.0060 mmol, 100%); 
1H NMR (400 MHz, D2O) δ 8.95 (app s, 1H, Ar H7), 8.73 (d, J = 6.8 Hz, 1H, 
Ar H5), 8.62 (d, J = 7.4 Hz, 1H, Ar H4), 7.81 (d, J = 7.9 Hz, 1H, Ar H6), 7.74 
(s, 1H, Ar H3), 6.80 (s, 2H, Mes H3+H5), 3.54 – 3.46 (m, 1H), 2.98 (d, J = 6.1 
Hz, 4H), 2.67 – 2.55 (m, 1H), 2.27 (s, 6H, Mes (CH3)2), 2.17 – 2.07 (m, 1H), 
2.04 (app s, 4H, Mes CH3+ ? ), 1.78 (d, J = 6.1 Hz, 3H), 1.62 – 1.53 (m, 2H), 
1.46 (dd, J = 19.6, 9.6 Hz, 2H); m/z (ES+) 539.6 ([M+H]+ 100%); HRMS 
Found ([M+H]+) 539.2316. C28H35O5N2S req. 539.2323. 
4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl) 
cyclobutanecarboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido) 
butanoic acid (119b) 
 
Methyl 4-((1r*,3R*)-3-(2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl) 
cyclobutanecarboxamido)-(S)-2-(2,4,6-trimethylphenylsulfonamido)butanoate 
73b (6.2 mg, 0.011 mmol) was stirred in 6 M aqueous HCl (0.5 ml) for 22 
hours at room temperature. The reaction mixture was then concentrated in 
vacuo to give the title compound 119b as a yellow oil (5.9 mg, 0.011 mmol, 
100%); 1H NMR (400 MHz, D2O) δ 7.35 (d, J = 7.4 Hz, 1H, Ar), 6.89 (s, 2H, 
Mes H3+H5), 6.40 (d, J = 7.4 Hz, 1H, Ar), 3.57 (dd, J = 9.6, 4.9 Hz, 1H), 3.29 
– 3.22 (m, 3H, ArCH2 + ?), 3.08 – 2.98 (m, 2H, NHCH2), 2.58 (t, J = 6.2 Hz, 
2H), 2.42 (t, J = 7.4 Hz, 2H), 2.38 (s, 6H, Mes (CH3)2), 2.11 (s, 3H, Mes CH3), 
2.07 – 1.98 (m, 3H), 1.89 – 1.78 (m, 1H), 1.74 – 1.68 (m, 2H), 1.67 – 1.59 (m, 
1H), 1.55 (dd, J = 13.8, 7.1 Hz, 2H), 1.46 (ddd, J = 15.0, 11.2, 5.2 Hz, 2H); 
m/z (ES+) 543.6 ([M+H]+ 100%); HRMS Found ([M+H]+) 543.2627. 
C28H39O5N2S req. 543.2636. 
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4.4 Towards a Total Synthesis of Providencin 
3-((tert-Butyldimethylsilyl)oxy)propan-1-ol (196a) 
 
Method.129 
1,3-Propandiol 195a  (0.51 ml, 532 mg, 7 mmol) was added to a stirred 
suspension of NaH (60% dispersion in oil, 200 mg, 5 mmol) in THF (10 ml) at 
0 °C under a blanket of N2. The resultant mixture was stirred for 40 minutes, 
TBSCl (750 mg, 5 mmol) was added and the reaction mixture stirred for a 
further 1 hour 45 minutes. The mixture was poured into saturated aqueous 
ammonium chloride solution (50 ml) and extracted with diethyl ether (2 × 40 
ml). The combined organic layers were dried (MgSO4) and concentrated in 
vacuo to give the title compound 196a as a clear oil (671 mg, 3.53 mmol, 
71% yield); Rf 0.55 (1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 3.79 – 3.69 
(m, 4H, CH2OTBS + CH2OH), 2.57 (br s, 1H, OH), 1.70 (qn J = 5.5 Hz, 2H, 
H2), 0.82 (s, 9H, tBu), -0.00 (s, 6H, (CH3)2). Consistent with literature.130 
4-((tert-Butyldimethylsilyl)oxy)butan-1-ol (196b) 
 
1,4-Butandiol 195b (0.44 ml, 450 mg, 5 mmol) was added to a stirred 
suspension of NaH (60% dispersion in oil, 140 mg, 3.5 mmol) in THF (3 ml) 
at 0 °C under a blanket of N2. The resultant mixture was stirred for 30 
minutes, TBSCl (525 mg, 3.5 mmol) was added and the reaction mixture 
stirred for a further 1 hour 15 minutes. The mixture was poured into saturated 
aqueous ammonium chloride solution (30 ml) and extracted with diethyl ether 
(3 × 20 ml). The combined organic layers were dried (MgSO4) and 
concentrated in vacuo to give the title compound 196b as a clear oil (715 mg, 
3.5 mmol, 100% yield); Rf 0.31 (2:8, EtOAc:PE);1H NMR (400 MHz, CDCl3) δ 
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3.64 – 3.54 (m, 4H, H1+H4), 1.63 – 1.50 (m, 4H, H2+H3), 0.83 (s, 9H, tBu), -
0.00 (s, 6H, (CH3)2). Consistent with literature.129 
5-((tert-Butyldimethylsilyl)oxy)pentan-1-ol (196c) 
 
Method.129 
1,5-Pentandiol 195c  (0.74 ml, 728 mg, 7 mmol) was added to a stirred 
suspension of NaH (60% dispersion in oil, 200 mg, 5 mmol) in THF (10 ml) at 
0 °C under a blanket of N2. The resultant mixture was stirred for 25 minutes, 
TBSCl (750 mg, 5 mmol) was added and the reaction mixture stirred for a 
further 1 hour 15 minutes. The mixture was poured into saturated aqueous 
ammonium chloride solution (50 ml) and extracted with diethyl ether (2 × 40 
ml). The combined organic layers were dried (MgSO4) and concentrated in 
vacuo to give the title compound 196c as a clear oil (778 mg, 3.57 mmol, 
71% yield); Rf 0.52 (1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 3.65 – 
3.52 (m, 4H, CH2OTBS + CH2OH), 1.60 – 1.44 (m, 4H, H2+H4), 1.42 – 1.29 
(m, 2H, H3), 0.84 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2). Consistent with 
literature.131 
6-((tert-Butyldimethylsilyl)oxy)hexan-1-ol (196d) 
 
1,6-Hexanediol 195d  (826 mg, 7 mmol) was added to a stirred suspension of 
NaH (60% dispersion in oil, 200 mg, 5 mmol) in THF (10 ml) at 0 °C under a 
blanket of N2. The resultant mixture was stirred for 40 minutes, TBSCl (750 
mg, 5 mmol) was added and the reaction mixture stirred for a further 1 hour 
45 minutes. The mixture was poured into saturated aqueous ammonium 
chloride solution (50 ml) and extracted with diethyl ether (2 × 40 ml). The 
combined organic layers were dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (1:1, EtOAc:PE) to 
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give the title compound 196d as a clear oil (515 mg, 2.22 mmol, 44% yield); 
Rf 0.48 (4:6, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 3.63 – 3.51 (m, 4H, 
CH2OTBS + CH2OH), 1.59 – 1.42 (m, 4H, H2+H5), 1.37 – 1.28 (m, 4H, 
H3+H4), 0.85 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2). Consistent with literature.132 
3-((tert-Butyldimethylsilyl)oxy)propyl ethyl fumarate (198a) 
 
EDCI (860 mg, 4.5 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197  (518 mg, 3.6 mmol), 3-((tert-butyldimethylsilyl)oxy)propan-1-ol 
196a  (671 mg, 3.53 mmol), DIPEA (0.78 ml, 581 mg, 4.5 mmol) and DMAP 
(44 mg, 0.36 mmol) in DCM (40 ml) under a blanket of N2 and the reaction 
mixture stirred for 23 hours. The reaction mixture was washed with 5% 
aqueous HCl (40 ml) and saturated aqueous sodium bicarbonate(40 ml), 
dried (MgSO4) and concentrated in vacuo to give the title compound 198a as 
an orange oil (941 mg, 2.98 mmol, 84% yield); Rf 0.70 (1:1, EtOAc:PE); 1H 
NMR (400 MHz, CDCl3) δ 6.80 (s, 2H, CH=CH), 4.26 (t, J = 5.9 Hz, 2H, 
OCH2), 4.22 (q, J = 6.7 Hz, 2H, OCH2CH3), 3.66 (t, J = 6.0 Hz, 2H, 
CH2OTBS), 1.91 – 1.77 (m, 2H, CH2CH2), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3), 
0.84 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 165.02 
(C), 133.68 (CH), 133.55 (CH), 62.37 (CH2), 61.36 (CH2), 59.21 (CH2), 30.95 
(CH2), 25.88 (CH3), 18.28 (C), 14.11 (CH3), -5.42 (CH3); m/z (AP+) 317.0 
([M+H]+, 100%); HRMS found ([M+H]+) 317.1782. C15H29O5Si req 317.1779. 
4-((tert-Butyldimethylsilyl)oxy)butyl ethyl fumarate (198b) 
 
Oxalyl chloride (2 M in DCM, 4.63 ml, 9.25 mmol) and DMSO (1 drop) were 
added to a stirred solution of ethyl hydrogen fumarate 197 (533 mg, 3.7 
mmol) in DCM (5 ml) at RT, under a blanket of N2 and the reaction mixture 
stirred for 5 hours. The reaction mixture was then concentrated in vacuo to 
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give the crude acid chloride which was redissolved in DCM (7 ml) and added 
slowly to a stirred mixture of 4-((tert-butyldimethylsilyl)oxy)butan-1-ol 196b 
(715 mg, 3.5 mmol) and NEt3 (0.51 ml, 3.7 mmol at RT, under a blanket of 
N2. The resultant mixture was stirred for 2 hours 20 minutes, concentrated in 
vacuo and purified via column chromatography (1:9, EtOAc:PE) to give the 
title compound 198b as a yellow oil (844 mg, 2.56 mmol, 73% yield); Rf 0.55 
(2:8, EtOAc:PE);1H NMR (400 MHz, CDCl3) δ 6.80 (s, 2H, CH=CH), 4.21 (dd, 
J = 12.8, 5.7 Hz, 2H, OCH2CH3), 4.17 (t, J = 5.2 Hz, 2H, OCH2), 3.59 (t, J = 
6.2 Hz, 2H, CH2OTBS), 1.75 – 1.65 (m, 2H, CH2), 1.59 – 1.48 (m, 2H, CH2), 
1.27 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.84 (s, 9H, tBu), -0.00 (s, 6H, (CH3)2); 13C 
NMR (101 MHz, CDCl3) δ 165.1 (C), 165.0 (C), 133.6 (CH), 133.6 (CH), 65.3 
(CH2), 62.5 (CH2), 61.3 (CH2), 29.1 (CH2), 25.9 (CH3), 25.2 (CH2), 18.3 (C), 
14.1 (CH3), -5.3 (CH3); m/z (ES+) 331.2 ([M+H]+, 100%); HRMS found 
331.1941. C16H31O5Si req. 331.1935. 
 5-((tert-Butyldimethylsilyl)oxy)pentyl ethyl fumarate (198c) 
 
EDCI (860 mg, 4.5 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197  (518 mg, 3.6 mmol), 5-((tert-butyldimethylsilyl)oxy)pentan-1-ol 
196c  (778 mg, 3.57 mmol), DIPEA (0.78 ml, 581 mg, 4.5 mmol) and DMAP 
(44 mg, 0.36 mmol) in DCM (40 ml) under a blanket of N2 and the reaction 
mixture stirred for 23 hours. The reaction mixture was washed with 5% 
aqueous HCl (40 ml) and saturated aqueous sodium bicarbonate(40 ml), 
dried (MgSO4) and concentrated in vacuo to give the title compound 198c as 
an orange oil (1.068 g, 3.1 mmol, 87% yield); Rf 0.70 (1:1, EtOAc:PE); 1H 
NMR (400 MHz, CDCl3) δ 6.80 (s, 2H, CH=CH), 4.21 (q, J = 7.1 Hz, 2H, 
OCH2CH3), 4.15 (t, J = 6.6 Hz, 2H, OCH2), 3.57 (t, J = 6.3 Hz, 2H, 
CH2OTBS), 1.74 – 1.60 (m, 2H), 1.57 – 1.44 (m, 2H), 1.45 – 1.33 (m, 2H), 
1.28 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.84 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2); 13C 
NMR (101 MHz, CDCl3) δ 165.09 (C), 164.67 (C), 133.63 (CH), 65.40 (CH2), 
62.84 (CH2), 61.34 (CH2), 32.32 (CH2), 28.30 (CH2), 25.95 (CH2), 22.25 
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(CH3), 18.35 (C), 14.12 (CH3), -5.29 (CH3); m/z (AP+) 345.0 ([M+H]+, 100%); 
HRMS found ([M+H]+) 345.2095. C17H33O5Si req 345.2092. 
 6-((tert-Butyldimethylsilyl)oxy)hexyl ethyl fumarate (198d) 
 
EDCI (550 mg, 2.88 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (331 mg, 2.3 mmol), 6-((tert-butyldimethylsilyl)oxy)hexan-1-ol 
196d  (515 mg, 2.22 mmol), DIPEA (0.5 ml, 372 mg, 2.88 mmol) and DMAP 
(28 mg, 0.23 mmol) in DCM (20 ml) under a blanket of N2 and the reaction 
mixture stirred for 20.5 hours. The reaction mixture was washed with 5% 
aqueous HCl (20 ml) and saturated aqueous sodium bicarbonate(20 ml), 
dried (MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (2:8, EtOAc:PE) to give the title compound 198d as 
a clear oil (429 mg, 1.2 mmol, 54% yield); Rf 0.60 (3:7, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 6.80 (s, 2H, CH=CH), 4.22 (q, J = 7.2 Hz, 2H, 
OCH2CH3), 4.15 (t, J = 6.6 Hz, 2H, OCH2), 3.56 (t, J = 6.4 Hz, 2H, 
CH2OTBS), 1.69 – 1.58 (m, 2H, H3), 1.52 – 1.42 (m, 2H, H5), 1.36 – 1.30 (m, 
4H, H3+H4), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.85 (s, 9H, tBu), 0.00 (s, 
6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 165.31 (C), 165.24 (C), 133.86 
(CH), 133.84 (CH), 65.64 (CH2), 63.26 (CH2), 61.55 (CH2), 32.89 (CH2), 
28.75 (CH2), 26.19 (CH3), 25.93 (CH2), 25.70 (CH2), 18.58 (C), 14.33 (CH3), -
5.06 (CH3); m/z (ES+) 359.2 ([M+H]+, 100%); HRMS found ([M+H]+) 
359.2251. C18H35O5Si req 359.2248. 
Ethyl (3-oxopropyl) fumarate (199a) 
 
pTSA∙H2O (29 mg, 0.15 mmol) was added to a stirred solution of 3-((tert-
butyldimethylsilyl)oxy)propyl ethyl fumarate 198a (450 mg, 1.42 mmol) in 
DCM:MeOH (15 ml, 1:1) at 0 °C and stirred for 2 hours. The reaction mixture 
 158 
 
was concentrated in vacuo to give the deprotected alcohol (189 mg, 0.94 
mmol) which was redissolved in DCM (20 ml). TEMPO (14 mg, 0.09 mmol) 
and BAIB (319 mg, 0.99 mmol) were added and the reaction mixture was 
stirred at RT under a blanket of N2 for 1 hour. TEMPO (14 mg, 0.09 mmol) 
was added and the reaction stirred for a further 3 hours. The reaction mixture 
was washed with saturated aqueous sodium thiosulfate solution(20 ml), 
extracted with DCM (20 ml), washed with saturated aqueous sodium 
bicarbonate (20 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (3:7, EtOAc:PE) to give the 
title compound 199a as a clear oil (93 mg, 0.47 mmol, 53% yield); Rf 0.67 
(1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.83 (d, J = 0.9 Hz, 1H, CHO), 
6.89 – 6.78 (m, 2H, CH=CH), 4.56 (t, J = 6.1 Hz, 2H, OCH2), 4.28 (q, J = 7.1 
Hz, 2H, OCH2CH3), 2.87 (td, J = 6.1, 1.2 Hz, 2H, CH2CHO), 1.34 (t, J = 7.1 
Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 198.75 (CH), 164.77 (C), 
164.75 (C), 134.37 (CH), 132.78 (CH), 61.43 (CH2), 58.71 (CH2), 42.49 
(CH2), 14.09 (CH3); m/z (ES+) 223.0 ([M+Na]+, 100%); HRMS found 
([M+H]+) 201.0754. C9H13O5 req 201.0757. 
Ethyl (4-oxobutyl) fumarate (199b) 
 
pTSA∙H2O (15 mg, 0.08 mmol) was added to a stirred solution of 4-((tert-
butyldimethylsilyl)oxy)butyl ethyl fumarate 198b (260 mg, 0.79 mmol) in 
DCM:MeOH (2 ml, 1:1) at 0 °C and stirred for 1 hour 20 minutes. The 
reaction mixture was concentrated in vacuo to give the deprotected alcohol 
which was redissolved in DCM (8 ml).TEMPO (12 mg, 0.08 mmol) and BAIB 
(280 mg, 0.87 mmol) were added and the reaction mixture was stirred at RT 
under a blanket of N2 for 1 hour. TEMPO (12 mg, 0.08 mmol) was added and 
the reaction stirred for a further 2 hours and 20 minutes. The reaction mixture 
was washed with saturated aqueous sodium thiosulfate solution (20 ml), 
extracted with DCM (30 ml), washed with saturated aqueous sodium 
bicarbonate (20 ml), dried (MgSO4) and concentrated in vacuo. The crude 
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residue was purified via column  chromatography (2:8→3:7, EtOAc:PE) to 
give the title compound 199b as a clear oil (106 mg, 0.50 mmol, 63% yield); 
Rf 0.51 (1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.74 (d, J = 1.0 Hz, 
1H, CHO), 6.77 (s, 2H, CH=CH), 4.29 – 4.10 (m, 4H, OCH2CH3+OCH2), 2.52 
(td, J = 7.1, 0.9 Hz, 2H, H3), 2.05 – 1.89 (m, 2H, H2), 1.25 (t, J = 7.1 Hz, 3H, 
OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 200.8 (CH), 164.9 (C), 134.1 (CH), 
133.1 (CH), 64.2 (CH2), 61.4 (CH2), 40.3 (CH2), 21.2 (CH2), 14.1 (CH3); m/z 
(AP+) 215.1 ([M+H]+, 100%); HRMS Found ([M+NH4]+) 232.1181. 
C10H18O5N req. 232.1179. 
Ethyl (5-oxopentyl) fumarate (199c) 
 
pTSA∙H2O (29 mg, 0.15 mmol) was added to a stirred solution of 5-((tert-
butyldimethylsilyl)oxy)pentyl ethyl fumarate 198c  (500 mg, 1.45 mmol) in 
DCM:MeOH (15 ml, 1:1) at 0 °C and stirred for 1 hour 40 minutes. The 
reaction mixture was concentrated in vacuo to give the deprotected alcohol 
which was redissolved in DCM (25 ml). TEMPO (23 mg, 0.15 mmol) and 
BAIB (531 mg, 1.65 mmol) were added and the reaction mixture was stirred 
at RT under a blanket of N2 for 1 hour. TEMPO (23 mg, 0.15 mmol) was 
added and the reaction stirred for a further 2 hours and 10 minutes. The 
reaction mixture was washed with saturated aqueous sodium thiosulfate 
solution(25 ml), extracted with DCM (25 ml), washed with saturated aqueous 
sodium bicarbonate (25 ml), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (3:7, EtOAc:PE) to 
give the title compound 199c as a clear oil (127 mg, 0.56 mmol, 39% yield); 
Rf 0.46 (1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.72 (t, J = 1.2 Hz, 1H, 
CHO), 6.78 (s, 2H, CH=CH), 4.20 (q, J = 7.2 Hz, 2H, OCH2CH3), 4.17 – 4.13 
(m, 2H, OCH2), 2.50 – 2.37 (m, 2H, CH2CHO), 1.75 – 1.60 (m, 4H, H2+H3), 
1.26 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 201.76 
(CH), 164.99 (C), 164.94 (C), 133.89 (CH), 133.35 (CH), 64.78 (CH2), 61.39 
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(CH2), 43.27 (CH2), 27.91 (CH2), 18.49 (CH2), 14.11 (CH3); m/z (AP-) 228.0 
([M]-, 100%); HRMS found ([M+NH4]+) 246.1338. C11H20O5N req 246.1336. 
Ethyl (6-oxohexyl) fumarate (199d) 
 
pTSA∙H2O (23 mg, 0.12 mmol) was added to a stirred solution of 6-((tert-
butyldimethylsilyl)oxy)hexyl ethyl fumarate 198d  (429 mg, 1.2 mmol) in 
DCM:MeOH (15 ml, 1:1) at 0 °C and stirred for 1 hour 30 minutes. The 
reaction mixture was concentrated in vacuo to give the deprotected alcohol 
which was redissolved in DCM (25 ml).TEMPO (19 mg, 0.12 mmol) and BAIB 
(425 mg, 1.32 mmol) were added and the reaction mixture was stirred at RT 
under a blanket of N2 for 1 hour. TEMPO (19 mg, 0.12 mmol) was added and 
the reaction stirred for a further 30 minutes. The reaction mixture was 
washed with saturated aqueous sodium thiosulfate solution (25 ml) and 
saturated aqueous sodium bicarbonate (25 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column  
chromatography (3:7, EtOAc:PE) to give the title compound 199d as a clear 
oil (205 mg, 0.85 mmol, 71% yield); Rf 0.33 (3:7, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 9.80 (s, 1H, CHO), 6.87 (s, 2H, CH=CH), 4.28 (q, J = 7.1 Hz, 
2H, OCH2CH3), 4.22 (t, J = 6.5 Hz, 2H, OCH2), 2.49 (td, J = 7.7, 6.8 Hz, 2H, 
CH2CHO), 1.79 – 1.64 (m, 4H), 1.50 – 1.40 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H, 
OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 202.30 (CH), 165.06 (C), 165.00 
(C), 133.79 (CH), 133.48 (CH), 65.04 (CH2), 61.40 (CH2), 43.71 (CH2), 28.34 
(CH2), 25.49 (CH2), 21.61 (CH2), 14.13 (CH3); m/z (ES+) 243.3 ([M+H]+, 
100%); HRMS found ([M+H]+) 243.1225. C12H19O5 req 243.1227. 
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Ethyl (1S*,6S*)-2-oxo-3-oxabicyclo[4.2.0]oct-7-ene-8-carboxylate (200b) 
 
Diethylamine (0.03 ml, 22 mg, 0.3 mmol) was added to a stirred solution of 
ethyl (4-oxobutyl) fumarate 199b (32 mg, 0.15 mmol) and K2CO3 (41 mg, 0.3 
mmol) in MeCN (2 ml) and stirred at RT under a blanket of N2 for 23.5 hours. 
The reaction mixture was then filtered through Celite® and concentrated in 
vacuo. The crude cyclobutane was dissolved in MeCN (2 ml) and MeI (0.047 
ml, 107 mg, 0.75 mmol) was added and the reaction mixture stirred at RT 
under a blanket of N2 for 90 hours. The reaction mixture was concentrated in 
vacuo and the crude residue dissolved in MeCN (3 ml) and K2CO3 (41 mg, 
0.3 mmol) was added and the reaction mixture heated at 60 °C for 24 hours. 
The reaction mixture was cooled and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:1, EtOAc:PE) to give the 
title compound 200b as a clear oil (12 mg, 0.061 mmol, 41% yield); Rf 0.21 
(1:1, EtOAc:PE); IR 2933.9 cm-1 (CH Sp3), 1715.8 cm-1 (C=O ester);1H NMR 
(400 MHz, CDCl3) δ 6.86 (s, 1H, H7), 4.34 – 4.21 (m, 2H, OCH2), 4.17 (q, J = 
7.1 Hz, 2H, OCH2CH3), 3.82 (d, J = 4.1 Hz, 1H, H1), 3.37 – 3.29 (m, 1H, H6), 
2.11 – 2.00 (m, 1H, OCH2CHH’), 1.96 (dd, J = 4.5, 2.3 Hz, 1H, OCH2CHH’), 
1.24 (t, J = 7.1 Hz, 3H, CH2CH3); 13C NMR (101 MHz, CDCl3) δ 169.1 (C), 
160.4 (C), 148.2 (CH), 135.8 (C), 64.6 (CH2), 61.0 (CH2), 45.1 (CH), 37.7 
(CH), 26.0 (CH2), 14.1 (CH3); m/z (AP+) 196.7 ([M+H]+, 100%); HRMS 
Found ([M+H]+) 197.0808. C10H13O4 req. 197.0808; LCMS rt 2.24, m/z (ES+) 
197.1 ([M+H]+, 100%), >95%. 
tert-Butyl ethyl fumarate  
 
DMAP (244 mg, 2 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (1.44 g, 10 mmol) and (Boc)2O (2.725 g, 12.5 mmol) in THF 
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(15 ml) at 0 °C and stirred for 19.5 hours while slowly warming to RT. The 
reaction mixture was diluted with EtOAc (15 ml), washed with 5% aqueous 
HCl solution (20 ml), followed by 1 M aqueous NaOH solution (20 ml), dried 
(MgSO4) and concentrated in vacuo to give the title compound as a brown oil 
(1.962 g, 9.81 mmol, 98% yield); Rf 0.68 (1:1, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 6.70 – 6.68 (m, 2H, CH=CH), 4.18 (q, J = 7.1 Hz, 2H, 
OCH2CH3), 1.43 (s, 9H, tBu), 1.24 (t, J = 7.1 Hz, 3H, OCH2CH3). Consistent 
with literature.133 
tert-Butyl hydrogen fumarate (207) 
 
LiOH (235 mg, 9.81 mmol) in water (49 ml) was added slowly to a stirred 
solution of tert-butyl ethyl fumarate (1.962 g, 9.81 mmol) in THF (40 ml) and 
stirred for 1 hour at RT. The reaction mixture was acidified (2 M HCl) and 
extracted with diethyl ether (4 × 25 ml), the combined organic layers washed 
with brine (50 ml), dried (MgSO4) and concentrated in vacuo to give the title 
compound 207 as a brown oil (1.61 g, 9.36 mmol, 95% yield); 1H NMR (400 
MHz, CDCl3) δ 6.80 (d, J = 15.7 Hz, 1H, CH=CH), 6.68 (d, J = 15.7 Hz, 1H, 
CH=CH), 1.45 (s, 9H, tBu). Consistent with literature.133 
tert-Butyl (4-((tert-butyldimethylsilyl)oxy)butyl) fumarate 
 
EDCI (2.15 g, 11.25 mmol) was added to a stirred solution of tert-butyl 
hydrogen fumarate 207 (1.548 g, 9 mmol), 4-((tert-
butyldimethylsilyl)oxy)butan-1-ol 196b (1.836 g, 9 mmol), DIPEA (1.56 ml, 
1.161 g, 9 mmol) and DMAP (220 mg, 1.8 mmol) in DCM (100 ml) under a 
blanket of N2 and the reaction mixture stirred for 19 hours. The reaction 
mixture was washed with 5% aqueous HCl (100 ml) and saturated aqueous 
sodium bicarbonate(100 ml), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (0:1→1:9, EtOAc:PE) 
to give the title compound as a clear oil (1.914 g, 5.35 mmol, 59% yield); Rf 
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0.44 (1:9, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 6.75 – 6.67   (m, 2H, 
CH=CH), 4.16 (t, J = 6.6 Hz, 2H, OCH2), 3.59 (t, J = 6.2 Hz, 2H, CH2OTBS), 
1.75 – 1.64 (m, 2H, CH2CH2), 1.60 – 1.49 (m, 2H, CH2CH2), 1.45 (s, 9H, tBu), 
0.84 (s, 9H, tBu), -0.00 (s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 165.29 
(C), 164.20 (C), 135.60 (CH), 132.62 (CH), 81.89 (C), 65.21 (CH2), 62.50 
(CH2), 29.14 (CH2), 27.98 (CH3), 25.94 (CH3), 25.17 (CH2), 18.32 (C), -5.33 
(CH3); m/z (ES+) 381.4 ([M+Na]+, 40%), 359.4 ([M+H]+, 20%), 325.4 
(100%); HRMS found ([M-TBS]+) 245.1379. C12H21O5 req. 245.1384. 
tert-Butyl (4-oxobutyl) fumarate (208) 
 
pTSA∙H2O (29 mg, 0.15 mmol) was added to a stirred solution of tert-butyl (4-
((tert-butyldimethylsilyl)oxy)butyl) fumarate (534 mg, 1.49 mmol) in 
DCM:MeOH (30 ml, 1:1) at 0 °C and stirred for 1.5 hours. The reaction 
mixture was concentrated in vacuo to give the deprotected alcohol which was 
redissolved in DCM (40 ml). TEMPO (23 mg, 0.15 mmol) and BAIB (531 mg, 
1.65 mmol) were added and the reaction mixture was stirred at RT under a 
blanket of N2 for 1 hour. TEMPO (23 mg, 0.15 mmol) was added and the 
reaction stirred for a further 2 hours. The reaction mixture was washed with 
saturated aqueous sodium thiosulfate solution (40 ml) and saturated aqueous 
sodium bicarbonate (40 ml), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (2:8, EtOAc:PE) to 
give the title compound 208 as a clear oil (222 mg, 0.92 mmol, 62% yield); Rf 
0.43 (3:7, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H, CHO), 6.79 
– 6.67 (m, 2H, CH=CH), 4.25 (t, J = 6.3 Hz, 2H, OCH2), 2.61 (td, J = 7.1, 0.8 
Hz, 2H, CH2CHO), 2.13 – 1.99 (m, 2H, CH2CH2), 1.53 (s, 9H, tBu); 13C NMR 
(101 MHz, CDCl3) δ 200.88 (CH), 165.10 (C), 164.05 (C), 136.02 (CH), 
132.15 (CH), 82.03 (C), 64.11 (CH2), 40.32 (CH2), 27.97 (CH3), 21.18 (CH2); 
m/z data not obtainable due to instability. 
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tert-Butyl(1S*,6S*)-2-oxo-3-oxabicyclo[4.2.0]oct-7-ene-8-carboxylate 
(209) 
 
Diethylamine (0.19 ml, 133 mg, 1.82 mmol) was added to a stirred solution of 
tert-butyl (5-oxopentan-2-yl) fumarate 208 (220 mg, 0. 19 mmol) and K2CO3 
(251 mg, 1.82 mmol) in MeCN (20 ml) and stirred at RT under a blanket of N2 
for 108 hours. The reaction mixture was filtered through Celite® and 
concentrated in vacuo. The crude cyclobutane was dissolved in MeCN (20 
ml) and MeI (0.31 ml, 710 mg, 5 mmol) was added and the reaction mixture 
stirred at RT under a blanket of N2 for 44 hours. The reaction mixture was 
concentrated in vacuo and the crude residue dissolved in MeCN (20 ml) and 
K2CO3 (251 mg, 1.82 mmol) was added and the reaction mixture heated at 
65 °C for 24 hours. The reaction was cooled to RT, filtered through Celite® 
and concentrated in vacuo. The crude residue was purified via column 
chromatography (1:1, EtOAc:PE) to give the title compound 209 as a yellow 
oil (40 mg, 0.18 mmol, 20% yield); Rf 0.23 (1:1, EtOAc:PE); IR 2934.1 cm-1 
(CH Sp3), 1714.9 cm-1 (C=O ester);1H NMR (400 MHz, CDCl3) δ 6.77 (s, 1H, 
H7), 4.34 – 4.17 (m, 2H, OCH2), 3.77 (d, J = 4.1 Hz, 1H, H1), 3.28 (app t, J = 
4.1 Hz, 1H, H6), 2.10 – 1.96 (m, 1H, CH2CHH’), 1.97 – 1.87 (m, 1H, 
CH2CHH’), 1.42 (s, 9H, tBu); 13C NMR (101 MHz, CDCl3) δ 169.16 (C), 
159.77 (C), 146.94 (CH), 137.07 (C), 82.03 (C), 64.50 (CH2), 45.25 (CH), 
37.20 (CH), 27.99 (CH3), 26.02 (CH2); m/z (AP+) 225.1 ([M+H]+, 20%), 169.0 
([M-tBu]+, 100%); HRMS found ([M+H]+) 225.1121. C12H17O4 req 225.1121; 
LCMS rt 3.78, m/z (ES+) 247.2 ([M+Na]+, 100%), >95%. 
4-((tert-Butyldimethylsilyl)oxy)butan-1-amine (211) 
 
TBSCl (2.022 g, 13.48 mmol) was added to a stirred mixture of 4-
aminobutan-1-ol 210 (1.034 ml, 1 g, 11.23 mmol) and pyridine (2 ml, 1.956 g, 
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24.76 mmol) and stirred at RT for 16 hours. The reaction mixture was 
concentrated in vacuo, partitioned between DCM (15 ml) and saturated 
aqueous sodium bicarbonate solution (15 ml), dried (MgSO4) and 
concentrated in vacuo to give the title compound 211 as an orange oil (2.28 
g, 11.23 mmol, 100% yield); Rf 0.14 (95:5, DCM:MeOH); 1H NMR (400 MHz, 
CDCl3) δ 3.58 (t, J = 5.6 Hz, 2H, OCH2), 2.75 (t, J = 6.4 Hz, 2H NCH2), 1.58 – 
1.46 (m, 4H, CH2CH2), 0.84 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2). Consistent with 
literature.134 
Ethyl (E)-4-((4-((tert-butyldimethylsilyl)oxy)butyl)amino)-4-oxobut-2-
enoate (212) 
 
EDCI (2.39 g, 12.5 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197  (1.58 g, 11 mmol), 4-((tert-butyldimethylsilyl)oxy)butan-1-
amine 211 (2.28 g, 11.23 mmol), DIPEA (2.61 ml, 1.94 g, 15 mmol) and 
DMAP (134 mg, 1.1 mmol) in DCM (100 ml) under a blanket of N2 and the 
reaction mixture stirred for 16.5 hours. The reaction mixture was washed with 
5% aqueous HCl (70 ml) and saturated aqueous sodium bicarbonate(70 ml), 
dried (MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (2:8, EtOAc:PE) to give the title compound 212 as a 
yellow oil (1.38 g, 4.19 mmol, 38% yield); Rf 0.51 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 6.79 (d J = 15.4 Hz, 1H, CH=CH), 6.77 (d, J = 15.4 Hz, 
1H, CH=CH), 4.18 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.59 (t, J = 5.7 Hz, 2H, 
NHCH2), 3.33 (q, J = 6.5 Hz, 2H, OCH2), 1.65 – 1.44 (m, 4H, CH2CH2), 1.24 
(t, J = 7.1 Hz, 3H, OCH2CH3), 0.83 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2); 13C NMR 
(101 MHz, CDCl3) δ 165.59 (C), 163.49 (C), 136.37 (CH), 130.28 (CH), 62.72 
(CH2), 61.12 (CH2), 39.67 (CH2), 30.06 (CH2), 26.06 (CH2), 25.96 (CH3), 
18.35 (C), 14.15 (CH3), -5.30 (CH3); m/z (ES+) 330.5 ([M+H]+, 100%); HRMS 
found ([M+H]+) 330.2098. C16H32O4NSi req. 330.2095. 
 
 166 
 
Ethyl (E)-4-oxo-4-((4-oxobutyl)amino)but-2-enoate (213) 
 
pTSA∙H2O (21 mg, 0.11 mmol) was added to a stirred solution of (E)-ethyl 4-
((4-((tert-butyldimethylsilyl)oxy)butyl)amino)-4-oxobut-2-enoate 212  (380 mg, 
1.15 mmol) in DCM:MeOH (20 ml, 1:1) at 0 °C and stirred for 2 hours. The 
reaction mixture was concentrated in vacuo to give the deprotected alcohol 
which was redissolved in DCM (30 ml). TEMPO (17 mg, 0.11 mmol) and 
BAIB (409 mg, 1.27 mmol) were added and the reaction mixture was stirred 
at RT under a blanket of N2 for 1 hour 40 minutes. TEMPO (17 mg, 0.11 
mmol) was added and the reaction stirred for a further 2 hours. The reaction 
mixture was washed with saturated aqueous sodium thiosulfate solution(30 
ml), extracted with DCM (30 ml), washed with saturated aqueous sodium 
bicarbonate (30 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (3:1, EtOAc:PE) to give the 
title compound 213 as a clear oil (77 mg, 0.36 mmol, 31% yield); Rf 0.30 (3:1, 
EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 7.99 (s, 1H, CHO), 6.79 (d, J = 15.3 
Hz, 2H, CH=CH), 6.77 (d, J = 15.4 Hz, 1H, CH=CH), 4.18 (q, J = 7.2 Hz, 2H, 
OCH2CH3), 4.13 (t, J = 6.2 Hz, 2H, NHCH2), 1.73 – 1.49 (m, 4H, CH2CH2), 
1.24 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 165.63 (C), 
163.72 (C), 161.10 (CH), 136.35 (CH), 130.61 (CH), 63.39 (CH2), 61.23 
(CH2), 39.42 (CH2), 25.98 (CH2), 14.15 (CH3); m/z not obtained due to 
instability. 
Ethyl (E)-4-((tert-butoxycarbonyl)(4-((tert-butyldimethylsilyl)oxy)butyl) 
amino)-4-oxobut-2-enoate (215) 
 
(Boc)2O (501 mg, 2.3 mmol) was added to a stirred solution of (E)-ethyl 4-((4-
((tert-butyldimethylsilyl)oxy)butyl)amino)-4-oxobut-2-enoate 212 (380 mg, 
1.15 mmol), NEt3 (0.16 ml, 116 mg, 1.15 mmol) and DMAP (140 mg, 1.15 
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mmol) in DCM (20 ml) and stirred at RT under a blanket N2 for 16 hours. 
(Boc)2O (501 mg, 2.3 mmol), NEt3 (0.16 ml, 116 mg, 1.15 mmol) and DMAP 
(140 mg, 1.15 mmol) were added and the reaction mixture stirred for a further 
8 hours. The reaction mixture was washed with 5% aqueous HCl (20 ml) and 
saturated aqueous sodium bicarbonate(20 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column 
chromatography (2:8, EtOAc:PE) to give the title compound 215 as a yellow 
oil (493 mg, 1.15 mmol, 100% yield); Rf 0.64 (3:7, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 7.61 (d, J = 15.5 Hz, 1H, CH=CH), 6.60 (d, J = 15.5 Hz, 1H, 
CH=CH), 4.21 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.75 – 3.63 (m, 2H, NCH2), 
3.58 (t, J = 6.2 Hz, 2H, OCH2), 1.63 – 1.52 (m, 2H, CH2CH2), 1.43 (app s, 
11H, tBu + CH2CH2), 1.27 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.84 (s, 9H, tBu), 
0.00 (s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 171.20 (C), 167.26 (C), 
165.61 (C), 137.93 (CH), 129.16 (CH), 84.08 (C), 62.74 (CH2), 61.07 (CH2), 
60.42 (CH2), 44.63 (CH2), 30.18 (CH2), 27.96 (CH3), 25.95 (CH3), 25.18 (C), 
14.21 (CH3), -5.30 (CH3); m/z (ES-) 429.2 ([M]-, 100%); HRMS found 
([M+H]+) 430.2609. C21H40O6NSi req. 430.2619. 
Ethyl (E)-4-((tert-butoxycarbonyl)(4-oxobutyl)amino)-4-oxobut-2-enoate 
(216) 
 
pTSA∙H2O (21 mg, 0.11 mmol) was added to a stirred solution of (E)-ethyl 4-
((tert-butoxycarbonyl)(4-((tert-butyldimethylsilyl)oxy)butyl)amino)-4-oxobut-2-
enoate 215 (493 mg, 1.15 mmol) in DCM:MeOH (15 ml, 1:1) at 0 °C and 
stirred for 1.5 hours. The reaction mixture was concentrated in vacuo to give 
the deprotected alcohol which was redissolved in DCM (20 ml). TEMPO (19 
mg, 0.12 mmol) and BAIB (425 mg, 1.32 mmol) were added and the reaction 
mixture was stirred at RT under a blanket of N2 for 2 hours 20 minutes. The 
reaction mixture was washed with saturated aqueous sodium thiosulfate 
solution(20 ml), extracted with DCM (20 ml), washed with saturated aqueous 
sodium bicarbonate (20 ml), dried (MgSO4) and concentrated in vacuo. The 
 168 
 
crude residue was purified via column chromatography (2:8, EtOAc:PE) to 
give the title compound 216 as a clear oil (230 mg, 0.73 mmol, 63% yield); Rf 
0.34 (3:7, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.80 (s, 1H, CHO), 7.66 
(d, J = 15.4 Hz, 1H, CH=CH), 6.66 (d, J = 15.4 Hz, 1H, CH=CH), 4.27 (q, J = 
7.1 Hz, 2H, OCH2CH3), 3.85 – 3.72 (m, 2H, NCH2), 2.51 (t, J = 7.0 Hz, 2H, 
CH2CHO), 2.01 – 1.84 (m, 2H, CH2CH2), 1.57 (s, 9H, tBu), 1.33 (t, J = 7.1 Hz, 
3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 201.19 (CH), 167.36 (C), 
165.49 (C), 152.53 (C), 137.61 (CH), 129.52 (CH), 84.62 (C), 61.14 (CH2), 
43.85 (CH2), 41.08 (CH2), 27.98 (CH3), 20.95 (CH2), 14.19 (CH3); m/z (ES+) 
313.3 ([M]-, 100%); HRMS found ([M+H]+) 314.1594. C15H24O6N req. 
314.1598. 
(1S*,6S*)-3-tert-Butyl 8-ethyl-2-oxo-3-azabicyclo[4.2.0]oct-7-ene-3,8-
dicarboxylate (217) 
 
Diethylamine (0.14 ml, 101 mg, 1.38 mmol) was added to a stirred solution of 
ethyl (E)-4-((tert-butoxycarbonyl)(4-oxobutyl)amino)-4-oxobut-2-enoate 216 
(215 mg, 0.69 mmol) and K2CO3 (190 mg, 1.38 mmol) in MeCN (20 ml) and 
stirred at RT under a blanket of N2 for 67.5 hours. The reaction mixture was 
filtered through Celite® and concentrated in vacuo. The crude cyclobutane 
was dissolved in MeCN (15 ml) and MeI (0.21 ml, 490 mg, 3.45 mmol) was 
added and the reaction mixture stirred at RT under a blanket of N2 for 72 
hours. The reaction mixture was concentrated in vacuo and the crude residue 
dissolved in MeCN (20 ml) and K2CO3 (190 mg, 1.38 mmol) was added and 
the reaction mixture heated at 65 °C for 25 hours. The reaction was cooled to 
RT and concentrated in vacuo. The crude residue was purified via column 
chromatography (1:1, EtOAc:PE) to give the title compound 217 as a yellow 
oil (73 mg, 0.25 mmol, 36% yield); Rf 0.27 (1:1, EtOAc:PE); IR 2980.8 cm-1 
(CH Sp3), 1768.5 cm-1 (C=O carbamate) 1711.2 cm-1 (C=O ester);1H NMR 
(400 MHz, CDCl3) δ 6.85 (s, 1H, H7), 4.19 – 4.11 (m, 2H, OCH2CH3), 4.01 
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(dt, J = 13.2, 3.2 Hz, 1H, H6), 3.77 (d, J = 4.1 Hz, 1H, H1), 3.35 – 3.21 (m, 
2H, NCH2), 1.97 – 1.92 (m, 1H, CHH’), 1.90 – 1.80 (m, 1H, CHH’), 1.45 (s, 
9H, tBu), 1.22 (t, J = 7.2 Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 
168.90 (C), 160.82 (C), 152.28 (C), 148.42 (CH), 136.28 (C), 83.13 (C), 
60.84 (CH), 49.18 (CH2), 40.69 (CH), 39.13 (CH2), 28.01 (CH3), 26.24 (CH2), 
14.16 (CH3); m/z (ES+) 296.1 ([M+H]+, 100%); HRMS found ([M+H]+) 
296.1490. C15H22O5N req 296.1492; LCMS rt 5.74, m/z (ES+) 245.1 ([M+H]+, 
100%), >95%. 
4-((tert-Butyldimethylsilyl)oxy)butanal (218) 
 
DMSO (0.49 ml, 533 mg, 6.84 mmol) was added over 10 minutes to a stirred 
solution of oxalyl chloride (2 M in DCM, 2.05 ml, 4.10 mmol) in DCM (10 ml) 
at -42 °C under a blanket of N2. 4-((tert-butyldimethylsilyl)oxy)butan-1-ol 
196b (698 mg, 3.42 mmol) in DCM (4 ml) was added and the reaction stirred 
for a further 10 minutes. NEt3 (1.04 ml, 549 mg, 7.52 mmol) was added and 
the reaction mixture stirred for 10 minutes, then allowed to warm to RT over 4 
hours. The reaction was quenched with H2O (30 ml), extracted with DCM (25 
ml), dried (MgSO4) and concentrated in vacuo to give the title compound 218 
as a clear oil (651 mg, 3.22 mmol, 94% yield); Rf 0.52 (2:8, EtOAc:PE); 1H 
NMR (400 MHz, CDCl3) δ 9.75 (t, J = 1.7 Hz, 1H, CHO), 3.61 (t, J = 6.0 Hz, 
2H, CH2OTBS), 2.46 (td, J = 7.1, 1.7 Hz, 2H, CH2CHO), 1.87 – 1.72 (m, 2H, 
H3), 0.84 (s, 9H, tBu), -0.00 (s, 6H, (CH3)2). Consistent with literature.135 
N-benzyl-4-((tert-butyldimethylsilyl)oxy)butan-1-amine (220) 
 
Benzylamine 219 (0.22 ml, 212 mg, 1.98 mmol) was added to a stirred 
solution of 4-((tert-butyldimethylsilyl)oxy)butanal 218 (400 mg, 1.98 mmol) in 
MeOH (10 ml) under a blanket of argon and the reaction mixture stirred for 
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6.5 hours. The reaction mixture was then cooled to 0 °C and NaBH4 (98 mg, 
2.57 mmol) was added, the reaction warmed to RT and stirred for 17.5 hours. 
The reaction mixture was concentrated in vacuo, partitioned between EtOAc 
(20 ml) and saturated aqueous sodium bicarbonate (20 ml), dried (MgSO4) 
and concentrated in vacuo to give the title compound 220 as an white oil (576 
mg, 1.98 mmol, 100% yield); 1H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 4.4 
Hz, 5H, Ar), 3.75 (s, 2H, PhCH2), 3.58 (dd, J = 7.9, 4.0 Hz, 2H, OCH2), 2.61 
(t, J = 6.7 Hz, 2H, NCH2), 1.52 (dt, J = 6.3, 3.3 Hz, 4H, CH2CH2), 0.85 (s, 9H, 
tBu), -0.00 (s, 6H, (CH3)2). Consistent with literature.136 
Ethyl (E)-4-(benzyl(4-((tert-butyldimethylsilyl)oxy)butyl)amino)-4-
oxobut-2-enoate (221) 
 
EDCI (478 mg, 2.5 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (288 mg, 2 mmol), N-benzyl-4-((tert-
butyldimethylsilyl)oxy)butan-1-amine 220  (576 mg, 1.98 mmol), DIPEA (0.43 
ml, 323 mg, 2.5 mmol) and DMAP (24 mg, 0.2 mmol) in DCM (20 ml) under a 
blanket of N2 and the reaction mixture stirred for 22.5 hours. The reaction 
mixture was washed with 5% aqueous HCl (20 ml) and saturated aqueous 
sodium bicarbonate (20 ml), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (2:8, EtOAc:PE)  to 
give the title compound 221 as an clear oil (536 mg, 1.29 mmol, 65% yield); 
Rf 0.43 (3:7, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 7.45 – 7.09 (m, 5H, 
Ar), 6.86 (d, J = 15.3 Hz, 1H, CH=CH), 6.81 (d, J = 15.3 Hz, 1H, CH=CH), 
4.62 (s, 2H, PhCH2), 4.30 – 4.13 (m, 2H, OCH2CH3), 3.56 (dd, J = 11.4, 5.9 
Hz, 2H, OCH2), 3.47 – 3.37 (m, 1H, NCHH’), 3.37 – 3.21 (m, 1H, NCHH’), 
1.65 – 1.56 (m, 2H, CH2CH2), 1.51 – 1.40 (m, 2H, CH2CH2), 1.29 (t, J = 7.2 
Hz, 3H, OCH2CH3), 0.85 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2); 13C NMR (101 
MHz, CDCl3) δ 165.75 (C), 165.04 (C), 137.04 (CH), 136.40 (CH), 133.72 
(C), 131.80 (CH), 128.66 (CH), 128.06 (CH), 62.37 (CH2), 61.10 (CH2), 48.95 
(CH2), 47.32 (CH2), 29.85 (CH2), 25.90 (CH3), 23.86 (C), 18.26 (CH2), 14.17 
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(CH3), -5.36 (CH3); m/z (AP+) 420.1 ([M+H]+, 100%); HRMS found ([M+H]+) 
420.2562. C23H38O4NSi req 420.2565. 
Ethyl (E)-4-(benzyl(4-oxobutyl)amino)-4-oxobut-2-enoate (222) 
 
pTSA∙H2O (29 mg, 0.15 mmol) was added to a stirred solution of (E)-ethyl 4-
(benzyl(4-((tert-butyldimethylsilyl)oxy)butyl)amino)-4-oxobut-2-enoate 221  
(639 mg, 1.53 mmol) in DCM:MeOH (30 ml, 1:1) at 0 °C and stirred for 2 
hours. The reaction mixture was concentrated in vacuo to give the 
deprotected alcohol which was redissolved in DCM (30 ml). TEMPO (24 mg, 
0.15 mmol) and BAIB (541 mg, 1.68 mmol) were added and the reaction 
mixture was stirred at RT under a blanket of N2 for 1 hour 15 minutes. The 
reaction mixture was washed with saturated aqueous sodium thiosulfate 
solution (30 ml) and saturated aqueous sodium bicarbonate (30 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (3:7, EtOAc:PE) to give the title compound 222 as a 
clear oil (360 mg, 1.19 mmol, 78% yield); Rf 0.28 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 9.77 (s, 1H, CHO), 7.52 – 7.14 (m, 6H, Ph + CH=CH), 
6.90 (d, J = 15.2 Hz, 1H, CH=CH), 4.65 (s, 2H, PhCH2), 4.27 (q, J = 7.1 Hz, 
2H, OCH2CH3), 3.52 – 3.28 (m, 2H, NCH2), 2.49 (dt, J = 13.6, 6.9 Hz, 2H, 
CH2CH2), 2.01 – 1.82 (m, 2H, CH2CH2), 1.28 (t, J = 7.1 Hz, 3H, OCH2CH3); 
13C NMR (101 MHz, CDCl3) δ 200.31 (CH), 165.33 (C), 164.75 (C), 136.11 
(C), 133.66 (CH), 132.05 (CH), 129.05 (CH), 126.58 (CH), 60.38 (CH2), 
51.33 (CH2), 45.54 (CH2), 41.15 (CH2), 19.79 (CH2), 14.19 (CH3); m/z (AP+) 
304.1 ([M+H]+, 100%); HRMS found ([M+O+H]+) 320.1495. C17H22O5N req 
320.1492 (from spontaneous oxidation from aldehyde to carboxylic acid). 
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Ethyl (1S*,6S*)-3-benzyl-2-oxo-3-azabicyclo[4.2.0]oct-7-ene-8-
carboxylate (223) 
 
Diethylamine (0.25 ml, 174 mg, 2.38 mmol) was added to a stirred solution of 
ethyl (E)-4-(benzyl(4-oxobutyl)amino)-4-oxobut-2-enoate 222 (360 mg, 1.19 
mmol) and K2CO3 (328 mg, 2.38 mmol) in MeCN (40 ml) and stirred at RT 
under a blanket of N2 for 53 hours. The reaction mixture was filtered through 
Celite® and concentrated in vacuo. The crude cyclobutane was dissolved in 
MeCN (30 ml) and MeI (0.37 ml, 845 mg, 5.95 mmol) was added and the 
reaction mixture stirred at RT under a blanket of N2 for 24 hours. The 
reaction mixture was concentrated in vacuo and the crude residue dissolved 
in MeCN (30 ml) and K2CO3 (328 mg, 2.38 mmol) was added and the 
reaction mixture heated at 65 °C for 18 hours. The reaction was cooled to 
RT, filtered through Celite® and concentrated in vacuo. The crude residue 
was purified via column chromatography (7:3, EtOAc:PE) to give the title 
compound 223 as a clear oil (82 mg, 0.29 mmol, 24% yield); Rf 0.21 (3:1, 
EtOAc:PE); IR 2933.9 cm-1 (CH Sp3), 1708.1 cm-1 (C=O ester), 1634.9 cm-1 
(C=O amide), 717.5 cm-1 (mono subs. Benzene);1H NMR (400 MHz, CDCl3) 
δ 7.29 – 7.07 (m, 5H, Ar), 6.83 (s, 1H, H7), 4.68 (d, J = 14.8 Hz, 1H, 
PhCHH’), 4.45 (d, J = 14.8 Hz, 1H, PhCHH’), 4.19 (dd, J = 9.8, 3.7 Hz, 2H, 
OCH2CH3), 3.79 (d, J = 4.0 Hz, 1H, H1), 3.22 (app s, 1H, H6), 3.18 – 2.97 
(m, 2H, NCH2), 1.81 – 1.63 (m, 2H, CH2CH2), 1.25 (t, J = 6.9 Hz, 3H, 
OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 168.47 (C), 161.14 (C), 148.24 
(CH), 137.33 (C), 136.14 (C), 128.57 (CH), 127.81 (CH), 127.38 (CH), 60.78 
(CH2), 50.78 (CH2), 47.09 (CH), 42.88 (CH2), 39.21 (CH), 26.66 (CH2), 14.24 
(CH3); m/z (AP+) 286.1 ([M+H]+, 100%); HRMS found ([M+H]+) 286.1439. 
C17H20O3N req 286.1438; LCMS rt 5.80, m/z (ES+) 286.2 ([M+H]+, 100%), 
>95%. 
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 5-((tert-Butyldimethylsilyl)oxy)pentan-2-ol (224a) 
 
A solution of methyl lithium (1.6M in THF, 10.98 ml, 17.56 mmol) was added 
to a stirred solution of 4-((tert-butyldimethylsilyl)oxy)butanal 218  (2.73 g, 
13.51 mmol) in THF (60 ml) at -78 ⁰C under a blanket of argon and stirred for 
3 hour before warming to 0 °C and stirring for a further 1 hour. The reaction 
was quenched with saturated aqueous ammonium chloride (70 ml), extracted 
with EtOAc (40 ml), washed with H2O (40 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column 
chromatography (2:8, EtOAc:PE)to give the title compound 224a as a clear 
oil (2.01 g, 9.22 mmol, 68% yield); Rf 0.27 (2:8, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 3.87 – 3.78 (m, 1H, CH), 3.73 – 3.62 (m, 2H, CH2OTBS), 2.68 
(s, 1H, OH), 1.70 – 1.56 (m, 4H), 1.20 (d, J = 6.3 Hz, 3H, CH3), 0.91 (s, 9H, 
tBu), 0.08 (s, 6H, (CH3)2). Consistent with literature.137 
6-((tert-Butyldimethylsilyl)oxy)hex-1-en-3-ol (224b) 
 
A solution of vinylmagnesium bromide (1 M in THF, 1.65 ml, 1.65 mmol) was 
added to a stirred solution of 4-((tert-butyldimethylsilyl)oxy)butanal 218 (257 
mg, 1.27 mmol) in THF (6 ml) at -78 °C under a blanket of argon and stirred 
for 1 hour 40 minutes. The reaction was quenched with saturated aqueous 
ammonium chloride (10 ml), extracted with EtOAc (15 ml), washed with H2O 
(10 ml), dried (MgSO4) and concentrated in vacuo to give the title compound 
224b as a clear oil (250 mg, 1.09 mmol, 86% yield); Rf 0.51 (2:8, EtOAc:PE); 
1H NMR (400 MHz, CDCl3) δ 5.81 (ddd, J = 17.1, 10.4, 5.8 Hz, 1H, CH=CH2), 
5.17 (dt, J = 17.1, 1.4 Hz, 1H, CH=CHH’), 5.03 (dt, J = 10.4, 1.4 Hz, 1H, 
CH=CHH’), 4.12 – 4.00 (m, 1H, CHOH), 3.60 (t, J = 5.6 Hz, 2H, CH2OTBS), 
2.53 (d, J = 4.2 Hz, 1H, OH), 1.62 – 1.52 (m, 4H, H4+H5), 0.83 (s, 9H, tBu), -
0.00 (s, 6H, (CH3)2). Consistent with literature.138 
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6-((tert-Butyldimethylsilyl)oxy)-2-methylhexan-3-ol (224c) 
 
A solution of iso-propylmagnesium bromide (2.9 M in THF, 1.34 ml, 3.9 
mmol) was added to a stirred solution of 4-((tert-
butyldimethylsilyl)oxy)butanal 218 (606 mg, 3 mmol) in THF (20 ml) at -78 ⁰C 
under a blanket of argon and stirred for 3 hours before warming to 0 °C and 
stirring for a further 1 hour. The reaction was quenched with saturated 
aqueous ammonium chloride (30 ml), extracted with EtOAc (30 ml), washed 
with H2O (20 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:9, EtOAc:PE) to give the 
title compound 103c as a clear oil (529 mg, 2.15 mmol, 72% yield); Rf 0.46 
(2:8, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 3.68 (t, J = 4.7 Hz, 2H, 
CH2OTBS), 3.41 – 3.31 (m, 1H, CHOH), 2.41 (d, J = 4.3 Hz, 1H, OH), 1.73 – 
1.59 (m, 4H), 1.51 – 1.33 (m, 1H, CH(CH3)2), 0.93 (d, J = 3.9 Hz, 3H, CH3), 
0.92 (d, J = 3.9 Hz, 3H, CH3), 0.91 (s, 9H, tBu), 0.07 (s, 6H, (CH3)2); 13C NMR 
(101 MHz, CDCl3) δ 76.4 (CH), 63.6 (CH2), 33.6 (CH), 31.1 (CH2), 29.4 
(CH2), 25.9 (CH3), 18.7 (CH3), 18.3 (C), 17.6 (CH3), -5.4 (CH3); m/z (AP+) 
247.2 ([M+H]+, 100%); HRMS found ([M+H]+) 247.2089. C13H31O2Si req 
247.2088. 
4-((tert-Butyldimethylsilyl)oxy)-1-phenylbutan-1-ol (224d) 
 
A solution of phenylmagnesium bromide (3 M in Et2O, 1.27 ml, 3.8 mmol) 
was added to a stirred solution of 4-((tert-butyldimethylsilyl)oxy)butanal 218 
(590 mg, 2.92 mmol) in THF (15 ml) at -78 ⁰C under a blanket of argon and 
stirred for 3 hours before warming to 0 °C and stirring for a further 2 hours 15 
minutes. The reaction was quenched with saturated aqueous ammonium 
chloride (20 ml), extracted with EtOAc (20 ml), washed with H2O (20 ml), 
dried (MgSO4) and concentrated in vacuo. The crude residue was purified via 
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column chromatography (0:1→1:9, EtOAc:PE) to give the title compound 
224d as a clear oil (399 mg, 1.43 mmol, 49% yield); Rf 0.3 (2:8, EtOAc:PE); 
1H NMR (400 MHz, CDCl3) δ 7.32 – 7.17 (m, 5H, Ph), 4.78 – 4.67 (m, 1H, 
CH), 3.73 – 3.65 (m, 2H, CH2OTBS), 1.92 – 1.80 (m, 2H), 1.71 – 1.63 (m, 
2H), 0.92 (s, 9H, tBu), 0.09 (s, 6H, (CH3)2).Consistent with literature.139 
5-((tert-Butyldimethylsilyl)oxy)pentan-2-yl ethyl fumarate (225a) 
 
EDCI (287 mg, 1.5 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197  (173 mg, 1.2 mmol), 5-((tert-butyldimethylsilyl)oxy)pentan-2-ol 
224a (255 mg, 1.17 mmol), DIPEA (0.26 ml, 194 mg, 1.5 mmol) and DMAP 
(15 mg, 0.12 mmol) in DCM (15 ml) under a blanket of N2 and the reaction 
mixture stirred for 24 hours. The reaction mixture diluted with DCM (15 ml) 
was washed with 5% aqueous HCl (30 ml) and saturated aqueous sodium 
bicarbonate (30 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (2:8, EtOAc:PE) to give the 
title compound 225a as a clear oil (227 mg, 0.66 mmol, 56% yield); Rf 0.51 
(2:8, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 6.84 (s, 2H, CH=CH), 5.05 (tq, 
J = 12.2, 6.2 Hz, 1H, CH), 4.27 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.62 (t, J = 6.1 
Hz, 2H, CH2OTBS), 1.71 – 1.60 (m, 2H), 1.60 – 1.51 (m, 2H), 1.33 (t, J = 7.1 
Hz, 3H, OCH2CH3), 1.29 (d, J = 6.2 Hz, 3H, CH3), 0.90 (s, 9H, tBu), 0.05 (s, 
6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 165.1 (C), 164.6 (C), 134.1 (CH), 
133.4 (CH), 72.2 (CH), 62.7 (CH2), 61.3 (CH2), 32.2 (CH2), 28.6 (CH2), 25.9 
(CH3), 19.9 (CH3), 18.3 (C), 14.1 (CH3), -5.3 (CH3); m/z (AP+) 345.2 ([M+H]+, 
100%); HRMS found ([M+H]+) 345.2091. C17H33O5Si req 345.2092. 
6-((tert-Butyldimethylsilyl)oxy)hex-1-en-3-yl ethyl fumarate (225b) 
 
EDCI (229 mg, 1.2 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (173 mg, 1.2 mmol), 6-((tert-butyldimethylsilyl)oxy)hex-1-en-3-
 176 
 
ol 224b (250 mg, 1.09 mmol) and DMAP (15 mg, 0.12 mmol) in DCM (20 ml) 
at 0 °C under a blanket of N2. After 10 minutes the reaction mixture was 
warmed to RT and stirred for 21 hours, then a further portion of EDCI (115 
mg, 0.6 mmol) was added and the reaction mixture stirred for a further 5 
hours. The reaction mixture was partitioned between DCM (25 ml) and 
saturated aqueous ammonium chloride (25 ml), the aqueous layer extracted 
with DCM (15 ml), and the combined organic layers were washed with 5% 
aqueous NaOH, dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:9, EtOAc:PE) to give the 
title compound 225b as a pale yellow oil (227 mg, 0.64 mmol, 59% yield); Rf 
0.56 (2:8, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 6.81 (s, 2H, CH=CH), 
5.76 (ddd, J = 17.1, 10.5, 6.5 Hz, 1H, CH=CH2), 5.32 (dd, J = 12.9, 6.5 Hz, 
1H, CH=CHH’), 5.19 (dd, J = 27.3, 13.8 Hz, 2H, CH=CHH’+OCH), 4.22 (q, J 
= 7.1 Hz, 2H, OCH2CH3), 3.58 (t, J = 6.2 Hz, 2H, CH2OTBS), 1.70 (dd, J = 
14.4, 7.4 Hz, 2H), 1.51 (dd, J = 12.6, 4.9 Hz, 2H), 1.28 (t, J = 7.1 Hz, 3H, 
CH2CH3), 0.84 (s, 9H, tBu), -0.00 (s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) 
δ 165.0 (C), 164.3 (C), 135.9 (CH), 133.7 (CH), 117.3 (CH2), 75.8 (CH), 62.5 
(CH2), 61.3 (CH2), 30.6 (CH2), 28.2 (CH2), 25.9 (C), 18.3 (CH3), 14.1 (CH3), -
5.3 (CH3); m/z (AP-) 356.0 ([M]-, 100%); HRMS Found ([M+H]+) 357.2097. 
C18H33O5Si req. 357.2092. 
6-((tert-Butyldimethylsilyl)oxy)-2-methylhexan-3-yl ethyl fumarate (225c) 
 
EDCI (248 mg, 1.3 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (144 mg, 1 mmol), 6-((tert-butyldimethylsilyl)oxy)-2-
methylhexan-3-ol 224c (234 mg, 0.95 mmol), DIPEA (0.23 ml, 168 mg, 1.3 
mmol) and DMAP (12 mg, 0.1 mmol) in DCM (10 ml) under a blanket of N2 
and the reaction mixture stirred for 45 hours. The reaction mixture diluted 
with DCM (10 ml) was washed with 5% aqueous HCl (20 ml) and saturated 
aqueous sodium bicarbonate(20 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via column chromatography (1:9, 
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EtOAc:PE) to give the title compound 225c as a clear oil (146 mg, 0.39 
mmol, 41% yield); Rf 0.37 (1:9, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 
6.82 (s, 1H, CH=CH), 6.81 (s, 1H, , CH=CH), 4.89 – 4.76 (m, 1H, CH), 4.23 
(q, J = 7.2 Hz, 2H, OCH2CH3), 3.56 (td, J = 6.2, 2.7 Hz, 2H, CH2OTBS), 1.85 
(dq, J = 13.5, 6.8 Hz, 1H, CH(CH3)2), 1.70 – 1.38 (m, 4H), 1.29 (t, J = 7.2 Hz, 
3H, OCH2CH3), 0.87 (d, J = 6.8 Hz, 6H, (CH3)2), 0.84 (s, 9H, tBu), -0.00 (s, 
6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 165.1 (C), 164.9 (C), 134.0 (CH), 
133.4 (CH), 79.6 (CH), 62.6 (CH2), 61.4 (CH2), 31.4 (CH), 28.7 (CH2), 27.3 
(CH2), 25.9 (CH3), 18.5 (CH3), 18.3 (C), 17.6 (CH3), 14.2 (CH3), -5.3 (CH3); 
m/z (AP+) 373.2 ([M+H]+, 100%); HRMS found ([M+H]+) 373.2406. 
C19H37O5Si req 373.2405. 
Ethyl (5-oxopentan-2-yl) fumarate (226a) 
 
pTSA∙H2O (8 mg, 0.04 mmol) was added to a stirred solution of 5-((tert-
butyldimethylsilyl)oxy)pentan-2-yl ethyl fumarate 225a (130 mg, 0.38 mmol) 
in DCM:MeOH (6 ml, 1:1) at 0 °C and stirred for 2 hour. The reaction mixture 
was concentrated in vacuo to give the deprotected alcohol which was 
redissolved in DCM (7 ml). TEMPO (6 mg, 0.04 mmol) and BAIB (142 mg, 
0.44 mmol) were added and the reaction mixture was stirred at RT under a 
blanket of N2 for 1 hour. TEMPO (6 mg, 0.04 mmol) was added and the 
reaction stirred for a further 2 hours 15 minutes. The reaction mixture was 
diluted with DCM (8 ml) washed with saturated aqueous sodium thiosulfate 
solution(15 ml) and saturated aqueous sodium bicarbonate (15 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (2:8, EtOAc:PE) to give the title compound 226a as 
a clear oil (73 mg, 0.32 mmol, 84% yield); Rf 0.33 (3:7, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 9.79 (t, J = 1.1 Hz, 1H, CHO), 6.83 (s, 2H, CH=CH), 
5.11 – 5.00 (m, 1H, CH), 4.27 (q, J = 7.1 Hz, 2H, OCH2CH3), 2.57 – 2.50 (m, 
2H), 2.00 – 1.91 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.31 (d, J = 6.2 
Hz, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 201.1 (CH), 165.0 (C), 164.5 
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(C), 133.9 (CH), 133.6 (CH), 71.3 (CH), 61.4 (CH2), 39.8 (CH2), 28.0 (CH2), 
19.9 (CH3), 14.1 (CH3); m/z data not obtainable due to instability. 
Ethyl (6-oxohex-1-en-3-yl) fumarate (226b) 
 
pTSA∙H2O (4 mg, 0.02 mmol) was added to a stirred solution of 6-((tert-
butyldimethylsilyl)oxy)hex-1-en-3-yl ethyl fumarate 225b (71 mg, 0.2 mmol) in 
DCM:MeOH (1 ml, 1:1) at 0 °C and stirred for 1 hour 55 minutes. The 
reaction mixture was concentrated in vacuo to give the deprotected alcohol 
which was redissolved in DCM (2 ml). TEMPO (3 mg, 0.02 mmol) and BAIB 
(71 mg, 0.22 mmol) were added and the reaction mixture was stirred at RT 
under a blanket of N2 for 2.5 hours. TEMPO (3 mg, 0.02 mmol) was added 
and the reaction stirred for a further 3 hours and 15 minutes. The reaction 
mixture was washed with saturated aqueous sodium thiosulfate (10 ml), and 
the aqueous layer extracted with DCM (2 × 20 ml). The combined organic 
layers were washed with saturated aqueous sodium bicarbonate, dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column  chromatography (3:7, EtOAc:PE) to give the title compound 226b as 
a clear oil (30 mg, 0.125 mmol, 63% yield); Rf 0.54 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 9.80 (s, 1H, CHO), 6.87 (s, 2H, CH=CH), 5.81 (ddd, J = 
17.1, 10.6, 6.4 Hz, 1H, CH=CH2), 5.41 (dd, J = 12.5, 6.4 Hz, 1H, CH=CHH’), 
5.35 – 5.25 (m, 2H, CH=CHH’+OCH), 4.29 (q, J = 7.1 Hz, 2H, OCH2CH3), 
2.55 (t, J = 7.2 Hz, 2H, CH2CHO), 2.11 – 2.00 (m, 2H, CH2), 1.35 (t, J = 7.1 
Hz, 3H, CH2CH3); 13C NMR (101 MHz, CDCl3) δ 200.7 (CH), 164.9 (C), 164.1 
(C), 135.0 (CH), 134.2 (CH), 133.3 (CH), 118.1 (CH2), 74.7 (CH), 61.4 (CH2), 
39.3 (CH2), 26.3 (CH2), 14.1 (CH3); m/z (AP+) 241.1 ([M+H]+, 60%), 96.8 
(100%); HRMS Found ([M+NH4]+) 258.1338. C12H20O5N req. 258.1336. 
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Ethyl (2-methyl-6-oxohexan-3-yl) fumarate (226c) 
 
pTSA∙H2O (25 mg, 0.13 mmol) was added to a stirred solution of 6-((tert-
butyldimethylsilyl)oxy)-2-methylhexan-3-yl ethyl fumarate 225c (470 mg, 1.26 
mmol) in DCM:MeOH (15 ml, 1:1) at 0 °C and stirred for 1 hour 40 minutes. 
The reaction mixture was concentrated in vacuo to give the deprotected 
alcohol which was dissolved in DCM (15 ml) and TEMPO (23 mg, 0.15 mmol) 
and BAIB (448 mg, 1.39 mmol) were added and the reaction mixture was 
stirred at RT under a blanket of N2 for 2 hours. TEMPO (23 mg, 0.15 mmol) 
was added and the reaction stirred for a further 24 hours. The reaction 
mixture was diluted with DCM (10 ml) washed with saturated aqueous 
sodium thiosulfate solution(20 ml) and saturated aqueous sodium 
bicarbonate (20 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:9, EtOAc:PE) to give the 
title compound 226c as a clear oil (158 mg, 0.62 mmol, 49% yield); Rf 0.28 
(2:8, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.77 (s, 1H, CHO), 6.86 (s, 
2H, CH=CH), 4.87 (ddd, J = 9.1, 5.6, 3.4 Hz, 1H, CH), 4.28 (q, J = 7.1 Hz, 
2H, OCH2CH3), 2.49 (t, J = 7.4 Hz, 2H, CH2CHO), 2.05 – 1.93 (m, 1H, 
CH(CH3)2), 1.93 – 1.82 (m, 2H), 1.34 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.94 (d, J 
= 6.8 Hz, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 201.2 (CH), 165.0 (C), 
164.9 (C), 134.0 (CH), 133.5 (CH), 78.9 (CH), 61.5 (CH2), 40.2 (CH2), 31.7 
(CH), 23.4 (CH2), 18.3 (CH3), 17.7 (CH3), 14.1 (CH3); m/z (AP+) 257.1 
([M+H]+, 100%); HRMS found ([M+NH4]+) 274.1650. C13H24O5N req 
274.1649. 
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Ethyl (1S*,4S*,6S*)-4-methyl-2-oxo-3-oxabicyclo[4.2.0]oct-7-ene-8-
carboxylate (227a) 
 
Diethylamine (0.08 ml, 58 mg, 0.8 mmol) was added to a stirred solution of 
ethyl (5-oxopentan-2-yl) fumarate 226a (90 mg, 0.39 mmol) and K2CO3 (110 
mg, 0.8 mmol) in MeCN (15 ml) and stirred at RT under a blanket of N2 for 
65.5 hours. The reaction mixture was filtered through Celite® and 
concentrated in vacuo. The crude cyclobutane was dissolved in MeCN (15 
ml) and MeI (0.12 ml, 277 mg, 1.95 mmol) was added and the reaction 
mixture stirred at RT under a blanket of N2 for 70 hours. The reaction mixture 
was concentrated in vacuo and the crude residue dissolved in MeCN (15 ml) 
and K2CO3 (110 mg, 0.8 mmol) was added and the reaction mixture heated 
at 65 °C for 24 hours. The reaction was cooled to RT and concentrated in 
vacuo. The crude residue was purified via column chromatography (1:1, 
EtOAc:PE) to give the title compound 227a as a clear oil (45 mg, 0.21 mmol, 
54% yield); Rf 0.22 (1:1, EtOAc:PE); IR 2984.7 cm-1 (CH sp3), 1710.8 cm-1 
(C=O ester);1H NMR (400 MHz, CDCl3) δ 6.81 (s, 1H, H7), 4.40 – 4.28 (m, 
1H, H4), 4.19 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.88 (d, J = 4.8 Hz, 1H, H1), 
3.27 – 3.14 (m, 1H, H6), 2.16 (ddd, J = 14.2, 7.8, 1.3 Hz, 1H, H5), 1.43 (app 
dt, J = 14.2, 10.7 Hz, 1H, H5’), 1.32 (d, J = 6.3 Hz, 3H, CH3), 1.25 (t, J = 7.1 
Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 169.9 (C), 161.2 (C), 
148.7 (CH), 136.9 (C), 76.2 (CH), 60.8 (CH2), 42.2 (CH), 37.8 (CH), 35.4 
(CH2), 21.0 (CH3), 14.2 (CH3); m/z (ES+) 233.1([M+Na]+, 100%) 211.1 
([M+H]+, 10%); HRMS found ([M+H]+) 211.0964. C11H15O4 req 211.0965; 
LCMS rt 2.71, m/z (ES+) 211.2 ([M+H]+, 100%), >95%. 
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Ethyl (1S*,4R*,6S*)-2-oxo-4-vinyl-3-oxabicyclo[4.2.0]oct-7-ene-8-
carboxylate (227b) 
 
Diethylamine (0.058 ml, 41 mg, 0.56 mmol) was added to a stirred solution of 
ethyl (6-oxohex-1-en-3-yl) fumarate 226b (68 mg, 0.28 mmol) and K2CO3 (77 
mg, 0.56 mmol) in MeCN (6 ml) and stirred at RT under a blanket of N2 for 64 
hours. The reaction mixture was filtered through Celite® and concentrated in 
vacuo. The crude cyclobutane was dissolved in MeCN (6 ml) and MeI (0.04 
ml, 99 mg, 0.7 mmol) was added and the reaction mixture stirred at RT under 
a blanket of N2 for 5 hours. A further portion of MeI (0.04 ml, 99 mg, 0.7 
mmol) was added and the reaction mixture stirred for 25 hours. Another 
portion of MeI (0.1 ml, 227 mg, 1.60 mmol) was added and the reaction 
mixture stirred for a further 22 hours. The reaction mixture was concentrated 
in vacuo and the crude residue dissolved in MeCN (6 ml) and K2CO3 (77 mg, 
0.56 mmol) was added and the reaction mixture heated at 65 °C for 20 
hours. The reaction was cooled to RT and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:1, EtOAc:PE) to give the 
title compound 227b as a clear oil (30 mg, 0.135 mmol, 48% yield); Rf 0.28 
(1:1, EtOAc:PE); IR 2993.3 cm-1 (C=C), 2942.9 cm-1 (CH sp3), 1721.1 cm-1 
(C=O ester), 1711.7 cm-1 (C=O ester);1H NMR (400 MHz, CDCl3) δ 6.82 (s, 
1H, H7), 5.80 (ddd, J = 17.2, 10.6, 5.7 Hz, 1H, CH=CH2), 5.29 (d, J = 17.2 
Hz, 1H, CH=CHH’), 5.17 (d, J = 10.6 Hz, 1H, CH=CHH’), 4.79 – 4.69 (m, 1H, 
OCH), 4.19 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.92 (d, J = 4.5 Hz, 1H, H1), 3.26 
(dddd, J = 9.0, 7.6, 4.6, 0.9 Hz, 1H, H6), 2.25 (ddd, J = 14.2, 7.6, 2.5 Hz, 1H, 
CHH’), 1.64 (dt, J = 14.2, 9.0 Hz, 1H, CHH’), 1.24 (t, J = 7.1 Hz, 3H, 
CH2CH3); 13C NMR (101 MHz, CDCl3) δ 169.23 (C), 161.0 (C), 149.0 (CH), 
136.7 (C), 135.5 (CH), 117.2 (CH2), 79.6 (CH), 60.8 (CH2), 42.8 (CH), 37.6 
(CH), 33.5 (CH2), 14.2 (CH3); m/z (AP+) 223.2 ([M+H]+, 100%); HRMS 
Found ([M+H]+) 223.0965. C12H15O4 req. 223.0967; LCMS rt 3.05, m/z (ES+) 
245.1 ([M+Na]+, 100%), >95%. 
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Ethyl (1S*,4R*,6S*)-4-isopropyl-2-oxo-3-oxabicyclo[4.2.0]oct-7-ene-8-
carboxylate (227c) 
 
Diethylamine (0.13 ml, 89 mg, 1.24 mmol) was added to a stirred solution of 
ethyl (2-methyl-6-oxohexan-3-yl) fumarate 226c (158 mg, 0.62 mmol) and 
K2CO3 (171 mg, 1.24 mmol) in MeCN (20 ml) and stirred at RT under a 
blanket of N2 for 70 hours. The reaction mixture was filtered through Celite® 
and concentrated in vacuo. The crude cyclobutane was dissolved in MeCN 
(20 ml) and MeI (0.19 ml, 440 mg, 3.1 mmol) was added and the reaction 
mixture stirred at RT under a blanket of N2 for 24 hours. MeI (0.19 ml, 440 
mg, 3.1 mmol) was added and the reaction mixture stirred ofr a further 24 
hours. The reaction mixture was concentrated in vacuo and the crude residue 
dissolved in MeCN (20 ml) and K2CO3 (171 mg, 1.24 mmol) was added and 
the reaction mixture heated at 65 °C for 25 hours. The reaction was cooled to 
RT and concentrated in vacuo. The crude residue was purified via column 
chromatography (3:7, EtOAc:PE) to give the title compound 227c as a clear 
oil (70 mg, 0.29 mmol, 47% yield); Rf 0.20 (3:7, EtOAc:PE); IR 2970.1 cm-1 
(CH sp3), 1720.2 cm-1 (C=O ester);1H NMR (400 MHz, CDCl3) δ 6.80 (s, 1H, 
H7), 4.19 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.96 (ddd, J = 10.9, 5.1, 0.9 Hz, 1H, 
H4), 3.89 (d, J = 4.5 Hz, 1H, H1), 3.19 – 3.12 (m, 1H, H6), 2.14 (ddd, J = 
14.0, 7.9, 1.2 Hz, 1H, H5), 1.90 – 1.80 (m, 1H, CH(CH3)2), 1.39 (dt, J = 14.0, 
10.9 Hz, 1H, H5’), 1.25 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.92 (d, J = 4.6 Hz, 3H, 
CH3), 0.91 (d, J = 4.6 Hz, 3H, CH3); 13C NMR (101 MHz, CDCl3) δ 170.0 (C), 
161.2 (C), 148.5 (CH), 137.0 (C), 84.3 (CH), 60.8 (CH2), 42.7 (CH), 37.9 
(CH), 31.9 (CH), 30.5 (CH2), 17.9 (CH3), 17.5 (CH3), 14.2 (CH3); m/z (AP+) 
239.1 ([M+H]+, 100%); HRMS found ([M+H]+) 239.1279. C13H19O4 req 
239.1278; LCMS rt 5.03, m/z (ES+) 239.2 ([M+H]+, 100%), >95%. 
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5-((tert-Butyldimethylsilyl)oxy)pentan-2-yl methanesulfonate 
 
Method140. 
NEt3 (1.93 ml, 1.40 g, 13.83 mmol) was added to s attired solution of 5-((tert-
butyldimethylsilyl)oxy)pentan-2-ol 224a (2.01 g, 9.22 mmol) in DCM (100 ml) 
at 0 °C and stirred for 10 minutes. MeSO2Cl (0.85 ml, 1.26 g, 11.06 mmol) 
was added and the reaction mixture stirred for 5 hours. The reaction mixture 
was then washed with saturated aqueous sodium bicarbonate solution (100 
ml), dried (MgSO4) and concentrated in vacuo to give the title compound as a 
clear oil which was used immediately due to high reactivity (2.73 g, 9.22 
mmol, quantitative);  Rf 0.44 (2:8, EtOAc:PE).   
((4-Azidopentyl)oxy)(tert-butyl)dimethylsilane (231) 
 
Sodium azide (408 mg, 6.28 mmol) was added to a stirred solution of 5-((tert-
butyldimethylsilyl)oxy)pentan-2-yl methanesulfonate (929 mg, 3.14 mmol) in 
DMF (30 ml) at RT under a blanket of argon and the reaction mixture stirred 
for 23 hours. The reaction mixture was concentrated in vacuo, partitioned 
between EtOAc (40 ml) and saturated aqueous sodium bicarbonate solution 
(60 ml), extracted with EtOAc (50 ml), the combined organic layers washed 
with brine (60 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:1, EtOAc:PE) to give the 
title compound 231 as a yellow oil (620 mg, 2.55 mmol, 81% yield); 1H NMR 
(400 MHz, CDCl3) δ 3.57 (dd, J = 7.6, 3.5 Hz, 2H, OCH2), 3.42 – 3.40 (m, 1H, 
CH), 1.62 – 1.47 (m, 4H, CH2CH2), 1.21 (d, J = 6.4 Hz, 3H, CH3), 0.84 (s, 9H, 
tBu), 0.00 (s, 6H, (CH2)2). Consistent with literature.141 
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5-((tert-Butyldimethylsilyl)oxy)pentan-2-amine (232) 
 
Method.142 
10% Pd/C (160 mg) was added to a stirred solution of ((4-
azidopentyl)oxy)(tert-butyl)dimethylsilane 231 (1.595 g, 6.56 mmol) and NEt3 
(2 drops) in MeOH (60 ml) and stirred at RT under 1 atm H2 for 21.5 hours. 
The reaction mixture was filtered through Celite® and concentrated in vacuo 
to give the title compound 232 as a clear oil (1.423 g, 6.56 mmol, 100% 
yield); 1H NMR (400 MHz, CDCl3) δ 3.57 (t, J = 6.5 Hz, 2H, OCH2), 2.90 – 
2.78 (m, 1H, CH), 1.58 – 1.40 (m, 2H, CH2CH2), 1.39 – 1.22 (m, 2H, 
CH2CH2), 1.02 (d, J = 6.4 Hz, 3H, CH3), 0.84 (s, 9H, tBu), -0.00 (s, 6H, 
(CH2)2). 
Ethyl (E)-4-((5-((tert-butyldimethylsilyl)oxy)pentan-2-yl)amino)-4-oxobut-
2-enoate (233) 
 
EDCI (1.64 g, 8.58 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (950 mg, 6.6 mmol), 5-((tert-butyldimethylsilyl)oxy)pentan-2-
amine 232 (1.423 g, 6.56 mmol), DIPEA (1.49 ml, 1.11 g, 8.5 mmol) and 
DMAP (85 mg, 0.7 mmol) in DCM (90 ml) under a blanket of argon and the 
reaction mixture stirred for 23.5 hours. The reaction mixture was washed with 
5% aqueous HCl (90 ml) and saturated aqueous sodium bicarbonate (90 ml), 
dried (MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (1:1, EtOAc:PE) to give the title compound 233 as a 
clear oil (1.311 g, 3.82 mmol, 58% yield); Rf 0.44 (3:7, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 6.76 (q, J = 15.3 Hz, 2H, CH=CH), 5.75 (d, J = 7.6 Hz, 
1H, NH), 4.19 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.08 – 3.96 (m, 1H, CH), 3.57 
(d, J = 1.9 Hz, 2H, OCH2), 1.50 (app s, 4H, CH2CH2), 1.25 (t, J = 7.1 Hz, 3H, 
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OCH2CH3), 1.14 (d, J = 6.6 Hz, 3H, CH3), 0.84 (s, 9H,tBu), -0.00 (s, 6H, 
(CH2)2); 13C NMR (101 MHz, CDCl3) δ 165.59 (C), 162.89 (C), 136.60 (CH), 
130.23 (CH), 62.76 (CH2), 61.09 (CH2), 45.63 (CH), 32.98 (CH2), 28.93 
(CH2), 25.96 (CH3), 20.78 (CH3), 18.36 (C), 14.15 (CH3), -5.29 (CH3); m/z 
(ES+) 344.3 ([M+H]+, 100%), 366.3 ([M+Na]+, 20%). 
Ethyl (E)-4-((tert-butoxycarbonyl)(5-((tert-butyldimethylsilyl)oxy)pentan-
2-yl)amino)-4-oxobut-2-enoate (234) 
 
(Boc)2O (153 mg, 0.7 mmol) was added to a stirred solution of ethyl (E)-4-((5-
((tert-butyldimethylsilyl)oxy)pentan-2-yl)amino)-4-oxobut-2-enoate 233 (120 
mg, 0.35 mmol), NEt3 (0.05 ml, 35 mg, 0.35 mmol) and DMAP (43 mg, 0.35 
mmol) in THF (10 ml) and heated at 65 °C under a blanket of N2 for 22 hours. 
The reaction mixture was allowed to cool to RT, diluted with EtOAc (20 ml) 
washed with saturated aqueous ammonium chloride solution (20 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (2:8, EtOAc:PE) to give the title compound 234 as a 
yellow oil (155 mg, 0.35 mmol, 100% yield); Rf 0.58 (3:7, EtOAc:PE); 1H 
NMR (400 MHz, CDCl3) δ 7.38 (d, J = 15.4 Hz, 1H, CH=CH), 6.59 (d, J = 
15.4 Hz, 1H, CH=CH), 4.57 (tq, J = 15.7, 6.8 Hz, 1H, CH), 4.22 (q, J = 7.1 
Hz, 2H, OCH2CH3), 3.55 (t, J = 6.4 Hz, 2H, OCH2), 1.85 (ddd, J = 18.2, 12.5, 
7.6 Hz, 1H, CHH’CH2), 1.64 (ddd, J = 14.6, 12.5, 5.5 Hz, 1H, CHH’CH2), 1.50 
(s, 9H, tBu), 1.42 – 1.38 (m, 2H, CH2CH2), 1.29 (d, J = 6.8 Hz, 3H, CH3), 1.28 
(t, J = 7.2 Hz, 3H, OCH2CH3), 0.85 (s, 9H, tBu), -0.00 (s, 6H, (CH2)2); 13C 
NMR (101 MHz, CDCl3) δ 167.52 (C), 165.63 (C), 153.08 (C), 138.37 (CH), 
128.64 (CH), 84.13 (C), 62.74 (CH2), 61.04 (CH2), 51.80 (CH), 30.54 (CH2), 
30.09 (CH3), 27.96 (CH2), 25.96 (CH3), 19.00 (CH3), 18.35 (C), 14.18 (CH3), -
5.31 (CH3); m/z (ES+) 444.3 ([M+H]+, 100%); HRMS found ([M+H]+) 
444.2765. C22H42O6NSi req 444.2776. 
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Ethyl (E)-4-((tert-butoxycarbonyl)(5-oxopentan-2-yl)amino)-4-oxobut-2-
enoate (235) 
 
pTSA∙H2O (10 mg, 0.05 mmol) was added to a stirred solution of ethyl (E)-4-
((tert-butoxycarbonyl)(5-((tert-butyldimethylsilyl)oxy)pentan-2-yl)amino)-4-
oxobut-2-enoate 234 (239 mg, 0.54 mmol) in DCM:MeOH (10 ml, 1:1) at 0 °C 
and stirred for 2 hours. The reaction mixture was concentrated in vacuo to 
give the deprotected alcohol which was redissolved in DCM (10 ml). TEMPO 
(9 mg, 0.06 mmol) and BAIB (193 mg, 0.6 mmol) were added and the 
reaction mixture was stirred at RT under a blanket of N2 for 2 hours. The 
reaction mixture was diluted with DCM (10 ml), washed with saturated 
aqueous sodium thiosulfate solution (20 ml) and saturated aqueous sodium 
bicarbonate (20 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (2:8, EtOAc:PE) to give the 
title compound 235 as a clear oil (66 mg, 0.21 mmol, 39% yield); Rf 0.48 (3:7, 
EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 9.65 (s, 1H, CHO), 7.31 (d, J = 15.4 
Hz, 1H, CH=CH), 6.54 (d, J = 15.4 Hz, 1H, CH=CH), 4.59 – 4.43 (m, 1H, 
CH), 4.16 (q, J = 7.1 Hz, 2H, OCH2CH3), 2.42 – 2.20 (m, 2H, CH2CH2), 2.18 
– 2.04 (m, 1H, CH2CHH’), 1.92 – 1.78 (m, 1H, CH2CHH’), 1.44 (s, 9H, tBu), 
1.26 (d, J = 6.9 Hz, 3H, CH3), 1.21 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR 
(101 MHz, CDCl3) δ 201.21 (CH), 167.59 (C), 165.50 (C), 152.81 (C), 137.97 
(CH), 129.11 (CH), 84.66 (C), 61.13 (CH2), 51.34 (CH), 41.13 (CH2), 27.94 
(CH3), 26.43 (CH2), 18.84 (CH3), 14.17 (CH3); m/z (ES-) 326.2 ([M-H]-, 
100%); HRMS found ([M+H]+) 326.1611. C16H24O6N req 326.1609. 
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(1S*,4S*,6S*)-3-tert-butyl 8-ethyl 4-methyl-2-oxo-3-azabicyclo[4.2.0]oct-
7-ene-3,8-dicarboxylate (236) 
 
Diethylamine (0.33 ml, 234 mg, 3.2 mmol) was added to a stirred solution of 
ethyl (E)-4-((tert-butoxycarbonyl)(5-oxopentan-2-yl)amino)-4-oxobut-2-enoate 
235 (507 mg, 1.6 mmol) and K2CO3 (442 mg, 1.6 mmol) in MeCN (70 ml) and 
stirred at RT under a blanket of N2 for 84 hours. The reaction mixture was 
filtered through Celite® and concentrated in vacuo. The crude cyclobutane 
was dissolved in MeCN (70 ml) and MeI (0.50ml, 1.136 g, 8 mmol) was 
added and the reaction mixture stirred at RT under a blanket of N2 for 80 
hours. The reaction mixture was concentrated in vacuo and the crude residue 
dissolved in MeCN (60 ml) and K2CO3 (442 mg, 1.6 mmol) was added and 
the reaction mixture stirred at RT for 4 days. The reaction mixture was 
concentrated in vacuo and the crude residue was purified via column 
chromatography (2:8, EtOAc:PE) to give the title compound 236 as a clear oil 
(128 mg, 0.43 mmol, 27% yield); Rf 0.50 (1:1, EtOAc:PE); IR 2980.5 cm-1 
(CH sp3), 1763.3 cm-1 (C=O carbamate), 1712.2 cm-1 (C=O ester); 1H NMR 
(400 MHz, CDCl3) δ 6.84 (s, 1H, H7), 4.45 – 4.33 (m, 1H, CH), 4.17 (q, J = 
7.1 Hz, 2H, OCH2CH3), 3.89 (d, J = 4.7 Hz, 1H, H1), 3.33 – 3.21 (m, 1H, H6), 
2.01 (ddd, J = 14.0, 7.2, 4.3 Hz, 1H, CHH’), 1.72 (ddd, J = 14.0, 10.5, 3.6 Hz, 
1H, CHH’), 1.45 (s, 9H, tBu), 1.29 – 1.18 (m, 6H, CH3 + OCH2CH3); 13C NMR 
(101 MHz, CDCl3) δ 169.52 (C), 161.55 (C), 152.26 (C), 148.78 (CH), 136.91 
(C), 83.17 (C), 60.65 (CH2), 52.33 (CH), 46.56 (CH), 37.14 (CH), 33.19 
(CH2), 27.99 (CH3), 19.18 (CH3), 14.21 (CH3); m/z (ES+) 332.0 ([M+Na]+, 
100%), 310.1 ([M+H]+, 40%); HRMS found ([M+H]+) 310.1650. C16H24O5N 
req 310.1649; LCMS rt 7.20, m/z (ES+) 310.1 ([M+H]+, 100%), >95%. 
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((4-(Benzyloxy)hex-5-en-1-yl)oxy)(tert-butyl)dimethylsilane (237) 
 
NaH (60% dispersion in oil, 20 mg, 0.50 mmol) was added to a stirred 
solution of 6-((tert-butyldimethylsilyl)oxy)hex-1-en-3-ol 224b (76 mg, 0.33 
mmol) in THF (3 ml) at 0 °C under a blanket of N2 and the resulting mixture 
stirred for 20 minutes. BnBr (0.057 ml, 86 mg, 0.50 mmol) and TBAI (18 mg, 
0.05 mmol) were added and the reaction mixture allowed to warm to RT and 
stirred for 16.5 hours. The reaction mixture was partitioned between 
saturated aqueous ammonium chloride (20 ml) and EtOAc (20 ml), extracted 
with EtOAc (20 ml), and the combined organic layers dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column 
chromatography (0:1→3:7, EtOAc:PE) to give the title compound 237 as a 
clear oil (82 mg, 0.26 mmol, 79% yield); Rf 0.61 (2:8, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.38 – 7.23 (m, 5H, Ph), 5.71 (ddd, J = 17.1, 10.6, 7.7 
Hz, 1H, CH=CH2), 5.23 – 5.11 (m, 2H, CH=CH2), 4.56 (d, J = 11.9 Hz, 1H, 
PhCHH’), 4.32 (d, J = 11.9 Hz, 1H, PhCHH’), 3.71 (dd, J = 13.4, 6.2 Hz, 1H, 
CHOBn), 3.61 – 3.50 (m, 2H, CH2OTBS), 1.67 – 1.45 (m, 4H, H2+H3), 0.85 
(s, 9H, tBu), -0.00 (s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 139.1 (CH), 
128.3 (CH), 127.7 (CH), 127.4 (CH), 117.1 (CH2), 80.4 (CH), 70.0 (CH2), 
63.1 (CH2), 31.8 (CH2), 28.7 (CH2), 26.0 (CH3), 18.4 (C), -5.3 (CH3); m/z 
(AP+) 321.2 ([M+H]+, 100%); HRMS found ([M+H]+) 321.2250. C19H33O2Si1 
req. 321.2244. 
3-(Benzyloxy)-6-((tert-butyldimethylsilyl)oxy)hexan-1-ol (194) 
 
A solution of BH3∙THF (1 M in THF, 1 ml, 1 mmol) was added to ((4-
(benzyloxy)hex-5-en-1-yl)oxy)(tert-butyl)dimethylsilane 237 (31 mg, 0.097 
mmol) at 0 °C under a blanket of N2 and stirred for 17 hours. A further portion 
of BH3∙THF (1 M in THF, 1 ml, 1 mmol) was added and the reaction mixture 
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stirred for 7 hours. A solution of 1 M aqueous NaOH (0.5 ml) and 30% H2O2 
(0.2 ml) were added and the reaction mixture stirred at RT for 18 hours. 
Saturated aqueous sodium potassium tartrate (10 ml) and H2O (10 ml) were 
added and the reaction mixture extracted with EtOAc (2 × 15 ml), and the 
combined organic layers dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column  chromatography (3:7, EtOAc:PE) to 
give the title compound 194 as a clear oil (13 mg, 0.038 mmol, 39% yield); Rf 
0.52 (1:1, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 7.37 – 7.22 (m, 5H, Ph), 
4.55 (d, J = 11.4 Hz, 1H, PhCHH’), 4.43 (d, J = 11.4 Hz, 1H, PhCHH’), 3.77 – 
3.67 (m, 2H, CH2OH), 3.67 – 3.60 (m, 1H, CHOBn), 3.57 (t, J = 6.1 Hz, 2H, 
CH2OTBS), 1.75 (dt, J = 12.3, 6.1 Hz, 2H, CH2), 1.67 – 1.57 (m, 2H, CH2), 
1.53 (dd, J = 13.0, 6.6 Hz, 2H, CH2), 0.85 (s, 9H, tBu), -0.00 (s, 6H, (CH3)2); 
m/z (AP+) 339.2 ([M+H]+, 100%); HRMS found ([M+H]+) 339.2356. 
C19H35O3Si1 req. 339.2350. 
3-(Benzyloxy)-6-((tert-butyldimethylsilyl)oxy)hexyl ethyl fumarate (238) 
 
EDCI (37 mg, 0.195 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (28 mg, 0.195 mmol), 3-(benzyloxy)-6-((tert-
butyldimethylsilyl)oxy)hexan-1-ol 194 (50 mg, 0.15 mmol) and DMAP (2 mg, 
0.02 mmol) in DCM (3 ml) at 0 °C under a blanket of N2. After 10 minutes the 
reaction mixture was warmed to RT and stirred for 16.5 hours, then a further 
portion of EDCI (20 mg, 0.1 mmol) was added and the reaction mixture 
stirred for a further 23.5 hours. The reaction mixture was partitioned between 
DCM (20 ml) and saturated aqueous ammonium chloride (20 ml), extracted 
with DCM (10 ml), the combined organic layers were washed with saturated 
aqueous sodium bicarbonate (20 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via column chromatography (1:9, 
EtOAc:PE) to give the title compound 238 as a pale yellow oil (46 mg, 0.099 
mmol, 66% yield); Rf 0.52 (2:8, EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 
7.33 – 7.25 (m, 5H, Ph), 6.75 (s, 2H, CH=CH), 4.51 (d, J = 11.4 Hz, 1H, 
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PhCHH’), 4.40 (d, J = 11.4 Hz, 1H, PhCHH’), 4.27 (t, J = 6.8 Hz, 2H, OCH2), 
4.22 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.57 (t, J = 5.9 Hz, 2H, CH2OTBS), 3.54 
– 3.49 (m, 1H, CHOBn), 1.85 (q, J = 6.4 Hz, 2H), 1.63 – 1.49 (m, 4H), 1.28 (t, 
J = 7.1 Hz, 3H, OCH2CH3), 0.85 (s, 9H, tBu), 0.00 (s, 6H, (CH3)2); 13C NMR 
(101 MHz, CDCl3) δ 165.0 (C), 165.0 (C), 138.5 (C), 133.7 (CH), 133.5 (CH), 
128.4 (CH), 127.9 (CH), 127.6 (CH), 75.2 (CH), 71.0 (CH2), 63.0 (CH2), 62.4 
(CH2), 61.3 (CH2), 33.0 (CH2), 23.0 (CH2), 28.2 (CH2), 26.0 (CH3), 18.3 (C), 
14.1 (CH3), -5.3 (CH3); m/z (AP+) 465.3 ([M+H]+ 100%); HRMS Found 
([M+H]+) 465.2666. C25H41O6Si req. 465.2667. 
3-(Benzyloxy)-6-oxohexyl ethyl fumarate (193) 
 
pTSA∙H2O (3.8 mg, 0.02 mmol) was added to a stirred solution of 3-
(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)hexyl ethyl fumarate 238 (94 mg, 
0.20 mmol) in DCM:MeOH (2 ml, 1:1) at 0 ⁰C and stirred for 1 hour. The 
reaction mixture was concentrated in vacuo to give the deprotected alcohol 
which was redissolved in DCM (3 ml). TEMPO (3 mg, 0.02 mmol) and BAIB 
(71 mg, 0.22 mmol) were added and the reaction mixture was stirred at RT 
under a blanket of N2 for 1.5 hours. TEMPO (3 mg, 0.02 mmol) was added 
and the reaction stirred for a further 1.5 hours. The reaction mixture was 
washed with saturated aqueous sodium thiosulfate (10 ml), and the aqueous 
layer extracted with DCM (15 ml). The combined organic layers were washed 
with saturated aqueous sodium bicarbonate (10 ml), dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column 
chromatography (3:7, EtOAc:PE) to give the title compound 193 as a clear oil 
(37 mg, 0.106 mmol, 53% yield); Rf 0.33 (3:7, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 9.70 (d, J = 1.2 Hz, 1H, CHO), 7.29 – 7.20 (m, 5H, Ph), 6.74 
(s, 2H, CH=CH), 4.41 (d, J = 2.4 Hz, 2H, PhCH2), 4.24 (t, J = 6.6 Hz, 2H, 
OCH2), 4.19 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.56 – 3.46 (m, 1H, CHOBn), 
2.46 (t, J = 7.2 Hz, 2H, CH2CHO), 1.97 – 1.73 (m, 4H, H2+H4), 1.26 (t, J = 
7.1 Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 201.9 (CH), 164.9 (C), 
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164.9 (C), 137.9 (C), 133.9 (CH), 133.3 (CH), 128.5 (CH), 128.0 (CH), 127.9 
(CH), 74.3 (CH), 71.2 (CH2), 62.0 (CH2), 61.4 (CH2), 39.5 (CH2), 32.8 (CH2), 
26.1 (CH2), 14.1 (CH3); m/z (ES+) 371.1 ([M+Na]+ 100%); HRMS found 
([M+NH4]+) 366.1911. C19H28O6N req. 366.1911. 
(R)-Butane-1,2,4-triol 
 
DMS∙BH3 (2 M in THF, 55.95 ml, 111.9 mmol) was added slowly to a stirred 
solution of malic acid 244 (5 g, 37.31 mmol) and B(OMe)3 (18.5 ml, 16.91 g, 
164.16 mmol) in THF (50 ml) at 0 °C under a blanket of argon. The reaction 
mixture was stirred for 30 minutes before warming to RT and stirring for 5 
days. The reaction was quenched with MeOH and the volatiles removed in 
vacuo to give the crude product that was used without further purification.116a 
(R)-2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethanol 
 
pTSA∙H2O (380 mg, 2 mmol) and MgSO4 (2.28 g, 19 mmol) were added to a 
stirred solution of (R)-butane-1,2,4-triol (3.95 g, 37.31 mmol) in acetone (100 
ml) and the reaction mixture heated at 56 °C under a blanket of argon for 44 
hours. The reaction mixture was then cooled to RT, solid sodium bicarbonate 
(798 mg, 9.5 mmol) was added and the reaction mixture filtered through 
Celite® and concentrated in vacuo. The crude residue was purified via 
column chromatography (1:1, EtOAc:PE) to give the title compound as a 
clear oil (5.19 g, 35.55 mmol, 95% yield); Rf 0.22 (1:1, EtOAc:PE); [α]D +3.6 
(c 1.0 in CHCl3) (lit.116a [α]D +3.1 (c 0.9 in CHCl3)); 1H NMR (400 MHz, CDCl3) 
δ 4.31 – 4.21 (m, 1H), 4.08 (dd, J = 8.0, 6.1 Hz, 1H), 3.79 (dd, J = 10.2, 4.9 
Hz, 2H), 3.58 (t, J = 7.6 Hz, 1H), 2.15 (t, J = 5.1 Hz, 1H), 1.81 (dd, J = 11.7, 
6.2 Hz, 2H), 1.41 (s, 3H, CH3), 1.35 (s, 3H, CH3). Consistent with 
literature.116a 
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(R)-4-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxolane 
 
(R)-2-(2,2-Dimethyl-1,3-dioxolan-4-yl)ethanol (3.31 g, 22.67 mmol) in DMF 
(10 ml) was added slowly to a stirred suspension of NaH (60% dispersion in 
oil, 1.08 g, 27.2 mmol) in DMF (40 ml) at RT under a blanket of N2 and the 
reaction mixture stirred for 40 minutes. Benzyl bromide (3.23 ml, 4.65 g, 27.2 
mmol) was added slowly while cooling and then stirred for 5 hours. The 
reaction mixture was quenched with water, concentrated in vacuo, partitioned 
between EtOAc (80 ml) and water (80 ml), washed with brine (80 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (1:9, EtOAc:PE) to give the title compound as a 
clear oil (3.09 g, 13.09 mmol, 58% yield); Rf 0.32 (1:9, EtOAc:PE); [α]D -0.680 
(c 1.0, CHCl3) (lit.143 [α]D -0.60 (c 1.0, CHCl3)); 1H NMR (400 MHz, CDCl3) δ 
7.42 – 7.29 (m, 5H, Ar), 4.53 (s, 2H, PhCH2), 4.29 – 4.19 (m, 1H, CH), 4.09 
(dd, J = 8.0, 5.9 Hz, 1H), 3.67 – 3.53 (m, 3H), 2.03 – 1.81 (m, 2H, CH2CH2), 
1.42 (s, 3H, CH3), 1.38 (s, 3H, CH3). Consistent with literature.116b 
(R)-4-(Benzyloxy)butane-1,2-diol 
 
(R)-4-(2-(Benzyloxy)ethyl)-2,2-dimethyl-1,3-dioxolane (3.09 g, 13.09 mmol) in 
THF (80 ml) and 2 M aqueous HCl (30 ml) was heated at 65 °C for 1 hour 25 
minutes. The reaction mixture was allowed to cool to RT, diluted with EtOAc 
(150 ml), washed with brine (100 ml), dried (MgSO4) and concentrated in 
vacuo to give the title compound as a yellow oil (2.46 g, 12.55 mmol, 96% 
yield); Rf 0.09 (1:1, EtOAc:PE); [α]D -4.902 (c 1.0, CHCl3) (lit.143 [α]D -4.2 (c 
1.1, CHCl3)); 1H NMR (400 MHz, CDCl3) δ 7.43 – 7.29 (m, 5H, Ar), 4.59 (s, 
2H, PhCH2), 4.09 (tt, J = 7.8, 4.0 Hz, 1H, CH), 3.86 (t, J = 5.5 Hz, 2H, OCH2), 
3.53 (dd, J = 9.4, 3.6 Hz, 1H, CHH’OH), 3.43 (dd, J = 9.3, 7.6 Hz, 1H, 
CHH’OH), 1.79 – 1.65 (m, 2H, CH2CH2). Consistent with literature.116c 
 
 193 
 
(R)-4-(Benzyloxy)-2-hydroxybutyl 4-methylbenzenesulfonate 
 
Tosyl chloride (2.38 g, 12.55 mmol) in CHCl3 (10 ml) was added to a stirred 
solution of (R)-4-(benzyloxy)butane-1,2-diol (2.46 g, 12.55 mmol), pyridine 
(2.02 ml, 1.98 g, 25.1 mmol) and DMAP (159 mg, 1.3 mmol) in CHCl3 (60 ml) 
at 0 °C under a blanket of argon and stirred for 70 hours. The reaction 
mixture was diluted with DCM (80 ml), washed with water (100 ml), dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (4:6, EtOAc:PE) to give the title compound as a 
clear oil (2.20 g, 6.29 mmol, 50% yield); Rf 0.38 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.81 (d, J = 8.3 Hz, 2H, Ar), 7.39 – 7.29 (m, 7H, Ar), 4.51 
(s, 2H, PhCH2), 4.10 – 4.05 (m, 1H, CH), 4.05 – 3.95 (m, J = 16.1, 9.8, 5.2 
Hz, 2H, OCH2), 3.73 – 3.60 (m, 2H, CH2OTs), 2.47 (s, 3H, PhCH3), 1.80 
(ddd, J = 11.9, 7.5, 4.6 Hz, 2H, CH2CH2). Consistent with literature.116d 
(R)-2-(2-(Benzyloxy)ethyl)oxirane 
 
K2CO3 (1.74 g, 12.58 mmol) was added to a stirred solution of (R)-4-
(benzyloxy)-2-hydroxybutyl 4-methylbenzenesulfonate (2.2 g, 6.29 mmol) in 
MeOH (70 ml) at RT and stirred for 2 hours. The reaction mixture was 
concentrated in vacuo, partitioned between diethyl ether (50 ml) and water 
(70 ml), the aqueous layer extracted with diethyl ether (2 × 50 ml), dried 
(MgSO4) and concentrated in vacuo to give the title compound as a clear oil 
(1.097 g, 6.16 mmol, 98% yield); Rf 0.50 (1:1, EtOAc:PE); [α]D +13.6 (c 1.0 in 
CH3Cl) (lit.116e [α]D +14.5 (c 1.1 in CH3Cl)); 1H NMR (400 MHz, CDCl3) δ 7.34 
– 7.19 (m, 5H, Ar), 4.46 (s, 2H, PhCH2), 3.60 – 3.49 (m, 2H, OCH2), 3.05 – 
2.93 (m, 1H), 2.72 (t, J = 4.2 Hz, 1H), 2.45 (dd, J = 5.0, 2.8 Hz, 1H), 1.94 – 
1.78 (m, 1H, CH2CHH’), 1.80 – 1.62 (m, 1H, CH2CHH’). Consistent with 
literature.116e 
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(S)-1-(Benzyloxy)hex-5-en-3-ol 
 
Vinylmagnesium bromide (1 M in THF, 9 ml, 9 mmol) was added to a stirred 
suspension of CuI (120 mg, 0.63 mmol) in THF (30 ml) at 0 °C under a 
blanket of argon and stirred for 5 minutes. (R)-2-(2-(benzyloxy)ethyl)oxirane 
(1.097 g, 6.16 mmol) in THF (10 ml) was added and stirred at 0 °C for 4 
hours. The reaction mixture was partitioned between EtOAc (40 ml) and 
saturated aqueous ammonium chloride solution (40 ml), extracted with 
EtOAc (40 ml) and the combined organic layers dried (MgSO4) and 
concentrated in vacuo. The crude residue was purified via column 
chromatography (3:7, EtOAc:PE) to give the title compound as a clear oil 
(909 mg, 4.43 mmol, 72% yield); Rf 0.42 (3:7, EtOAc:PE); [α]D -4.998 (c 1.0, 
CHCl3) (lit.144 [α]D -5.3 (c 1.2, CHCl3)); 1H NMR (400 MHz, CDCl3) δ 7.40 – 
7.29 (m, 5H, Ar), 5.86 (ddt, J = 17.3, 10.3, 7.1 Hz, 1H, CH=CH2), 5.17 – 5.09 
(m, 2H, CH=CH2), 4.55 (s, 2H, PhCH2), 3.94 – 3.86 (m, 1H, CH), 3.78 – 3.71 
(m, 1H, OCHH’), 3.71 – 3.64 (m, 1H, OCHH’), 2.84 (d, J = 2.9 Hz, 1H, OH), 
2.27 (app t, J = 6.7 Hz, 2H, CH2CH), 1.83 – 1.78 (m, 2H, CH2CH2). 
Consistent with literature.116f 
 (S)-6-(Benzyloxy)hexane-1,4-diol (226) 
 
BH3∙THF (1 M in THF, 0.51 ml, 0.51 mmol) was added to a stirred solution of 
(S)-1-(benzyloxy)hex-5-en-3-ol (70 mg, 0.34 mmol) in THF (5 ml) at 0 °C 
under a blanket of N2 and stirred for 2 hours 50 minutes. 1 M NaOH (0.68 ml, 
0.68 mmol) and 30% aqueous H2O2 (0.25 ml) was added and the reaction 
mixture stirred for 17 hours. Saturated potassium tartrate (15 ml) and water 
(15 ml) was added and then extracted with DCM (2 × 30 ml), the combined 
organic layers were dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (3:1, EtOAc:PE) to give the 
 195 
 
title compound 226 as a white solid (36 mg, 0.16 mmol, 47% yield); Rf 0.20 
(3:1, EtOAc:PE); [α]D -0.729 (c 0.365, CHCl3), (lit.116g [α]D -8.98 (c 3.4, 
CHCl3));1H NMR (400 MHz, CDCl3) δ 7.33 – 7.19 (m, 5H, Ar), 4.46 (s, 2H, 
PhCH2), 3.87 – 3.75 (m, 1H, CH), 3.68 (dt, J = 9.6, 4.8 Hz, 1H, OCHH’), 3.60 
(app dt, J = 9.0, 5.3 Hz, 3H, OCHH’ + CH2OH), 1.85 – 1.69 (m, 1H), 1.69 – 
1.58 (m, 3H), 1.57 – 1.42 (m, 2H). Consistent with literature.116g 
(S)-1-(Benzyloxy)-6-((tert-butyldimethylsilyl)oxy)hexan-3-ol (191) 
 
TBSCl (512 mg, 3.41 mmol) was added to a stirred solution of (S)-6-
(benzyloxy)hexane-1,4-diol 226 (760 mg, 3.39 mmol), NEt3 (0.48 ml, 344 mg, 
3.41 mmol) and DMAP (49 mg, 0.4 mmol) in THF (30 ml) and the reaction 
mixture was stirred for 24 hours at RT under a blanket of N2. Further TBSCl 
(512 mg, 3.41 mmol), NEt3 (0.48 ml, 344 mg, 3.41 mmol) and DMAP (49 mg, 
0.4 mmol) and the reaction heated at 65 °C for 24 hours. The reaction was 
cooled to RT, partitioned between saturated aqueous ammonium chloride 
solution (50 ml) and EtOAc (50 ml), dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via column chromatography (2:8, 
EtOAc:PE) to give the title compound 191 as a clear oil (1.146 g, 3.39 mmol, 
quantitative yield); Rf 0.30 (2:8, EtOAc:PE); [α]D -0.116 (c 1.10, CHCl3); 1H 
NMR (400 MHz, CDCl3) δ 7.40 – 7.27 (m, 5H, Ar), 4.53 (s, 2H, ArCH2), 3.87 
– 3.79 (m, 1H, CH), 3.76 – 3.68 (m, 1H), 3.69 – 3.62 (m, 3H), 3.33 (d, J = 3.1 
Hz, 1H, OH), 1.82 – 1.71 (m, 2H), 1.70 – 1.43 (m, 4H), 0.90 (s, 9H, tBu), 0.06 
(s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 138.1 (C), 128.5 (CH), 127.7 
(CH), 73.3 (CH2), 70.7 (CH), 69.0 (CH2), 63.4 (CH2), 36.6 (CH2), 34.4 (CH2), 
29.1 (CH2), 26.0 (CH3), 18.4 (C), -5.3 (CH3); m/z (AP+) 339.4 ([M+H]+, 50%), 
114.9 (100%); HRMS found ([M+H]+) 339.2351. C19H35O3Si req 339.2350. 
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(S)-1-(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)hexan-3-yl ethyl 
fumarate (239) 
 
EDCI (837 mg, 4.38 mmol) was added to a stirred solution of ethyl hydrogen 
fumarate 197 (504 mg, 3.5 mmol), (S)-1-(benzyloxy)-6-((tert-
butyldimethylsilyl)oxy)hexan-3-ol 191 (1.15 g, 3.39 mmol), DIPEA (0.76 ml, 
565 mg, 4.38 mmol) and DMAP (49 mg, 0.4 mmol) in DCM (80 ml) under a 
blanket of N2 and the reaction mixture stirred for 40 hours. Further EDCI (325 
mg, 1.7 mmol), ethyl hydrogen fumarate (252 mg, 1.75 mmol), DIPEA (0.30 
ml, 219 mg, 1.7 mmol) and DMAP (49 mg, 0.4 mmol) were added and the 
reaction mixture stirred for a further 24 hours. The reaction mixture was 
washed with 5% aqueous HCl (70 ml) and saturated aqueous sodium 
bicarbonate (70 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (1:9, EtOAc:PE) to give the 
title compound 239 as a clear oil (1.435 g, 3.09 mmol, 91% yield); Rf 0.30 
(1:9, EtOAc:PE); [α]D +0.309 (c 0.21, CHCl3);1H NMR (400 MHz, CDCl3) δ 
7.37 – 7.28 (m, 5H, Ar), 6.82 (s, 2H, CH=CH), 5.26 – 5.13 (m, 1H, CH), 4.47 
(s, 2H, ArCH2), 4.27 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.60 (t, J = 6.2 Hz, 2H, 
CH2OTBS), 3.54 – 3.45 (m, 2H, BnOCH2), 1.93 (app q, J = 6.3 Hz, 2H), 1.76 
– 1.62 (m, 2H), 1.61 – 1.48 (m, 2H), 1.33 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.88 
(s, 9H, tBu), 0.04 (s, 6H, (CH3)2); 13C NMR (101 MHz, CDCl3) δ 165.1 (C), 
164.7 (C), 138.2 (C), 133.9 (CH), 133.5 (CH), 128.4 (CH), 127.8 (CH), 127.6 
(CH), 73.1 (s), 72.9 (CH), 66.5 (CH2), 62.7 (CH2), 61.3 (CH2), 34.3 (CH2), 
30.7 (CH2), 28.4 (CH2), 26.0 (CH3), 18.3 (C), 14.1 (CH3), -5.3 (CH3); m/z 
(AP+) 464.4 ([M+H]+, 100%); HRMS found ([M+H]+) 465.2644. C25H41O6Si 
req 465.2667. 
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(S)-1-(Benzyloxy)-6-oxohexan-3-yl ethyl fumarate (190) 
 
pTSA∙H2O (59 mg, 0.31 mmol) was added to a stirred solution of (S)-1-
(benzyloxy)-6-((tert-butyldimethylsilyl)oxy)hexan-3-yl ethyl fumarate 239 
(1.435 g, 3.09 mmol) in DCM:MeOH (80 ml, 1:1) at 0 °C and stirred for 1 hour 
20 minutes. The reaction mixture was concentrated in vacuo to give the 
deprotected alcohol which was redissolved in DCM (60 ml).TEMPO (47 mg, 
0.3 mmol) and BAIB (1.09 g, 3.40 mmol) were added and the reaction 
mixture was stirred at RT under a blanket of N2 for 2 hours. TEMPO (47 mg, 
0.30 mmol) and BAIB (1.09 g, 3.40 mmol) was added and the reaction stirred 
for a further 2 hours. The reaction mixture was washed with saturated 
aqueous sodium thiosulfate solution(60 ml) and saturated aqueous sodium 
bicarbonate (60 ml), dried (MgSO4) and concentrated in vacuo. The crude 
residue was purified via column chromatography (3:7, EtOAc:PE) to give the 
title compound 190 as a clear oil (776 mg, 2.23 mmol, 72% yield); Rf 0.30 
(3:7, EtOAc:PE); [α]D -0.206 (c 0.65, CHCl3);1H NMR (400 MHz, CDCl3) δ 
9.76 (s, 1H, CHO), 7.40 – 7.28 (m, 5H, Ar), 6.81 (s, 2H, CH=CH), 5.28 – 5.12 
(m, 1H, CH), 4.46 (s, 2H, ArCH2), 4.27 (q, J = 7.1 Hz, 2H, OCH2CH3), 3.59 – 
3.40 (m, 2H), 2.52 (t, J = 7.5 Hz, 2H, CH2CHO), 2.01 – 1.86 (m, 4H), 1.33 (t, 
J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (101 MHz, CDCl3) δ 201.0 (CH), 164.9 
(C), 164.6 (C), 138.0 (C), 134.0 (CH), 133.4 (CH), 128.4 (CH), 127.8 (CH), 
127.7 (CH), 73.2 (CH2), 72.2 (CH), 66.2 (CH2), 61.4 (CH2), 39.8 (CH2), 34.3 
(CH2), 26.6 (CH2), 14.1 (CH3); m/z (ES+) 398.2 (100%), 366.2 ([M+NH4]+, 
70%); HRMS data not obtainable due to instability. 
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Ethyl (1R,4S,6R)-4-(2-(benzyloxy)ethyl)-2-oxo-3-oxabicyclo[4.2.0]oct-7-
ene-8-carboxylate (189) 
 
Diethylamine (0. 36 ml, 256 mg, 3.56 mmol) was added to a stirred solution 
of (S)-1-(benzyloxy)-6-oxohexan-3-yl ethyl fumarate 190 (620 mg, 1.78 
mmol) and K2CO3 (491 mg, 3.56 mmol) in MeCN (60 ml) and stirred at RT 
under a blanket of N2 for 47 hours. The reaction mixture was then filtered 
through Celite® and concentrated in vacuo. The crude cyclobutane was 
dissolved in MeCN (60 ml) and MeI (0.55 ml, 1.26 g, 8.9 mmol) was added 
and the reaction mixture stirred at RT under a blanket of N2 for 95 hours. The 
reaction mixture was concentrated in vacuo and the crude residue dissolved 
in MeCN (60 ml) and K2CO3 (491 mg, 3.56 mmol) was added and the 
reaction mixture heated at 65 °C for 24 hours. The reaction mixture was 
cooled and concentrated in vacuo. The crude residue was purified via column 
chromatography (1:1, EtOAc:PE) to give the title compound 189 as a clear oil 
(364 mg, 1.10 mmol, 62% yield); Rf 0.38 (1:1, EtOAc:PE); [α]D +0.499 (c 
0.57, CHCl3); IR 2928.8 cm-1 (CH sp3), 1718.1 cm-1 (C=O ester); 1H NMR 
(400 MHz, CDCl3) δ 7.40 – 7.28 (m, 5H, Ar), 6.86 (s, 1H, H7), 4.52 (d, J = 
11.7 Hz, 1H, ArCHH’), 4.48 (app d, J = 11.7 Hz, 2H, ArCHH’ + H4), 4.26 (q, J 
= 7.1 Hz, 2H, OCH2CH3), 3.96 (d, J = 4.8 Hz, 1H, H1), 3.68 (td, J = 8.9, 4.6 
Hz, 1H, BnOCHH’), 3.64 – 3.57 (m, 1H, BnOCHH’), 3.30 – 3.18 (m, 1H,H6), 
2.25 (dd, J = 14.1, 7.9 Hz, 1H, H5), 2.04 – 1.83 (m, 2H), 1.52 (app dt, J = 
13.9, 10.7 Hz, 1H, H5’), 1.32 (t, J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (101 
MHz, CDCl3) δ 169.8 (C), 161.2 (C), 148.6 (CH), 138.1 (C), 136.9 (C), 128.4 
(CH), 127.7 (CH), 77.0 (CH), 73.2 (CH2), 65.8 (CH2), 60.8 (CH2), 42.6 (CH), 
37.8 (CH), 35.4 (CH2), 33.9 (CH2), 14.2 (CH3); m/z (ES+) 331.0 ([M+H]+, 
100%); HRMS found ([M+H]+) 331.1541. C19H23O5 req 331.1540; LCMS rt 
7.73, m/z (ES+) 331.2 ([M+H]+, 100%), >95%. 
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4-(Benzyloxy)butan-1-ol  
 
1,4-Butanediol 195b (1.77 ml, 1.80 g, 20 mmol) was added slowly to a stirred 
suspension of NaH (60% in oil, 672 mg, 16.8 mmol) in THF (20 ml) at 0 °C 
under a blanket of argon and the solution stirred for 10 minutes. Benzyl 
bromide (2.04 ml, 17.2 mmol) and TBAI (221 mg, 0.6 mmol) were added and 
the reaction mixture was allowed to warm to RT and stirred for 24 hours. The 
reaction mixture was partitioned between saturated aqueous NH4Cl and 
EtOAc, extracted with EtOAc, dried (MgSO4) and concentrated under 
reduced pressure. The crude residue was purified via column 
chromatography (3:7, EtOAc:PE) to give the title compound as a clear oil 
(2.95 g, 16.36 mmol, 97% yield); Rf 0.29 (3:7, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 7.42 – 7.30 (m, 5H, Ph), 4.55 (s, 2H, PhCH2), 3.67 (app q, J = 
5.8 Hz, 2H, CH2OH), 3.55 (t, J = 5.8 Hz, 2H, BnOCH2), 1.81 – 1.63 (m, 4H, 
H2+H3). Consistent with literature.145 
4-(Benzyloxy)butanal (245) 
 
4-(benzyloxy)butan-1-ol (2.945 g, 16.36 mmol) was dissolved in DCM (60 
ml), MgSO4 (8 g) and PCC (10.5 g, 49 mmol) were added and the reaction 
mixture stirred for 1 hour 50 minutes. The reaction mixture was filtered 
through Celite® and concentrated under reduced pressure. The crude 
residue was filtered through a plug of silica (3:7, EtOAc:PE) to remove the 
PCC residues and the filtrate concentrated under reduced pressure and 
purified via column chromatography (1:9, EtOAc:PE) to give the title 
compound 245 as a clear oil (2.260g, 12.70 mmol, 78% yield); Rf 0.45 (3:7, 
EtOAc:PE);1H NMR (400 MHz, CDCl3) δ 9.81 (t, J = 1.5 Hz, 1H, COH), 7.42 
– 7.25 (m, 5H, Ph), 4.51 (s, 2H, PhCH2), 3.53 (t, J = 6.1 Hz, 2H, BnOCH2), 
2.58 (td, J = 7.1, 1.5 Hz, 2H, H2), 2.02 – 1.90 (m, 2H, H3). Consistent with 
literature.145 
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Dimethyl (1S*,4R*)-4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-
dicarboxylate (246) 
 
Diethylamine (1.37 ml, 967 mg, 13.24 mmol) was added to a stirred 
suspension of 4-(benzyloxy)butanal 245 (1.17 g, 6.62 mmol) and K2CO3 
(1.83 g, 13.24 mmol) in MeCN (30 ml) at RT, under a blanket of N2 and 
stirred for 3 hours. Dimethyl fumarate 187 (1.91 g, 13.24 mmol) was added 
and the reaction mixture stirred for 67 hours, filtered through Celite® and 
concentrated in vacuo to give the crude cyclobutane. The cyclobutane was 
dissolved in MeCN (30 ml) and MeI (1.03 ml, 2.35 g, 16.55 mmol) was added 
and the reaction mixture stirred at RT under a blanket of N2 for 23 hours. It 
was then concentrated in vacuo, dissolved in MeCN (30 ml) and K2CO3 (1.83 
g, 13.24 mmol) was added and the reaction mixture heated at reflux while 
stirring for 22 hours. The reaction mixture was then cooled to RT, filtered 
through celite and concentrated in vacuo. The crude residue was purified via 
column chromatography (2:8, EtOAc:PE) to give the title compound 246 as a 
clear oil (1.327 g, 4.37 mmol, 66% yield); Rf 0.28 (3:7, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.41 – 7.30 (m, 5H, Ph), 7.03 (s, 1H, H3), 4.51 (s, 2H, 
PhCH2), 3.76 (s, 3H, OCH3), 3.72 (s, 3H, OCH3), 3.58 (t, J = 6.0 Hz, 2H, 
BnOCH2), 3.45 (d, J = 1.6 Hz, 1H, H1), 3.03 (dd, J = 8.1, 6.9 Hz, 1H, H4), 
1.92 (td, J = 7.1, 3.5 Hz, 2H, BnOCH2CH2); 13C NMR (101 MHz, CDCl3) δ 
172.0 (C), 161.7 (C), 151.3 (CH), 138.2 (C), 135.2 (C), 128.4 (CH), 127.7 
(CH), 127.6 (CH), 73.2 (CH2), 68.4 (CH2), 52.0 (CH3), 51.6 (CH3), 49.8 (CH), 
43.2 (CH), 32.6 (CH2); m/z (ES+) 305.1 ([M+H]+, 100%); HRMS Found 
([M+H]+) 305.1390. C17H21O5 req. 305.1384. 
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((1S*,4R*)-4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-diyl)dimethanol 
(251) 
 
(1S*,4R*)-dimethyl 4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-dicarboxylate 
246 (200 mg, 0.66 mmol) in diethyl ether (3 ml) was slowly added to a stirred 
solution of LiAlH4 (50 mg, 1.32 mmol) in diethyl ether (4 ml) at 0 °C under a 
blanket of N2 and stirred for 1 hour. The reaction was quenched slowly with 
H2O (0.05 ml) followed by the addition of 15% aqueous NaOH(0.05 ml) and 
H2O (0.275 ml) then stirred for 1 hour. The reaction mixture was dried 
(MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (7:3, EtOAc:PE) to give the title compound 251 as a 
clear oil (58 mg, 0.23 mmol, 35% yield); Rf 0.13 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.34 – 7.20 (m, 5H, Ph), 5.95 (s, 1H, H3), 4.43 (s, 2H, 
PhCH2), 4.02 (q, J = 13.4 Hz, 2H, CH2OH), 3.73 (dd, J = 10.5, 5.7 Hz, 1H, 
CHH’OH), 3.50 – 3.40 (m, 3H, BnOCH2+CHH’OH), 3.02 (bs, 1H, OH), 2.82 
(bs, 1H, OH), 2.56 (dd, J = 7.8, 6.2 Hz, 1H, H1), 2.32 (t, J = 7.3 Hz, 1H, H4), 
1.78 – 1.65 (m, 2H, BnOCH2CH2); 13C NMR (101 MHz, CDCl3) δ 149.2 (C), 
138.3 (C), 132.9 (CH), 128.4 (CH), 127.7 (CH), 127.7 (CH), 73.0 (CH2), 69.5 
(CH2), 64.9 (CH2), 59.9 (CH2), 51.6 (CH), 40.4 (CH), 33.2 (CH2); m/z (AP+) 
249.0 ([M+H]+, 100%); HRMS Found ([M+H]+) 249.1483. C15H21O3 req. 
249.1485. 
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((1S*,4R*)-4-(2-(benzyloxy)ethyl)-2-(((tert-butyldimethylsilyl)oxy)methyl) 
cyclobut-2-en-1-yl)methanol (254a) 
((3R*,4S*)-3-(2-(benzyloxy)ethyl)-4-(((tert-butyldimethylsilyl)oxy)methyl) 
cyclobut-1-en-1-yl)methanol (254b) 
 
NaH (60% in oil) (10 mg, 0.25 mmol) was added to a stirred solution of 
((1S*,4R*)-4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-diyl)dimethanol 250 (25 
mg, 0.1 mmol) in THF (4 ml) at 0 °C under a blanket of N2 and stirred for 30 
minutes. TBSCl (38 mg, 0.25 mmol) was added and the reaction mixture was 
allowed to warm to RT and stirred for 1.5 hours. The reaction mixture was 
partitioned between saturated aqueous ammonium chloride solution (10 ml) 
and EtOAc (10 ml), the aqueous layer extracted with EtOAc (10 ml) and the 
combined organic layers were dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (3:7, EtOAc:PE) to 
give an inseparable mixture (0.8:0.2) of the two title compounds 254a-b (38 
mg, 0.10 mmol, 100% yield); Rf 0.52 (1:1, EtOAc:PE); 1H NMR (400 MHz, 
CDCl3) δ 7.28 – 7.21 (m, 4H, Ph), 7.21 – 7.17 (m, 1H, Ph), 5.89 (s, 0.8H, 
H3), 5.86 (d, J = 0.7 Hz, 0.2H, H2), 4.40 (s, 2H, PhCH2), 4.07 – 3.92 (m, 2H, 
CH2OH), 3.78 (dd, J = 9.9, 5.1 Hz, 0.2H, CHH’OH), 3.64 (ddd, J = 10.8, 7.9, 
5.6 Hz, 0.8H, CHH’OH), 3.47 – 3.34 (m, 2.2H, BnOCH2+CHH’OH), 3.26 – 
3.13 (m, 0.8H, CHH’OH), 2.52 (dd, J = 7.3, 6.3 Hz, 0.8H, H1), 2.47 (dd, J = 
10.6, 4.7 Hz, 0.2H, H4), 2.30 (t, J = 7.3 Hz, 0.8H, H4), 2.21 (t, J = 7.3 Hz, 
0.2H, H3), 1.76 – 1.62 (m, 2H, BnOCH2CH2), 0.81 (s, 7.2H, tBu), 0.80 (s, 
1.8H, tBu), -0.00 (s, 4.8H, (CH3)2), -0.03 (s, 1.2H, (CH3)2). 
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((2R*,3S*)-3-(2-(benzyloxy)ethyl)-5-oxabicyclo[2.1.0]pentane-1,2-
diyl)dimethanol (254) 
 
mCPBA (77% max, 45 mg, 0.20 mmol) was added to a stirred solution of 
((1S*,4R*)-4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-diyl)dimethanol 251 (42 
mg, 0.17 mmol) in DCM (4 ml) at 0 °C. The reaction mixture was allowed to 
warm to RT and stirred for 3 hours.  The reaction mixture was diluted with 
DCM (10 ml), washed with saturated aqueous sodium thiosulfate (5 ml) 
followed by saturated aqueous sodium bicarbonate (5 ml), dried (MgSO4) 
and concentrated in vacuo. The crude residue was purified via column 
chromatography (1:0→9:1, DCM:MeOH) to give the title compound 254 as a 
clear oil (31 mg, 0.12 mmol, 70% yield); Rf 0.35 (EtOAc); 1H NMR (400 MHz, 
CDCl3) δ 7.32 – 7.20 (m, J = 11.0, 7.5, 3.1 Hz, 5H, Ph), 4.41 (s, 2H, PhCH2), 
4.02 (d, J = 12.5 Hz, 1H, CHH’OH), 3.88 (s, 1H, H4), 3.62 – 3.53 (m, 2H, 
CHH’OH+CHH’OH), 3.48 – 3.41 (m, 2H, BnOCH2), 3.41 – 3.34 (m, 1H, 
CHH’OH), 2.93 (bs, 2H, (OH)2), 2.13 – 2.07 (m, 1H, H2), 1.79 – 1.70 (m, 3H, 
BnOCH2CH2+H3); 13C NMR (101 MHz, CDCl3) δ 138.1 (C), 128.5 (CH), 
127.8 (CH), 127.7 (CH), 73.2 (CH2), 68.4 (CH2), 64.7 (C), 61.6 (CH2), 60.3 
(CH), 59. 6 (CH2), 50.7 (CH), 40.5 (CH), 30.9 (CH2); m/z (AP+) 264.9 
([M+H]+,100%); HRMS Found ([M+H]+) 265.1438. C15H21O4 req. 264.1434. 
((2-((1R*,4S*)-3,4-bis(((2-methoxypropan-2-yl)oxy)methyl)cyclobut-2-en-
1-yl)ethoxy)methyl)benzene (252c) 
 
pTSA∙H2O (1.1 mg, 0.006 mmol) was added to a stirred solution of 
((1S*,4R*)-4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-diyl)dimethanol 250 (15 
mg, 0.06 mmol) in 2,2-dimethoxypropane (0.5 ml, 4.1 mmol) and stirred at 
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RT for 1.5 hours. The reaction mixture was partitioned between saturated 
aqueous sodium bicarbonate solution (5 ml) and EtOAc (5 ml), extracted with 
EtOAc (5 ml), dried (MgSO4) and concentrated in vacuo. The crude residue 
was purified via column chromatography (1:1, EtOAc:PE) to give the title 
compound 251c as a yellow oil (10 mg, 0.025 mmol, 43% yield); Rf 0.51 (1:1, 
EtOAc:PE); 1H NMR (400 MHz, CDCl3) δ 7.26 (d, J = 4.4 Hz, 4H, Ph), 7.22 – 
7.19 (m, 1H, Ph), 5.96 (s, 1H, H3), 4.43 (d, J = 0.7 Hz, 2H, PhCH2), 3.86 (q, J 
= 13.7 Hz, 2H, CH2OH), 3.50 – 3.42 (m, 3H, BnOCH2+CHH’OH), 3.36 (dd, J 
= 9.0, 8.2 Hz, 1H, CHH’OH), 3.12 (s, 3H, OCH3), 3.09 (s, 3H, OCH3), 2.47 (t, 
J = 6.8 Hz, 1H, H1), 2.36 (t, J = 7.3 Hz, 1H, H4), 1.81 – 1.68 (m, 2H, 
BnOCH2CH2), 1.28 (s, 6H, (CH3)2), 1.24 (s, 6H, (CH3)2); 13C NMR (101 MHz, 
CDCl3) δ 147.0 (C), 138.7 (C), 132.0 (CH), 128.3 (CH), 127.6 (CH), 127.5 
(CH), 100.0 (C), 99.72 (C), 73.0 (CH2), 69.6 (CH2), 63.0 (CH2), 58.3 (CH2), 
49.1 (CH), 48.5 (CH3), 48.4 (CH3), 42.1 (CH), 33.7 (CH2), 24.4 (CH3), 24.4 
(CH3); m/z (ES+) 415.3 ([M+Na]+); HRMS data not obtainable due to 
instability. 
((2-((1R*,4S*)-3,4-bis((methoxymethoxy)methyl)cyclobut-2-en-1-
yl)ethoxy)methyl)benzene (252e) 
 
Method of Narasaka.146 
MOMCl (0.17 ml, 179 mg, 2.24 mmol) was added to a stirred suspension of 
NaI (26 mg, 1.76 mmol) in 1,2-dimethoxyethane (1 ml) at RT under a blanket 
of N2 and stirred for 10 minutes. ((1S*,4R*)-4-(2-(benzyloxy)ethyl)cyclobut-2-
ene-1,2-diyl)dimethanol 251 (54 mg, 0.22 mmol) and DIPEA (0.42 ml, 312 
mg, 2.42 mmol) in 1,2-dimethoxyethane (3 ml) were added and the reaction 
mixture stirred at RT for 1 hour 10 minutes before heating to reflux for 1 hour 
50 minutes. The reaction mixture was cooled to RT, saturated aqueous 
sodium carbonate solution (5 ml) and water (5 ml) were added and the 
mixture was extracted with EtOAc (3 × 15 ml), dried (MgSO4) and 
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concentrated in vacuo. The crude residue was purified via column 
chromatography (1:1, EtOAc:PE) to give the title compound 252e as a yellow 
oil (73 mg, 0.217 mmol, 98% yield); Rf 0.66 (1:1, EtOAc:PE); 1H NMR (400 
MHz, CDCl3) δ 7.28 – 7.25 (m, 4H, Ph), 7.23 – 7.19 (m, 1H, Ph), 6.02 (d, J = 
0.7 Hz, 1H, H3), 4.57 (s, 2H, OCH2O), 4.53 (s, 2H, OCH2O), 4.43 (s, 2H, 
PhCH2), 3.97 (s, 1H, CHH’OMOM), 3.95 (s, 1H, CHH’OMOM), 3.58 – 3.52 
(m, 2H, CH2OMOM), 3.46 (t, J = 6.5 Hz, 2H, BnOCH2), 3.30 (s, 3H, OCH3), 
3.27 (s, 3H, OCH3), 2.57 (t, J = 6.1 Hz, 1H, H1), 2.43 (t, J = 7.0 Hz, 1H, H4), 
1.75 (ddd, J = 13.8, 6.5, 1.6 Hz, 2H, BnOCH2CH2); 13C NMR (101 MHz, 
CDCl3) δ 145.8 (C), 138.6 (C), 133.7 (CH), 128.3 (CH), 127.6 (CH), 127.5 
(CH), 96. 6 (CH2), 95.8 (CH2), 73.0 (CH2), 69.5 (CH2), 69.4 (CH2), 64.2 (CH2), 
55.3 (CH3), 55.1 (CH2), 48.8 (CH), 41.6 (CH), 33.6 (CH2); m/z 354.2 
([M+NH4]+, 100%), 337.2 ([M+H]+, 10%); HRMS found ([M+NH4]+) 
354.2276. C19H32O5N req. 354.2275. 
(2R*,3S*)-3-(2-(benzyloxy)ethyl)-1,2-bis((methoxymethoxy)methyl)-5-
oxabicyclo [2.1.0]pentane (250d) 
 
mCPBA (77% max, 58 mg, 0.26 mmol) was added to a stirred solution of ((2-
((1R*,4S*)-3,4-bis((methoxymethoxy)methyl)cyclobut-2-en-1-
yl)ethoxy)methyl)benzene 251e (73 mg, 0.217 mmol) in DCM (7 ml) at 0 °C 
and the reaction mixture stirred for 2 hours 30 minutes. A further portion of 
mCPBA (77% max, 30 mg, 0.134 mmol) was added and the reaction mixture 
stirred for 20 hours while warming to RT. The reaction mixture was 
partitioned between saturated aqueous sodium thiosulfate (10 ml) and DCM 
(20 ml), washed with saturated aqueous sodium bicarbonate solution (10 ml), 
dried (MgSO4) and concentrated in vacuo. The crude residue was purified via 
column chromatography (3:7, EtOAc:PE) to give the title compound 249d as 
a clear oil (57 mg, 0.16 mmol, 74% yield); Rf 0.47 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.31 – 7.19 (m, 5H, Ph), 4.57 (s, 2H, OCH2O), 4.49 (q, J 
= 6.4 Hz, 2H, PhCH2), 4.42 (s, 2H, OCH2O), 3.80 (s, 1H, H4), 3.77 (s, 1H, 
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CHH’OMOM), 3.75 (s, 1H, CHH’OMOM), 3.63 (dd, J = 9.5, 8.5 Hz, 1H, 
CHH’OMOM), 3.53 – 3.39 (m, 2H, BnOCH2), 3.35 – 3.30 (m, 1H, 
CHH’OMOM), 3.29 (s, 3H, OCH3), 3.26 (s, 3H, OCH3), 2.15 (t, J = 7.6 Hz, 
1H, H2), 1.77 (app t, J = 4.4 Hz, 3H, BnOCH2CH2+H3); 13C NMR (101 MHz, 
CDCl3) δ 138.3 (CH), 136.9 (C), 128.4 (CH), 127.6 (CH), 96.5 (CH2), 96.3 
(CH2), 73.1 (CH2), 68.5 (CH2), 65.5 (CH2), 65.4 (CH2), 62.4 (C), 59.5 (CH), 
55.3 (CH3), 55.1 (CH3), 47.5 (CH), 41.2 (CH), 31.2 (CH2); m/z 370.3 
([M+NH4]+, 10%), 353.2 ([M+H]+, 5%), 321.2 ([M-OMe]+, 15%), 199.2 
(100%); HRMS found ([M+NH4]+) 370.2227. C19H32O6N req. 370.2224. 
Dimethyl 3-(2-(benzyloxy)ethyl)-5-oxabicyclo[2.1.0]pentane-1,2-
dicarboxylate (249) 
Dimethyl 3-(2-(benzyloxy)ethyl)-4-(tert-butoxy)-1-hydroxycyclobutane-
1,2-dicarboxylate (261) 
 
Method of Pfeffer.147 
A solution of tBuOOH (5 M in decane, 0.08 ml, 0.4 mmol) was added to a 
stirred solution of dimethyl 4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-
dicarboxylate 246 (61 mg, 0.2 mmol) in THF (4 ml) at 0 °C under a blanket of 
N2 and stirred for 10 minutes. tBuOK (11 mg, 0.1 mmol) was added and the 
reaction mixture was allowed to warm to RT while stirring for 16.5 hours. The 
reaction was quenched with 10% aqueous sodium sulfate(0.3 mmol), 
partitioned between H2O (15 ml) and DCM (15 ml), extracted with DCM (15 
ml), and the combined organic layers dried (MgSO4) and concentrated in 
vacuo. The crude residue was purified via column chromatography (3:7, 
EtOAc:PE) to give the two title compounds: 
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dimethyl 3-(2-(benzyloxy)ethyl)-5-oxabicyclo[2.1.0]pentane-1,2-
dicarboxylate (249):  
clear oil (8 mg, 0.025 mmol, 12% yield); Rf 0.48 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.31 – 7.20 (m, 5H, Ph), 4.43 (s, 2H, PhCH2), 4.19 (s, 
1H, H4), 3.73 (s, 3H, OCH3), 3.62 (s, 3H, OCH3), 3.57 – 3.48 (m, 2H, 
BnOCH2), 3.14 (d, J = 3.5 Hz, 1H, H2), 2.41 (td, J = 7.7, 3.6 Hz, 1H, H3), 
1.88 (dt, J = 13.9, 6.9 Hz, 2H, BnOCH2CH2); 13C NMR (101 MHz, CDCl3) δ 
169. 9 (C), 166.4 (C), 138.1 (C), 128.5 (CH), 127.7 (CH), 127.6 (CH), 73.4 
(CH2), 68.3 (CH2), 61.8 (CH), 57.1 (C), 52.7 (CH3), 52.1 (CH3), 47.9 (CH), 
43.8 (CH), 30.7 (CH2); m/z (AP+) 321.1 ([M+H]+, 100%); HRMS found 
([M+NH4]+) 338.1604. C17H24O6N req. 338.1598. 
dimethyl 3-(2-(benzyloxy)ethyl)-4-(tert-butoxy)-1-hydroxycyclobutane-
1,2-dicarboxylate (261):  
clear oil (25 mg, 0.063 mmol, 32% yield); Rf 0.52 (1:1, EtOAc:PE); 1H NMR 
(400 MHz, CDCl3) δ 7.34 (s, 5H, Ph), 4.48 (s, 2H, PhCH2), 4.29 (t, J = 7.4 Hz, 
1H, H4), 3.74 (s, 3H, OCH3), 3.65 (s, 3H, OCH3), 3.55 (dd, J = 14.8, 6.5 Hz, 
2H, BnOCH2), 3.32 (dd, J = 9.3, 7.3 Hz, 1H, H2), 2.74 – 2.61 (m, 1H, H3), 
1.93 (dd, J = 15.0, 6.5 Hz, 2H, BnOCH2CH2), 1.24 (s, 9H, tBu); 13C NMR (101 
MHz, CDCl3) δ 172.8 (C), 172.1 (C), 138.4 (C), 128.3 (CH), 127.6 (CH), 
127.5 (CH), 80.6 (CH), 80.5 (C), 73.1 (CH2), 67.9 (CH2), 52.1 (CH3), 52.0 
(CH3), 46.0 (CH), 41.3 (C), 38.8 (CH), 33.1 (CH2), 26.3 (CH3); m/z (AP+) 
395.2 ([M+H]+, 100%); HRMS found ([M+NH4]+) 412.2332. C21H34O7N req. 
412.230. 
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Dimethyl (3S*,4R*)-4-(2-(benzyloxy)ethyl)-9-oxatricyclo[4.2.1.02,5]non-7-
ene-2,3-dicarboxylate (271a) 
 
Method of Pednekar.117a 
A solution of TiCl4 (1 M in DCM, 0.05 ml, 0.05 mmol) was added to a stirred 
solution of (1S*,4R*)-dimethyl 4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-
dicarboxylate 246 (31 mg, 0.1 mmol) in diethyl ether (2 ml) at 0 °C under a 
blanket of N2 and stirred for 5 minutes. Furan (0.15 ml, 136 mg, 2 mmol) 
followed by TMSCl (0.025 ml, 0.2 mmol) was added and the reaction mixture 
was stirred for 23.5 hours at RT. Water (10 ml) was added and the resulting 
mixture extracted with DCM (2 × 20 ml). The combined organic layers were 
washed with water (15 ml), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified via column chromatography (2:8, EtOAc:PE) to 
give the title compound 271a as a clear oil (28 mg, 0.075 mmol, 75% yield); 
Rf 0.33 (1:1, EtOAc:PE); IR 2951.2 cm-1 (CH Sp3), 2858.6 cm-1 (C=C) 1727.6 
cm-1 (C=O ester), 1095.1 cm-1 (ether), 698.4 cm-1 (C=C bend);1H NMR (400 
MHz, CDCl3) δ 7.30 – 7.20 (m, 5H, Ar), 6.22 (d, J = 1.3 Hz, 1H, H7 or H8), 
6.22 (d, J = 1.3 Hz, 1H, H7 or H8), 5.14 (d, J = 1.3 Hz, 1H, H1 or H6), 4.63 
(d, J = 1.3 Hz, 1H, H1 or H6), 4.43 (s, 1H, PhCHH’), 4.42 (s, 1H, BPhCHH’), 
3.64 (s, 3H, OCH3), 3.61 (s, 3H, OCH3), 3.49 (t, J = 6.4Hz, 2H, BnOCH2), 
2.97 (d, J = 6.5 Hz, 1H, H3), 2.32 – 2.23 (m, 1H, H4) 2.07 (d, J = 4.0 Hz, 1H, 
H5), 1.94 – 1.86 (m, 2H, BnOCH2CH2); 13C NMR (101 MHz, CDCl3) δ 173.0 
(C), 171.7 (C), 138.5 (C), 134.9 (CH), 134.4 (CH), 128.4 (CH), 127.7 (CH), 
81.8 (CH), 78.2 (CH), 73.2 (CH2), 68.6 (CH2), 53.0 (C),52.2 (CH3), 51.7 
(CH3), 45.6 (CH), 45.1 (CH), 34.7 (CH2), 34.0 (CH); m/z (ES+) 373.2 
([M+H]+, 100%); HRMS Found ([M+H]+) 373.1644. C21H25O6 req. 373.1646; 
LCMS rt 8.69, m/z (ES+) 373.2 ([M+H]+, 100%), >95%. 
 
 209 
 
2-Boronofuran-3-carboxylic acid (274) 
 
BuLi (2.5 M in hexanes, 7.6 ml, 19 mmol) was added slowly to stirred solution 
of diisopropylamine (2.68 ml, 1.92 g, 19 mmol) in THF (5 ml) at 0 °C under a 
blanket of N2 and stirred for 3 hours. The reaction mixture was then cooled to 
−78 °C and 3-furoic acid 171 (1 g, 8.92 mmol) in THF (10 ml) was added 
dropwise and then stirred for 1 hour. B(OiPr)3 (5.47 ml, 6.71 g, 35.68 mmol) 
was added and the reaction stirred for 18 hours while slowly warming to RT. 
The reaction mixture was quenched with water (40 ml) and extracted with 
diethyl ether (2 × 30 ml). The aqueous layer was acidified to pH 1 with 2 M 
HCl and then cooled to 0 °C over night. The resulting crystals were filtered 
and then rinsed with water:EtOH (10 ml, 1:1) to give the title compound 274 
as pale yellow crystals (500 mg, 3.22 mmol, 36% yield); 1H NMR (400 MHz, 
DMSO) δ 7.94 (d, J = 1.7 Hz, 1H), 6.80 (d, J = 1.7 Hz, 1H). Consistent with 
literature.148 
(3-(Methoxycarbonyl)furan-2-yl)boronic acid (275) 
 
Concentrated H2SO4 (2 drops) was added to a stirred solution of 2-
boronofuran-3-carboxylic acid 274 (210 mg, 1.35 mmol) in MeOH (6 ml) and 
the reaction heated at 65 °C for 26.5 hours. The reaction mixture was cooled 
to RT, concentrated in vacuo, partitioned between diethyl ether (20 ml) and 2 
M aqueous HCl, extracted with diethyl ether (20 ml), dried (MgSO4) and 
concentrated in vacuo to give the title compound 275 as a pale yellow solid 
(212 mg, 1.25 mmol, 92% yield); 1H NMR (400 MHz, MeOD) δ 7.72 (s, 1H, 
Furan), 6.79 (s, 1H, Furan), 3.90 (s, 3H, OCH3). Consistent with literature.148 
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Dimethyl(1R*,2R*,3S*,4S*)-3-(2-(benzyloxy)ethyl)-4-(3-
(methoxycarbonyl)furan-2-yl)cyclobutane-1,2-dicarboxylate (270c) 
 
[Rh(COD)Cl]2 (4.4 mg, 0.009 mmol) was added to a stirred solution of 
dimethyl (1R*,4S*)-4-(2-(benzyloxy)ethyl)cyclobut-2-ene-1,2-dicarboxylate 
246 (54 mg, 0.175 mmol), (3-(methoxycarbonyl)furan-2-yl)boronic acid 153 
(148 mg, 0.88 mmol), NEt3 (0.06 ml, 44 mg, 0.44 mmol) in dioxane:water 
(10:1, 3.3 ml) and stirred at RT for 21.5 hours. The reaction mixture was then 
concentrated in vacuo and purified via column chromatography (2:8, 
EtOAc:PE) to give the title compound 270c as a clear oil (31 mg, 0.072 
mmol, 41% yield); Rf 0.30 (3:7, EtOAc:PE); IR 2952.9 cm-1 (CH sp3), 1719.4 
cm-1 (C=O ester), 731.9 cm-1 (mono subs. Benzene);1H NMR (400 MHz, 
CDCl3) δ 7.28 – 7.08 (m, 6H, Ph + Furan), 6.58 (d, J = 1.9 Hz, 1H, Furan), 
4.23 (q, J = 11.8 Hz, 2H, PhCH2), 3.97 (t, J = 9.6 Hz, 1H, H4), 3.71 (s, 3H, 
OCH3), 3.60 (s, 3H, OCH3), 3.59 (s, 3H, OCH3), 3.53 (t, J = 9.6 Hz, 1H, H1), 
3.42 – 3.31 (m, 2H OCH2), 3.01 (t, J = 9.6 Hz, 1H, H2), 2.88 (tt, J = 9.6, 7.3 
Hz, 1H, H3), 1.96 – 1.75 (m, 2H, CH2CH2); 13C NMR (101 MHz, CDCl3) δ 
173.0 (C), 172.3 (C), 172.3 (C), 159.2 (C), 141.5 (C), 138.2 (C), 128.3 (CH), 
127.5 (CH), 127.5 (CH), 114.1 (C), 111.1 (CH), 73.0 (CH2), 67.6 (CH2), 52.1 
(CH3), 52.0 (CH3), 51.5 (CH3), 43.2 (CH), 42.5 (CH), 39.8 (CH), 38.6 (CH), 
34.6 (CH2); m/z (AP+) 431.1 ([M+H]+, 100%); HRMS found 431.1700. 
C23H27O8 req. 431.1700; LCMS rt 10.17, m/z (ES+) 453.2 ([M+Na]+, 100%), 
>95%. 
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